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ABSTRACT
Herpes simplex virus type 1 (HSV-1) is a ubiquitous neurotropic alphaherpesvirus
transmitted by contact with mucocutaneous surfaces of infected individuals. HSV-1 enters the
host by fusion of the viral envelope with the host cell plasma membrane, followed by
translocation of the viral capsids to the nucleus where viral DNA is injected into the host cell
nucleus to initiate viral replication. To generate infectious virions, newly assembled capsids
travel to the cytoplasm and undergo a process called secondary envelopment by budding into
cytoplasmic vesicles derived from the trans-Golgi network. Cytoplasmic envelopment is a
complex process involving interactions between a multitude of viral membrane and tegument
proteins. To investigate the relative importance of a subset of viral membrane and tegument
proteins in secondary envelopment, a number of recombinant viruses were constructed in the
HSV-1(F) genetic background. A mutant virus unable to express gE, gM and the C-terminus of
gD was characterized and compared to additional mutants unable to express both gE and gM or
gE and the C-terminus of gD and to mutants lacking expression of just one of these
glycoproteins, in addition to mutants lacking expression of both pUL11 and gM, and pUL20
alone. Characterization of all mutant viruses by plaque morphology, viral replication kinetics,
electron microscopy and particle-to-PFU ratios revealed a hierarchy of defects in cytoplasmic
envelopment and infectious virus production, with deletion of pUL20 having the greatest effect,
followed by the deletion of pUL11 and gM. Characterization of additional mutants containing
multiple mutations revealed that gE, gM and gD do not function in a redundant manner in
cytoplasmic envelopment supporting a preeminent role for the pUL20/gK protein complex in
cytoplasmic envelopment and egress. An epitope tag insertion adjacent to the pUL37 Y480
ix

(DC480) exhibited a severe defect in cytoplasmic envelopment similar to gK and pUL20-null
viruses. Importantly, this mutant virus was partially complemented when grown on cells
expressing pUL20, suggesting an interaction with the pUL20/gK protein complex. This pUL37
interaction with pUL20/gK was verified by co-immunoprecipitation and proximity ligation
assays suggesting that it facilitates cytoplasmic virion envelopment.
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CHAPTER I: INTRODUCTION
Statement of Problem and Hypothesis
Herpes simplex viruses are responsible for a wide spectrum of human disease ranging
from cutaneous eruptions to life-threatening viral encephalitis. Infection occurs by direct
contact, leading to viral replication at the site of infection before the virus penetrates sensory
neurons and travels to dorsal root ganglia to establish a lifelong latent infection punctuated by
periods of recurrence at the site of infection. Viral entry into host cells is mediated by assembly
of viral fusion proteins that trigger fusion between the viral envelope and the plasma
membrane, thus releasing capsids into the cell. Capsids travel to the nucleus to release their
cargo of viral DNA for transcription and initiation of progeny virus production.
Virion assembly and egress is a complex multi-step process whereby newly assembled
capsids of herpes simplex virus type-1 (HSV-1) must undergo two envelopment steps on their
journey out of the cell. Capsids are assembled in the nucleus and undergo primary
envelopment and budding into the perinuclear space before losing the envelope by fusion with
the outer nuclear envelope to deliver capsids into the cytoplasm. Cytoplasmic capsids travel to
sites of secondary envelopment at trans-Golgi membranes and endosomes enriched with viral
glycoproteins and associated outer tegument proteins. Interactions between the capsid, the
tegument, and viral envelope proteins at TGN membranes facilitate budding of capsids into
TGN vesicles to form enveloped virions which are then transported by exocytosis to the cell
periphery for release.
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The process of secondary envelopment is poorly understood. Deletions of individual
membrane and tegument proteins, with the notable exceptions of the membrane proteins
pUL20 and gK and the tegument proteins pUL36 and pUL37, do not lead to significant defects in
cytoplasmic envelopment, leading to a proliferation of envelopment models in which they
function in a redundant or synergistic manner to promote cytoplasmic envelopment. The
hypothesis promulgated in this dissertation is that cytoplasmic envelopment is the result of a
coordinated action of protein-protein interactions between the cytoplasmic portions of viral
membrane proteins and viral tegument proteins that are brought together in close proximity
during envelopment. The hypothesis predicts that the pUL20/gK protein complex and the
pUL37 tegument protein, both of which are known to play preeminent roles in cytoplasmic
envelopment, physically and functionally interact to facilitate the virion envelopment process.
Statement of Research Objectives
The first goal of this research was to assess the synergistic importance of herpes simplex
virus type-1 (HSV-1) membrane glycoproteins gD, gE and gM and the membrane-associated
tegument protein pUL11 in cytoplasmic virion envelopment in comparison to the membrane
proteins pUL20 and gK, which are known to be essential determinants of cytoplasmic virion
envelopment. The second goal of this work was to explore the potential role of the inner
tegument protein pUL37 in cytoplasmic virion envelopment and to probe the relationship
between pUL37 and the pUL20/gK membrane protein complex in order to shed further light on
the network of interactions between viral membrane and tegument proteins involved in
cytoplasmic virion envelopment. The specific aims of this research include:
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I. To clarify the relative contribution of the viral proteins gD, gE, gM and pUL11 to cytoplasmic
envelopment and infectious virus production, either alone or in various combinations, in
relation to pUL20.
a. To construct a recombinant virus in the HSV-1(F) genetic background using a BAC
mutagenesis system with mutations abrogating expression of gE, gM and the
carboxyl-terminal 29 amino acids of gD simultaneously.
b. To construct additional recombinant viruses in the HSV-1(F) genetic background
using a BAC mutagenesis system with mutations abrogating expression of gM alone,
pUL11 alone, gE and gM simultaneously, and gM and pUL11 simultaneously.
c. To fully characterize the newly constructed viruses in addition to previously
constructed viruses with mutations abrogating expression of pUL20 alone, gE alone,
the carboxyl terminus of gD alone, and gE and the carboxyl terminus of gD
simultaneously

by

analyzing

plaque

morphology,

viral

growth

kinetics,

ultrastructural morphology, and particle-to-PFU ratios.
II. To elucidate the potential role of a poorly characterized domain of pUL37 in cytoplasmic
virion envelopment and to explore the possibility of a physical relationship between pUL37
and the pUL20/gK protein complex.
a. To construct a recombinant virus in the HSV-1(F) genetic background using a BAC
mutagenesis system with a mutant pUL37 containing a 12 amino acid protein C
epitope tag inserted immediately following Y480 and to fully characterize it by
analyzing plaque morphology, viral growth kinetics, ultrastructural morphology, and
particle-to-PFU ratios.
3

b. To test for the existence of interactions between the inner tegument protein pUL37
and the membrane proteins pUL20 and gK by two-way co-immunoprecipitation and
proximity ligation assays.
Overall, the results obtained from this work indicate that:
I. Single mutant viruses unable to express gD, gE, gM or pUL11 do not exhibit significant
defects in cytoplasmic virion envelopment or infectious virus production. Double mutants
unable to express gM and gE or gE and the carboxyl terminus of gD exhibit mild reduction in
average plaque size, infectious virus production, and cytoplasmic virion envelopment in
comparison to the single mutants, with the mutant lacking gE and the carboxyl terminus of
gD showing marginally greater reduction. The mutant virus with simultaneous deletions of
gE, gM and the carboxyl terminus of gD shows mild reduction in average plaque size,
infectious virus production, and cytoplasmic virion envelopment in comparison to the
aforementioned double mutants, suggesting that gE, gM and the carboxyl terminus of gD do
not function in a redundant manner in cytoplasmic envelopment. A double mutant lacking
both pUL11 and gM exhibits more substantial defects in cytoplasmic virion envelopent and
infectious virus production that are greater than those observed with the aforementioned
triple mutant. However, all of these mutants exhibit significantly less severe defects than
the pUL20-null virus, which illustrates the important role pUL20 and its interacting partner
gK play in cytoplasmic virion envelopment.
II. A recombinant HSV-1 with a mutated pUL37 containing a 12 amino acid protein C tag
inserted in-frame following Y480 exhibits drastically impaired cytoplasmic envelopment and
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infectious virus production similar to that of a pUL37-null virus when grown on Vero cells,
but is complemented for virus replication and spread when grown in FRT cells expressing
the UL20 gene while the pUL37-null virus is not, suggesting a direct or indirect interaction
with the pUL20/gK protein complex. Co-immunoprecipitation experiments and proximity
ligation assays show that pUL37 interacts with both pUL20 and gK in infected cells to
facilitate cytoplasmic virion envelopment.
The work presented here is placed into individual chapters in a manuscript format with
chapter titles reflecting the central theme of the research contained therein.

5

CHAPTER II: LITERATURE REVIEW
History of Herpes
Herpesviruses have been co-evolving with their hosts, including humans, for millions of
years (172, 201). Herpes simplex viruses in particular are well suited to co-migrate and diversify
with their human hosts due to their ability to establish latent and persistent infections in their
hosts. This intricate evolutionary linkage is illustrated by phylogenetic analyses of Herpes
simplex virus type 1 (HSV-1) and Herpes simplex virus type 2 (HSV-2) that estimate the
divergence time for HSV-1 and HSV-2 at approximately 2.2 million years BP, roughly
corresponding to the advent of the genus Homo. (83, 172). Furthermore, the HSV-1 clade
structure closely corresponds with the timing and routes of past global human migrations, with
HSV-1 strains first diverging in Africa approximately 50,300±16,700 years BP, the Eurasian
strains diverging 32,800±10,900 years BP, and the American KOS strain diverging from the Asian
CR38 strain at 15,760±5,300 years BP which closely fits the estimated time period in which
humans from Asia began to populate the North American continent (165, 172).
For most of human history, disease has been an enigmatic phenomenon, variously
ascribed to causes ranging from imbalances of bodily humors to supernatural factors such as
divine retribution. Consequently, modern efforts to identify pathogens such as HSV from
historical sources are fraught with difficulty, particularly when the disease in question is not
known for having dramatic and deadly clinical outcomes. Many of the lesions mentioned in
ancient texts are described poorly and may not have been caused by HSV at all, instead
resulting from skin malignancies, concurrent infection with a number of other pathogens, or
6

even by cutaneous diseases that simply do not exist in modern times. These difficulties are
further exacerbated by the inconsistent historical usage of the term “herpes”. It was commonly
used to refer to a number of other skin conditions, such as lupus, that are not associated with
herpesviruses, and, for a time, was even abolished in favor of “formica”. (265).
The earliest evidence of symptoms possibly linked to infection by a herpes simplex virus
shows up as descriptions of genital lesions in a ~3000 BC Sumerian tablet and in the ~1500 BC
Ebers Papyrus. The first recorded usage of the Greek word “ἕρπης“, or “herpes”, was by
Hippocrates in order to describe lesions that appear to crawl along the skin. The Roman author
Celsus, writing in the 1st century BCE, described round lesions that eventually “diffused like a
serpent to form a belt”, which arguably fits varicella-zoster virus (VZV) better than HSV.
Herodotus is believed to be the first to record a link between cutaneous eruptions and fever,
and his work was expanded and elaborated by the prominent Greek physician Galen in the 2nd
century AD. Galen’s description of lesions that tended to recur at the same anatomical site is
notable as the earliest hint of viral latency and reactivation following HSV infection (97, 265).
Better definitions of herpesviral disease had to wait until the 18th century, coinciding
with upheavals and innovations in medical science that would later lead to widespread
acceptance of the germ theory of disease and the birth of modern medicine. Daniel Turner
described a number of cutaneous diseases in his 1714 treatise De Morbis Cutaneis, including
“facial herpes” (presumably herpes simplex type-1) and “herpes miliaris” (presumably varicellazoster virus). The first description of “herpes genitalis” followed in 1736 in De Morbis Venereis,
written by John Astruc and based on his studies of French prostitutes in his capacity as
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physician for King Louis XIV. Accounts of genital herpes proliferated after this point, becoming
closely associated with prostitution. In 1886, Charles-Paul Diday and Adrien Doyon published
Les Herpes Genitaux, the first book specifically dedicated to herpes. A decade later, Jean Alfred
Fournier released his treatise on the diagnosis and treatment of genital herpes, recommending
abstaining from alcohol, tobacco and “sexual excesses” in order to treat and prevent infections.
Notably, Paul Gerson Unna described genital herpes in 1883 as a “vocational disease” of
women, albeit a disease that is “one of the most benign of affections both to the patient and
her public” (97, 265). This nonchalant attitude towards genital herpes persisted up until the
mid-1970’s, as evidenced by the absence of genital herpes from studies of psychological
morbidity in clinics dealing with sexually transmitted diseases (199). Public awareness of genital
herpes peaked in the early 1980's largely due to the development and marketing of acyclovir as
an effective herpes treatment and the 1982 publication of a TIME cover story branding it as
"The New Scarlet Letter", which likely contributed to a stigmatization of the condition.
However, herpes was soon supplanted in the public consciousness by the arrival of the human
immunodeficiency virus and the worrying prospect of a global HIV epidemic (70, 164).
In the late 19th century, herpes research began to progress from being merely
descriptive to experimentation designed to elucidate the nature of the disease. The French
dermatologist Jean Baptiste Émile Vidal in 1873 was the first to show that HSV was infectious by
passing the infection from one human volunteer to another. However, credit for the isolation of
HSV usually goes to Wilhelm Grüter, who used an animal model in his 1924 paper to show that
HSV can be serially transmitted between rabbits. Another key to the understanding of HSV
biology was published by Andrews and Carmichael in 1930. They observed that recurrent HSV
8

infections only occurred in adults who carried neutralizing antibodies, thus igniting a debate
that culminated in a 1939 publication by Burnet and Williams that promoted the modern view
that HSV infection persists for life in a latent state and may be reactivated at any time to
produce new lesions due to trauma, fever or other stimuli (97, 265). The existence of two
separate types of HSV and their association with either orolabial herpes (HSV-1) or genital
herpes (HSV-2) was only demonstrated in 1971 by Schneweis and Nahmias, over four decades
after Grüter’s original isolation of HSV (277).
During the latter half of the 20th century, rapid technological advances in molecular
biology and the advent of electron microscopy have enabled us to isolate and visualize viruses
with relative ease, thus leading to the discovery and classification of a growing number of
herpesviruses infecting a wide variety of animals, including humans. Advancements in cell
culture techniques during the 1950s led to the discovery and isolation of varicella-zoster virus
(VZV) and human cytomegalovirus (CMV) (68, 308). Further cell culture developments led to
the cultivation of B lymphocytes, resulting in the discovery of Epstein-Barr virus (EBV) in 1964
(89). Human herpesviruses 6A, 6B and 7 were isolated in the late 1980s after the development
of techniques to cultivate T lymphocytes (105, 190, 270). The most recently discovered human
herpesvirus is HHV-8, otherwise known as Kaposi’s sarcoma-associated herpesvirus (KSHV).
KSHV was found in 1994 using a then-novel technique called representational difference
analysis (RDA) which can be employed to find sequence differences between two complex
genomes (47). The proliferation of relatively cheap high-throughput sequencing technologies
will undoubtedly lead to the discovery of a plethora of novel herpesviruses, in addition to
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providing valuable insights into the inner workings of familiar viruses due to the ready
availability of genomic data (124).
Taxonomy of Herpesviruses
Taxonomy is the systematic classification of organisms into groups, or taxa, which are
collectively defined by a consensus group of properties (95). Unlike other organisms that have
“domain” as the most inclusive taxonomic rank, virus taxa are limited to order, family,
subfamily, genus and species, as defined by the International Committee on Taxonomy of
Viruses (ICTV). The ICTV was established in 1971 as a means to standardize the classification of
viruses, spurred by the growing numbers of viruses being discovered due to advances in
molecular biology. While early virologists had to depend on broad biological properties such as
host range and disease manifestation to classify novel viruses, the growing use of electron
microscopy and improved cell culture techniques provided detailed information on viral
morphology and physiology that enabled more accurate viral classification. The development of
specific antibodies further refined virus taxonomy by allowing researchers to distinguish
between closely related viruses, and advances in nucleotide sequencing led to an explosion of
granular genomic data and the eventual adoption of sequence-based phylogenetic analysis as
the key taxonomic determinant for all organisms, including viruses (75).
Herpesviruses are a morphologically distinct group, possessing a linear, double-stranded
DNA genome varying from 125 kbp to 290 kbp that is contained within an icosahedral capsid
that is surrounded by a proteinaceous matrix called the tegument, which is in turn surrounded
by a host-derived lipid envelope containing an assortment of membrane-associated viral
10

proteins. Despite their morphological similarities, herpesviruses comprise three discrete genetic
groups and have subsequently been split by the ICTV into three families that together form the
order Herpesvirales. The family Herpesviridae incorporates viruses of mammals, birds and
reptiles, while the family Alloherpesviridae contains viruses that infect fish and frogs, and the
family Malacoherpesviridae is home to viruses that infect molluscs (76).
The first ICTV report in 1971 contained a mere 290 different viruses, and all 23 different
herpesviruses recognized at the time were placed in the genus Herpesvirus (144). This genus
was elevated to family and renamed to Herpetoviridae in the second ICTV report, which is also
notable for the addition of Human herpesvirus 2 as a close relative of Human herpesvirus 1 (96).
The family was renamed again to Herpesviridae in the third ICTV report, presumably to avoid
the implied association of Herpetoviridae with reptiles. The third ICTV report also marked the
division of the family Herpesviridae into the three currently recognized subfamilies:
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae (198). The modern herpesviral
taxonomic structure originated prior to the ninth ICTV report with the creation of a new order,
Herpesvirales, containing the family Herpesviridae and the new families Alloherpesviridae and
Malacoherpesviridae (76). According to the most recent (2013) online version of the official
ICTV taxonomy available at ictvonline.org, there are now a total of 2828 recognized viral
species, while the order Herpesvirales currently consists of 3 families, 3 subfamilies, 19 genera
and 102 species (Table 2.1).
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Table 2.1: Classification of herpesviruses. Adapted with permission from [Veterinary Microbiology
143(1-2): 52-69, Herpesvirus systematics]. Copyright (2010) Elsevier. Table has been updated with
data from the 2013 ICTV virus taxonomy release available at ictvonline.org. Asterisks indicate the
type species in each genus.
(Table 2.1 continued)
Taxon name

Common name

Acronym

Lucké tumor herpesvirus
Frog virus 4

RaHV1
RaHV2

Eel herpesvirus
Carp pox herpesvirus
Goldfish haematopoietic necrosis virus
Koi herpesvirus

AngHV1
CyHV1
CyHV2
CyHV3

Channel catfish virus
Black bullhead herpesvirus
White sturgeon herpesvirus 2

IcHV1
IcHV2
AciHV2

Herpesvirus salmonis
Oncorhynchus masou herpesvirus
Epizootic epitheliotropic disease virus

SalHV1
SalHV2
SalHV3

Infectious laryngotracheitis virus
Pacheco's disease virus

GaHV1
PsHV1

Duck enteritis virus
Pigeon herpesvirus
Marek's disease virus type 1
Marek's disease virus type 2
Turkey herpesvirus

AnHV1
CoHV1
GaHV2
GaHV3
MeHV1

Chelonid fibropapilloma-associated herpesvirus

ChHV5

Order Herpesvirales
Family Alloherpesviridae
Genus Batrachovirus
Ranid herpesvirus 1*
Ranid herpesvirus 2
Genus Cyprinivirus
Anguillid herpesvirus 1
Cyprinid herpesvirus 1
Cyprinid herpesvirus 2
Cyprinid herpesvirus 3*
Genus Ictalurivirus
Ictalurid herpesvirus 1*
Ictalurid herpesvirus 2
Acipenserid herpesvirus 2
Genus Salmonivirus
Salmonid herpesvirus 1*
Salmonid herpesvirus 2
Salmonid herpesvirus 3
Family Herpesviridae
Subfamily Alphaherpesvirinae
Genus Iltovirus
Gallid herpesvirus 1*
Psittacid herpesvirus 1
Genus Mardivirus
Anatid herpesvirus 1
Columbid herpesvirus 1
Gallid herpesvirus 2*
Gallid herpesvirus 3
Meleagrid herpesvirus 1
Genus Scutavirus
Chelonid herpesvirus 5*
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(Table 2.1 continued)
Taxon name

Common name

Genus Simplexvirus
Ateline herpesvirus 1
Spider monkey herpesvirus
Bovine herpesvirus 2
Bovine mammillitis virus
Cercopithecine herpesvirus 2 Simian agent 8
Human herpesvirus 1*
Herpes simplex virus type 1
Human herpesvirus 2
Herpes simplex virus type 2
Leporid herpesvirus 4
Leporid herpesvirus 4
Macacine herpesvirus 1
B virus
Macropodid herpesvirus 1
Parma wallaby herpesvirus
Macropodid herpesvirus 2
Dorcopsis wallaby herpesvirus
Papiine herpesvirus 2
Herpesvirus papio 2
Saimiriine herpesvirus 1
Marmoset herpesvirus
Genus Varicellovirus
Bovine herpesvirus 1
Infectious bovine rhinotracheitis virus
Bovine herpesvirus 5
Bovine encephalitis herpesvirus
Bubaline herpesvirus 1
Water buffalo herpesvirus
Canid herpesvirus 1
Canine herpesvirus
Caprine herpesvirus 1
Goat herpesvirus
Cercopithecine herpesvirus 9 Simian varicella virus
Cervid herpesvirus 1
Red deer herpesvirus
Cervid herpesvirus 2
Reindeer herpesvirus
Equid herpesvirus 1
Equine abortion virus
Equid herpesvirus 3
Equine coital exanthema virus
Equid herpesvirus 4
Equine rhinopneumonitis virus
Equid herpesvirus 8
Asinine herpesvirus 3
Equid herpesvirus 9
Gazelle herpesvirus
Felid herpesvirus 1
Feline herpesvirus 1
Human herpesvirus 3*
Varicella-zoster virus
Phocid herpesvirus 1
Harbour seal herpesvirus
Suid herpesvirus 1
Pseudorabies virus
Unassigned species in the subfamily
Chelonid herpesvirus 6
Lung-eye-trachea disease-associated virus
Subfamily Betaherpesvirinae
Genus Cytomegalovirus
Aotine herpesvirus 1
Herpesvirus aotus type 1
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Acronym
AtHV1
BoHV2
CeHV2
HHV1
HHV2
LeHV4
McHV1
MaHV1
MaHV2
PaHV2
SaHV1
BoHV1
BoHV5
BuHV1
CaHV1
CpHV1
CeHV9
CvHV1
CvHV2
EHV1
EHV3
EHV4
EHV8
EHV9
FHV1
HHV3
PhoHV1
SuHV1
ChHV6

AoHV1

(Table 2.1 continued)
Taxon name

Common name

Cebine herpesvirus 1
Capuchin herpesvirus AL-5
Cercopithecine herpesvirus 5 Simian cytomegalovirus
Human herpesvirus 5*
Human cytomegalovirus
Macacine herpesvirus 3
Rhesus cytomegalovirus
Panine herpesvirus 2
Chimpanzee cytomegalovirus
Papiine herpesvirus 3
Baboon cytomegalovirus
Saimiriine herpesvirus 4
Squirrel monkey cytomegalovirus
Genus Muromegalovirus
Murid herpesvirus 1*
Murine cytomegalovirus
Murid herpesvirus 2
Rat cytomegalovirus
Murid herpesvirus 8
English rat cytomegalovirus
Genus Probiscivirus
Elephantid herpesvirus 1*
Elephant endotheliotropic herpesvirus
Genus Roseolovirus
Human herpesvirus 6A*
Human herpesvirus 6A
Human herpesvirus 6B
Human herpesvirus 6B
Human herpesvirus 7
Human herpesvirus 7
Unassigned species in the subfamily
Caviid herpesvirus 2
Guinea pig cytomegalovirus
Suid herpesvirus 2
Pig cytomegalovirus
Tupaiid herpesvirus 1
Tupaiid herpesvirus
Subfamily Gammaherpesvirinae
Genus Lymphocryptovirus
Callitrichine herpesvirus 3
Marmoset lymphocryptovirus
Cercopithecine herpesvirus 14 African green monkey EBV-like virus
Gorilline herpesvirus 1
Gorilla herpesvirus
Human herpesvirus 4*
Epstein–Barr virus
Macacine herpesvirus 4
Rhesus lymphocryptovirus
Panine herpesvirus 1
Herpesvirus pan
Papiine herpesvirus 1
Herpesvirus papio
Pongine herpesvirus 2
Orangutan herpesvirus
Genus Macavirus
Alcelaphine herpesvirus 1*
Wildebeest-associated malignant catarrhal fever virus
Alcelaphine herpesvirus 2
Hartebeest malignant catarrhal fever virus
Bovine herpesvirus 6
Bovine lymphotropic herpesvirus
14

Acronym
CbHV1
CeHV5
HHV5
McHV3
PnHV2
PaHV3
SaHV4
MuHV1
MuHV2
MuHV8
ElHV1
HHV6A
HHV6B
HHV7
CavHV2
SuHV2
TuHV1

CalHV3
CeHV14
GoHV1
HHV4
McHV4
PnHV1
PaHV1
PoHV2
AlHV1
AlHV2
BoHV6

(Table 2.1 continued)
Taxon name

Common name

Caprine herpesvirus 2
Caprine herpesvirus 2
Hippotragine herpesvirus 1
Roan antelope herpesvirus
Ovine herpesvirus 2
Sheep-associated malignant catarrhal fever virus
Suid herpesvirus 3
Porcine lymphotropic herpesvirus 1
Suid herpesvirus 4
Porcine lymphotropic herpesvirus 2
Suid herpesvirus 5
Porcine lymphotropic herpesvirus 3
Genus Percavirus
Equid herpesvirus 2*
Equine herpesvirus 2
Equid herpesvirus 5
Equine herpesvirus 5
Mustelid herpesvirus 1
Badger herpesvirus
Genus Rhadinovirus
Ateline herpesvirus 2
Herpesvirus ateles strain 810
Ateline herpesvirus 3
Herpesvirus ateles
Bovine herpesvirus 4
Bovine herpesvirus 4
Cricetid herpesvirus 2
Pygmy rice rat herpesvirus
Human herpesvirus 8
Kaposi’s sarcoma-associated herpesvirus
Macacine herpesvirus 5
Rhesus rhadinovirus
Murid herpesvirus 4
Murine herpesvirus 68
Murid herpesvirus 7
Wood mouse herpesvirus
Saimiriine herpesvirus 2*
Herpesvirus saimiri
Unassigned species in the subfamily
Equid herpesvirus 7
Asinine herpesvirus 2
Phocid herpesvirus 2
Phocid herpesvirus 2
Saguinine herpesvirus 1
Herpesvirus saguinus
Unassigned species in the family
Iguanid herpesvirus 2
Iguana herpesvirus
Family Malacoherpesviridae
Genus Aurivirus
Haliotid herpesvirus 1*
Abalone herpesvirus
Genus Ostreavirus
Ostreid herpesvirus 1*
Oyster herpesvirus
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Acronym
CpHV2
HiHV1
OvHV2
SuHV3
SuHV4
SuHV5
EHV2
EHV5
MusHV1
AtHV2
AtHV3
BoHV4
CrHV2
HHV8
McHV5
MuHV4
MuHV7
SaHV2
EHV7
PhoHV2
SgHV1
IgHV2

AbHV1
OsHV1

A formal system for naming herpesviruses was implemented prior to the third ICTV
report in 1979 (75). It states that each herpesvirus species must be named after the taxon
(family or subfamily) of its primary natural host. This host-derived term is followed by the word
herpesvirus, and an Arabic number (76). Furthermore, according to a set of rules established by
the ICTV that govern viral nomenclature, a species name must be italicized with the first letter
of the name being capitalized (e. g. Human herpesvirus 1), while a virus name must be written
in lower case (unless a proper noun is part of the virus name) and without italics (e. g. herpes
simplex virus type 1) (175). The species name cannot be abbreviated; if an abbreviation is used,
it represents the physical virus and not the species (75). Like all taxonomic classes, a species is
an abstract concept, and the species demarcation criteria can be drastically different among the
various established viral categories depending on the quantity of available information. A virus
name, on the other hand, represents a physical entity that can be manipulated and can be
further subdivided into strains, variants and isolates. An isolate is the most granular unit,
representing experimental material that corresponds to a specific instance of a given virus.
Furthermore, multiple isolates of the same variant may also have sequence differences due to
the presence of quasispecies, which are a mixture of related genotypes that may be present in
an environment of high mutation rate (175).
In 1991, the ICTV adopted the definition of a virus species as "a polythetic class of
viruses that constitutes a replicating lineage and occupies a particular ecological niche" (301).
Based on this definition, current guidelines state that herpesviruses can be classified as
separate species only if “(a) their nucleotide sequences differ in a readily assayable and
distinctive manner across the entire genome and (b) they occupy different ecological niches by
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virtue of their distinct epidemiology and pathogenesis or their distinct natural hosts” (75).
These guidelines are now somewhat obsolete due to the fact that modern classification of all
organisms, including viruses, is driven by phylogenetic analysis based on sequence comparison
data that allows for evolutionary classification (175). The ICTV Herpesvirales Study Group is
currently considering updates to the herpesvirus species definition and to the methods used to
assign viruses to discrete taxonomic groups in order to emphasize sequence-based phylogeny
and also to aid in classifying the rapidly growing number of herpesviruses that have been
detected only by polymerase chain reaction (PCR) (75).
Herpesviral Disease
Herpesviruses are a diverse group, encompassing over 100 different viruses infecting a
wide variety of hosts, both verterbrate and invertebrate. The structure of herpesviruses is
characteristic of the group, consisting of a linear double-stranded DNA genome that varies in
size from 125 kbp to 290 kbp and is enclosed in an icosahedral capsid composed of 12
pentavalent and 150 hexavalent capsomeres. The capsid is coated by a matrix of tegument
proteins, and is further surrounded by a host-derived lipid envelope that contains a variety of
membrane-associated viral proteins and glycoproteins (75). Herpesviruses can be further
distinguished by their ability to establish a reversible state termed latency where the viral
genome persists in the host cell without lytic gene expression or new virus production (97). In
contrast to viruses such as retroviruses that rely on viral genome integration into the host cell’s
chromosomes for their survival, herpesvirus DNA typically persists in the host cell nucleus as
circularized extrachromosomal structures called episomes which replicate using the rolling-
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circle mechanism, creating long concatemeric DNA strands that are eventually cleaved to
produce single genomes to be packaged into newly synthesized capsids. Chromosomal
integration of viral DNA has been documented in several herpesviruses but the majority of
these cases involve subgenomic DNA fragments, thereby precluding the possibility of
reactivation and infectious virus production from the integrated DNA. Currently, the only
herpesviruses known to exhibit integration of full-length viral DNA are Epstein-Barr virus (HHV4), HHV-6A/6B, and Marek’s disease virus (GaHV-2) (220).
Nine different herpesviruses have been routinely isolated from humans and implicated
in causing human disease. These human herpesviruses consist of herpes simplex virus 1 (HHV1), herpes simplex virus 2 (HHV-2), varicella-zoster virus (HHV-3), Epstein-Barr virus (HHV-4),
cytomegalovirus (HHV-5), Kaposi’s sarcoma-associated herpesvirus (HHV-8), and the cluster of
HHV-6A, HHV-6B and HHV-7 commonly referred to as roseola virus (23). In addition, the
monkey B virus (CeHV-1) and murine gammaherpesvirus-68 (MuHV-4) are occasionally
encountered in humans, particularly in laboratory workers handling infected animals, as
zoonoses from macaque monkeys and mice, respectively (138, 140).
Herpes simplex viruses (HHV-1 and HHV-2)
Herpes simplex viruses are transmitted by intimate contact between an individual who
is shedding virus and a susceptible host. After coming into contact with the mucosa or abraded
skin of the susceptible individual, the virus replicates in epithelial cells at the site of infection.
The primary infection often results in the presence of vesicular lesions at the site of inoculation,
but can also be asymptomatic. Eventually, the virus invades sensory nerve endings and is
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transported to neuronal ganglia where it establishes latency that persists for the life of the
host. Latent virus may reactivate and start replicating again at any time, possibly triggered by a
number of stimuli such as stress or exposure to ultraviolet light. Reactivation typically results in
transport of the virus along the peripheral sensory nerves back to the initial site of infection
where it replicates and causes transient outbreaks of vesicular lesions termed recurrent
infections (23, 97).
Herpes simplex virus 1 (HSV-1) most commonly infects the oropharyngeal area via
kissing or other intimate contact and establishes a latent infection in the host's trigeminal
ganglia (97). Oropharyngeal HSV-1 infection in adults typically manifests as cold sores on the
lips, also known as herpes simplex labialis. Gingivostomatitis is more common in children
younger than five years old, and is characterized by intraoral and pharyngeal lesions,
accompanied by fever, sore throat and pharyngeal edema. HSV-1 can also infect the eye,
leading to dendritic lesions on the cornea accompanied by conjunctivitis. Termed herpetic
keratitis, this is the most common infectious cause of blindness in the U.S. (23). Herpes simplex
virus 2 (HSV-2) is usually transmitted by genital contact during sexual activity and establishes
latency in the host's sacral ganglia (97). Genital HSV-2 infection is known as genital herpes, and
manifests as recurrent vesicular lesions usually involving the vulva, vagina and cervix in women,
and the penis in affected men (23). HSV-2 clinical manifestations are reportedly less severe in
individuals harboring preexisting antibodies to HSV-1 due to previous infection by HSV-1 (317).
Using data from the National Health and Nutrition Examination Survey (NHANES),
researchers looked at HSV-1 and HSV-2 seroprevalence in U.S. individuals between 14 and 49
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years of age during the period of 2005-2010, showing seroprevalence of 53.9% for HSV-1 and
15.7% for HSV-2. While HSV-2 seroprevalence stayed relatively constant, HSV-1 seroprevalence
exhibited a marked decline, particularly in individuals between 14 and 19 years of age whose
HSV-1 seroprevalence declined by over 29% from the period of 1976-1980 to the period of
2005-2010, potentially leaving this population at greater risk of genital HSV-2 infection when
they begin to engage in sexual activity due to the protective nature of HSV-1 antibodies (33).
European serological surveys covering the period between 1989 and 2000 revealed extensive
variation in the seroprevalence of HSV-1 and HSV-2 among different countries, although the
probability of infection increased with age in all cases. Age standardized HSV-1 seroprevalence
varied from a low of 52% in Finland to a high of 84% in Bulgaria. HSV-2 seroprevalence among
individuals older than 12 years of age ranged from a low of 4% in England and Wales to a high
of 24% in Bulgaria (248). Worldwide, an estimated 536 million people between the ages of 15
and 49 were living with HSV-2 infections in 2003, with an increased prevalence among women
and in developing regions (188).
Although less common, HSV-1 and HSV-2 infections can potentially manifest at any skin
site. Herpetic lesions on the fingers are known as herpetic whitlow, while individuals
participating in contact sports such as wrestling can develop disseminated cutaneous lesions in
a condition called herpes gladiatorum (23). Furthermore, HSV-1 is responsible for nearly 30% of
genital herpes infections in the U.S. In fact, the frequency of genital HSV-1 infections has been
increasing to the point that HSV-1 is the prevailing cause of genital herpes in select populations
of U.S. college students, accounting for up to 78% of all genital isolates, presumably due to the
growing ubiquity of oral sex practices (164, 261).
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The ability of HSV to invade and replicate in neurons allows the virus to establish latency
in neuronal ganglia, but it can also lead to a life-threatening condition called herpes simplex
encephalitis where the virus invades the central nervous system, leading to hemorrhagic
necrosis of the temporal lobes accompanied by fever, altered consciousness, and often death
(23). HSV encephalitis is the most common cause of sporadic fatal encephalitis in the U.S. with
an incidence of approximately 1 in 200,000 individuals per year and a mortality rate exceeding
70% in untreated individuals, with only 2.5% of patients able to retain normal neurologic
function (97). The causative agent of HSV encephalitis is HSV-1 in virtually all recorded cases
(309). However, HSV-2 is the predominant causative agent in a different CNS infection called
recurrent aseptic meningitis, also known as Mollaret's meningitis in older litarature (299).
Unlike cases of HSV encephalitis, cases of recurrent aseptic meningitis are usually benign and
self-limiting, resolving without clinical intervention (278).
Neonatal HSV infection is a potentially serious condition typically caused by vertical
transmission of HSV from the mother to the infant, occurring in up to 1 in 3000 deliveries in the
U.S. HSV-2 is the causative agent in approximately 70% of cases, commonly due to fetal contact
with the infected mother's genital secretions during delivery. Disease manifestation and
prognosis for neonatal HSV infection varies greatly, ranging from cutaneous lesions affecting
the skin, mouth and eyes (~0% mortality rate), to CNS involvement and encephalitis (~15%
mortality rate), and potentially to disseminated infection that involves multiple organ systems
(~60% mortality rate) (23).
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A greater risk for severe HSV infections is borne by individuals with impaired immune
function, which may occur due to malnutrition, immunosuppressive therapy for organ
transplantation, or underlying disease such as cancer or acquired immunodeficiency syndrome
(AIDS). HSV infection in these patients can manifest in a variety of ways, ranging from
disseminated cutaneous lesions to esophagitis, pneumonitis, colitis, or devastating systemic
infections. Recurrent HSV is also more common in immunocompromised patients, particularly
in individuals infected with human immunodeficiency virus (HIV) whose disease has progressed
to AIDS (97). The genital ulcerations caused by HSV have also been linked to an increased risk of
HIV transmission. In a 2002 meta-analysis, researchers estimated that among individuals
seropositive for HSV-2, 52% of sexually transmitted HIV infections are attributable to HSV-2
infection, suggesting that widespread treatment and management of HSV-2 could be an
effective strategy for HIV prevention (305).
HSV-1 is a ubiquitous, neurotropic virus, and these qualities also made it an obvious
pathogen to examine as a possible aetiological agent in the development of Alzheimer's
disease. Indeed, research has shown that infection with HSV-1 may predispose individuals to
develop Alzheimer's disease, although it is not the sole causative agent. HSV-1 is a particularly
strong risk factor for Alzheimer's disease when it is present in the central nervous system of
individuals possessing the type 4 allele of the apolipoprotein E gene (APOE-epsilon4) (84).
Further studies have found HSV-1 DNA in amyloid plaques within the brains of human
Alzheimer's disease patients, and showed that beta-amyloid tends to accumulate in HSV-1
infected mouse brains and cell cultures (315). Elevated HSV-1 antibody titers are also
significantly more frequent in Alzheimer's disease patients and are positively correlated with
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grey matter volumes (195). Others have suggested that HSV-1 infection may accelerate
neurodegeneration in Alzheimer's disease patients by an autoimmune response caused by viral
mimicry of key Alzheimer's disease-related proteins (44).
Varicella-zoster virus (HHV-3)
Varicella-zoster virus (VZV) is the alphaherpesvirus responsible for chickenpox and
shingles and is present in up to 95% of adult humans. VZV is highly contagious and can be
spread by contact with airborne droplets launched by coughing or sneezing in addition to
physical contact with rash secretions. Initial viral replication occurs in the oropharynx, followed
by spread to dorsal root and cranial nerve ganglia where the virus establishes latency. Primary
VZV infection in young children manifests as a disseminated vesicular rash that typically lasts
from three to five days and is commonly referred to as chickenpox (23, 115). Herpes zoster,
commonly known as shingles, is the recurrent form of VZV infection that occurs after
reactivation of latent virus. Herpes zoster is characterized by a painful vesicular rash localized to
an area of skin supplied by a single spinal nerve called a dermatome. The rash lasts two to four
weeks and is often accompanied by postherpetic neuralgia. Herpes zoster usually affects adults,
and occurs with greater frequency and severity in immunocompromised individuals (288).
Cytomegalovirus (HHV-5)
Cytomegalovirus (CMV) is a betaherpesvirus that preferentially replicates and persists in
human salivary glands, kidneys and peripheral blood leukocytes. CMV infection is typically
spread by saliva, urine, or breast milk and is symptomatic in only around 10% of cases (23).
Infected individuals may experience an infectious mononucleosis-like syndrome characterized
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by fever, pharyngitis and lymphadenopathy (31). Cytomegalovirus retinitis causes retinal
necrosis and primarily affects immunosuppressed individuals. CMV retinitis is the most
common cause of vision loss in AIDS patients (28). Congenital CMV infection can also occur,
particularly if a woman develops primary CMV infection during gestation. Approximately 1% of
live births in the U.S. are affected by congenital CMV (23).
Kaposi’s sarcoma-associated herpesvirus (HHV-8)
Kaposi's

sarcoma-associated

herpesvirus

(KSHV)

is

an

oncogenic

human

gammaherpesvirus that was discovered in 1994 by using a then-novel technique called
representational difference analysis to compare genomic DNA between Kaposi's sarcomaaffected tissue and unaffected tissue (47). KSHV is spread by close contact and infects a variety
of human cell types, including epithelial cells and lymphocytes, with a tendency to establish
latency in B lymphocytes (48). Clinical disease caused by KHSV such as the eponymous Kaposi's
sarcoma, a cutaneous tumor, typically occurs only in AIDS patients and other
immunocompromised individuals (9). KSHV can also cause a hyperproliferation of B
lymphocytes, leading to primary effusion lymphomas or multicentric Castleman's disease,
which is characterized by the development of lymphatic tumors at multiple sites, possibly due
to expression of virally encoded interleukin-6 (vIL-6) (10, 46, 48).
Human herpesvirus 7 (HHV-7)
Human herpesvirus 7 and its relatives human herpesvirus 6A and human herpesvirus 6B
are members of the betaherpesviral genus Roseolovirus and are closely associated with the
childhood disease roseola, which is characterized by fever and an accompanying facial rash
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(23). Human herpesvirus 6B is believed to be the primary causative agent of roseola, but
infection with HHV-7 may help reactivate latent HHV-6B, leading to roseola symptoms. HHV-7
infects and goes latent in CD4+ T lymphocytes and is ubiquitous in the population, particularly
among children (155). Over 95% of adults are seropositive for HHV-7, with over 75% of children
seropositive by age 6 (45, 58).
Human herpesvirus 6 (HHV-6A and HHV-6B)
Human herpesvirus 6A and human herpesvirus 6B share 95% sequence homology and
were only recognized as distinct species in 2012 (3, 125). HHV-6 is a betaherpesvirus relative of
cytomegalovirus and is highly prevalent in the population, infecting more than 90% of young
children. Clinical disease is primarily due to infection with HHV-6B, manifesting as the disease
exanthem subitum, also known as roseola infantum (11, 155). After primary infection, HHV-6
preferentially replicates in activated CD4+ T lymphocytes and persists in a latent state in
monocytes for the life of the host (98). Several studies have shown evidence of complete HHV-6
integration into host genomes, with estimates of integrated HHV-6 prevalence in the world
human population approaching 1%. HHV-6 is also able to integrate into the genomes of human
germ line cells and thus transmit itself from parent to offspring, leading to individuals carrying
chromosomally-intergrated HHV-6 in every nucleated cell in the body at chromosomal sites
identical to their parents. HHV-6 appears to preferentially incorporate itself into the telomeric
regions of human chromosomes, possibly with the aid of a recently identified protein (encoded
by the U94 gene) that shares partial homology with a parvovirus protein (REP68/78) implicated
in chromosomal integration. This genomic integration is thought to occur by chromosomal
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incorporation of the viral concatemeric DNA formed after rolling-circle replication of the
episome, rather than by incorporating the episomal DNA itself or the initial linear viral DNA
genome. Notably, HHV-6 is one of only three herpesviruses, along with Epstein-Barr virus and
Marek’s disease virus, that are known to undergo chromosomal integration of full-length viral
DNA (11, 220).
Epstein-Barr virus (HHV-4)
Epstein-Barr virus (EBV) is an oncogenic human gammaherpesvirus that preferentially
infects B lymphocytes and epithelial cells. EBV infection is associated with infectious
mononucleosis and with tumors such as Hodgkin’s lymphoma, Burkitt’s lymphoma and various
nasopharyngeal carcinomas. EBV chromosomal integration was primarily observed in activated
B lymphocytes, presumably due to increased permissiveness of replicating DNA to viral
integration, but integration in epithelial cells has also been documented. The chromosomal
regions where EBV preferentially integrates are typically associated with gene-poor
heterochromatin regions containing multiple repeats (141, 220).
Marek’s disease virus (GaHV-2)
Marek’s disease virus (MDV) is an oncogenic avian alphaherpesvirus that targets T
lymphocytes, leading to the development of lymphoid tumors in chickens and turkeys. Similarly
to HHV-6, MDV preferentially integrates into telomeric regions, presumably aided by an RNA
telomerase subunit that is thought to aid in genomic integration by forming telomeric
elongations at the ends of the MDV genome. Chromosomally integrated MDV has long been
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recognized in MDV-associated lymphoma cell lines, which suggests a possible correlation
between oncogenicity and chromosomal integration in MDV (78, 220, 263).
In addition to the possible link between chromosomal integration and tumor formation
in MDV, several integration sites during EBV infection have been shown to overlap with cellular
genes, including tumor suppressor genes and proto-oncogenes, raising the possibility of
tumorigenesis occurring through changes in cellular gene expression caused by viral genome
integration. HHV-6 chromosomal integration can also be of great physiological significance due
to the documented ubiquity of integration and vertical transmission of integrated HHV-6 in
humans. Individuals carrying integrated HHV-6 in every cell due to vertical transmission can be
misdiagnosed as having active HHV-6 infections due to the presence of HHV-6 DNA in blood
samples. Chromosomally-integrated HHV-6 could also be spread from such individuals via tissue
and cord blood transplants, possibly leading to complications. Furthermore, telomeric
integration of viral genomes as occurring in HHV-6 and MDV could destabilize the telomeres
and lead to defects such as telomere truncations, premature chromosomal senescence, or the
disruption of telomeric regions associated with various rare syndromes such as chromosome 9q
subtelomere deletion syndrome (220).
Prevention and Treatment of Herpes Simplex Virus Infection
Apart from obvious preventative measures such as maintaining good hygiene, avoiding
contact with infected individuals and using condoms or other barrier methods during sexual
activity, the existence and use of an effective vaccine would be the ideal method of preventing
HSV infection. Unfortunately, several strategies for HSV vaccine construction have been tested
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with limited success, including inactivated virus vaccines, genetically attenuated live virus
vaccines, recombinant subunit vaccines (typically expressing gB or gD), genetic immunization
using DNA plasmids expressing HSV proteins, and the use of replicating nonpathogenic vectors
to express HSV antigens. More recently, encouraging results were published regarding the use
of epitope-based lipopeptide vaccines (72). Several vaccine candidates are currently undergoing
clinical testing. ACAM529 is a vaccine under development by Sanofi Pasteur that is undergoing
phase I clinical trials. ACAM529 is a replication-defective vaccine constructed by deleting the
UL5 and UL29 genes of HSV-2, and has been shown to induce a strong immune and protective
response in vivo (225). ImmunoVEX-HSV2, developed by BioVex, is a live-attenuated vaccine
constructed by deleting a number of HSV-2 genes responsible for evading the host's immune
response, specifically the genes responsible for blocking interferon (IFN) responses and for
downregulating major histocompatibility complex (MHC) presentation and dendritic cell
activation. ImmunoVEX-HSV2 showed promising results in phase I clinical trials, but its current
fate is uncertain following Amgen's acquisition of BioVex in 2011 (60, 152, 196).
Acyclovir is the current mainstay of therapeutic anti-HSV treatments, and is particularly
effective against HSV-1, HSV-2, VZV and EBV (158). Developed in the late 1970’s, acyclovir
quickly became a blockbuster drug for Burroughs Wellcome Co., largely due to effective
marketing practices and broader public awareness of HSV infection (70, 164, 238). Acyclovir is a
nucleoside analogue that mimics deoxyguanosine. In infected cells, acyclovir is selectively
phosphorylated by viral thymidine kinase at significantly higher efficiency than by mammalian
thymidine kinase, forming acyclovir monophosphate which is subsequently converted to
acyclovir diphosphate and acyclovir triphosphate by various cellular enzymes. Acyclovir
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triphosphate inhibits HSV DNA polymerase by acting as a substrate and being incorporated into
the growing DNA chain instead of deoxyguanosine triphosphate (dGTP), terminating strand
elongation and trapping the DNA polymerase when it is unable to add a new deoxynucleoside
triphosphate due to lack of a 3’ hydroxyl moiety on acyclovir. Penciclovir and ganciclovir
(particularly effective against CMV) have a mode of action highly analogous to that of acyclovir,
except they are not obligate chain terminators of DNA synthesis due to the presence of a 3’
hydroxyl-like moiety. Valacyclovir, Famciclovir and Valganciclovir are prodrugs of acyclovir,
penciclovir and ganciclovir, respectively, which have been structurally modified to improve oral
bioavailability. These drugs have largely replaced older nucleoside analogues such as
vidarabine, idoxuridine and trifluridine due to greater selectivity and lower patient toxicity (97).
Other common drugs that are active against a broad range of herpes viruses and act by
preventing transcription by the viral DNA polymerase are cidofovir and foscarnet. Cidofovir is a
deoxynucleotide analogue of deoxycytidine monophosphate (dCMP). Inside infected cells,
cidofovir is metabolized by cellular enzymes to a diphosphorylated form that inhibits viral DNA
polymerase by incorporating into DNA, slowing elongation and eventually resulting in chain
termination when two cidofovir residues are incorporated in a row (97, 173). Foscarnet is a
non-nucleoside inhibitor of viral DNA polymerase. It is a pyrophosphate analogue that inhibits
viral DNA polymerase directly by competitively inhibiting the release of normal pyrophosphate
that is required for the DNA polymerase to continue strand elongation. Foscarnet is
nephrotoxic and typically used as a last line of defense against viruses exhibiting resistance to
the abovementioned nucleoside analogues (97). Fomivirsen is a relatively new drug targeted at
treating CMV patients using a different mode of action. It is an antisense drug consisting of a
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synthetic 21-member phosphorothioate oligonucleotide that binds to complementary
messenger RNA of a major immediate early region protein of CMV, thus blocking translation of
the targeted messenger RNA (111). Another drug called docosanol has proven to be effective
against both HSV-1 and HSV-2 when applied topically. It consists of a 22-carbon saturated
alcohol that is believed to work by inhibiting fusion of the HSV viral envelope with the host cell
plasma membrane, preventing viral entry into target cells (157).
Numerous experimental drugs such as viral helicase-primase inhibitors have shown
great promise as anti-HSV drugs in a number of studies (166). Imiquimod, a toll-like receptor
agonist that causes localized immune system upregulation when applied topically, has
documented anti-HSV activity (133). Withaferin A, a compound derived from the plant
Withania somnifera is also reported to have anti-HSV activity via inhibition of viral DNA
polymerase (120). Less conventionally, treatment with narrowband laser light at 1072-nm has
been shown to reduce the healing time of HSV-1 cold sores (126). Furthermore, extracts from
the plants Aloe vera, Swertia chirata and Melissa officinalis, as well as a vast amount of other
plants or plant-derived compounds used in traditional medicine have shown promising anti-HSV
activity in preliminary studies (162, 200, 302, 304). Numerous alternative medicines and dietary
supplements have also been advocated for the treatment or prevention of HSV-associated
disease, but the antiviral activity of most of these compounds (such as zinc, L-lysine, etc.) is yet
to be established by rigorous peer-reviewed studies (249).
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Structure of the Herpes Virion
A mature HSV-1 virion is composed of four distinct elements. The core consists of the
~152 kb linear double-stranded DNA genome arranged as a toroidal structure and enclosed
within a T-16 symmetrical icosahedral capsid composed of 162 capsomeres. The capsid is
coated with a layer of viral proteins called the tegument, and is in turn enclosed by a lipid
envelope originating from host cellular membranes that is enriched with viral glycoproteins and
other membrane-associated proteins. A variety of interactions between the viral proteins that
make up the capsid, tegument and envelope are responsible for shepherding the viral particle
through the complex assembly process within the host cell, and for maintaining the structural
integrity of mature virions. Further interactions between viral envelope proteins and receptors
on the cell membranes of host cells are responsible for fusion of the viral envelope with the
targeted cell’s plasma membrane, thus perpetuating the HSV-1 life cycle by enabling entry of
virus particles into uninfected cells (97, 214).
HSV-1 genome
The HSV-1 genome is comprised of two unique regions designated as the unique long
(UL) and unique short (US) that are flanked by repeating sequences designated as internal
repeats (IR) or terminal repeats (TR) based on their relative position within the HSV-1 genome
(Figure 2.1). The repeats surrounding the unique long segment are approximately 9000 bp in
length, while the repeats flanking the unique short segment are shorter at approximately 60007400 bp. The entire HSV-1 genome is around 152 kbp in length with the exact number varying
slightly between different HSV-1 isolates, and is characterized by a relatively high G+C content
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of ~68%, a trait shared with the closely related HSV-2. By comparison, the genomic G+C content
of varicella-zoster virus, a fellow alphaherpesvirus, is a mere ~46% (19).

Figure 2.1: Arrangement of the HSV-1 genome. UL: unique long region, US: unique short region,
TR: terminal repeats, IR: internal repeats.

The number of open reading frames (ORFs) within the HSV-1 genome is approximately
90, and most ORFs have a polyadenylation site at the 3' end and are flanked at the 5' end by a
transcription initiation site with an upstream TATA box and a promoter even further upstream
(Figure 2.2). Over 80% of HSV genes do not undergo splicing and many genes share
polyadenylation sites. The exact number of encoded proteins is difficult to determine because
not all RNAs are ultimately translated to proteins. Other complications include the presence of
antisense ORFs, the occasional lack of TATA boxes, and the disregard of predicted transcription
termination sites for several genes late in infection resulting in oversized run-on transcripts (74,
97).
Generally speaking, the genes encoded in the unique short segment tend to be less
conserved among other alphaherpesviruses than the genes encoded in the unique long
segment. Genes that encode enzymes responsible for DNA replication and metabolism show
the highest relative conservation and include UL5, UL15, UL30 and UL40. The repeating regions
that surround these segments also regulate the expression of several genes, but the repeats are
less conserved than the UL and US segments themselves. The most conserved part of the long
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repeated region flanking the UL segment encodes the ICP0 gene, while the most conserved
area of the short repeated region flanking the US segment is the ICP4 gene, both of which are
immediate-early genes that regulate viral and host cell gene expression and are important for
reactivation of latent HSV infection (19, 90, 185).
A number of genes also exist that are unique to the two simplexviruses HSV-1 and HSV-2
and are not found in other alphaherpesviruses. A notable example is γ1 34.5, which encodes a
263 aa protein that is a critical determinant of HSV neurovirulence and has been implicated in
autophagy inhibition and in the dephosphorylation of the α subunit of eukaryotic translation
initiation factor 2 (eIF-2α) in order to prevent shutoff of viral protein synthesis by the action of
activated double-stranded RNA-dependent protein kinase (PKR), which are abilities that γ1 34.5
shares to some extent with the similarly simplexvirus-restricted gene product encoded by US11
(128, 191). Another example is the latency associated transcript (LAT), which accumulates in
the nuclei of sensory neurons that harbor latent HSV infections. Other genes unique to
simplexviruses include the US4 gene encoding glycoprotein G (gG) which is ~1500 bp smaller in
HSV-1 compared to HSV-2 and has been used in serologic assays to differentiate between the
two viruses, the US5 gene encoding glycoprotein J (gJ) which is involved in preventing cytotoxic
T-lymphocyte-induced apoptosis of infected cells, the US8.5 gene which encodes a
phosphorylated protein that tends to localize in the nucleoli of infected cells, and the US12
gene encoding ICP47 which interferes with MHC-I mediated antigen presentation in infected
cells (19, 112, 113, 148, 179, 323).
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Figure 2.2: Genetic map of HSV-1, showing gene arrangement and orientation. Plus strand
genes are colored blue and represented by arrows pointing to the right, minus strand genes are
colored teal and represented by arrows pointing to the left, intergenic regions are colored grey,
transfer RNA is colored red, ribosomal RNA is colored yellow, and repeats are colored black.
Available from the Los Alamos National Laboratory: Human Oral Genomic and Metagenomic
Resource at www.oralgen.org.
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HSV-encoded proteins often perform multiple functions and exhibit a complex web of
protein-protein interactions, making them difficult to characterize. While a number of proteins
have been labeled in the literature as "nonessential" for viral replication in vitro, this label only
applies within the narrow context of a particular study, typically performed on a single cell line.
Many of these "nonessential" proteins are essential in vivo and play important roles in infecting
a variety of host cell types, neurotropism, latency, and evasion of host immune responses (237).
Furthermore, most studies are performed using highly passaged viral strains that have adapted
to life in laboratory tissue culture. Low-passage clinical isolates typically have more aggressive
and neurovirulent phenotypes than laboratory strains and these differences are reflected in
their genomes, with numerous amino acid differences detected using high-throughput
sequencing (193, 293).
HSV-1 capsid
HSV-1 has a highly uniform and symmetric icosahedral capsid 1250 Å in diameter with a
total molecular mass of the capsid shell of approximately 200 MDa. Capsids are composed of
five structural proteins: the 149 kD major capsid protein VP5 (UL19), the 12 kD protein VP26
(UL35), the 34 kD protein VP23 (UL18), the 50 kD protein VP19C (UL38), and the portal protein
pUL6. Two additional proteins, pUL25 and pUL17, make up the C-capsid specific components in
mature DNA-filled capsids (Table 2.2) (35, 324).
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Table 2.2: Protein composition of C-capsids. Adapted with permission from [Current Opinion in
Virology 1(2): 142-149, Herpesvirus capsid assembly: insights from structural analysis]. Copyright
(2011) Elsevier.
Gene
UL19
UL38
UL18
UL35
UL6
UL17
UL25

Protein
VP5
VP19C
VP23
VP26
pUL6
pUL17
pUL25

Amino acids
1374
465
318
112
676
703
546

Copies/capsid
955
320
640
900
12
60
60

Location in capsid
Hexons; pentons
Triplexes
Triplexes
Tip of hexon
Unique vertex
Near vertices
Near vertices

Capsids have 162 capsomeres subdivided into 150 hexons, 12 pentons and 320 triplexes
that lie on a T-16 symmetrical icosahedral frame (Figure 2.3). Each penton has 5 copies of VP5,
while each hexon has 6 copies of VP5 and 6 copies of VP26 (324). The hexons form the edges
and faces of the icosahedral capsid (276). The triplexes serve as links between adjacent
capsomeres and are composed of two copies of VP23 and one copy of VP19C arranged as a
heterotrimer (324). Pentons are located at capsid vertices and are in contact with the
surrounding tegument layer in mature virions, specifically interacting with the tegument
protein UL36 which forms filamentous structures extending from the pentons (43, 231).
Pentons are found on 11 of the 12 capsid vertices, with the 12th vertex occupied by a portal
structure similar to ones found in tailed bacteriophages (276). This portal vertex is a hollow
cylindrical structure 9 nm in length and 16.5 nm in outside diameter with a ~3 nm diameter
axial channel and is composed of 12 copies of pUL6, exhibiting 12-fold rotational symmetry
(35). The portal presumably provides the route for the release and packaging of viral DNA, and
therefore may also be important for successful docking of the viral capsid at nuclear pore
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complexes (NPCs), which are responsible for mediating transport between the cytosol and the
nucleus (218). The distal end of the portal vertex has been shown to extend through the
tegument layer and possibly lie in contact with the envelope, suggesting that the location of the
portal vertex may have an influence on the spatial arrangement of viral tegument and envelope
that surrounds the capsid (276).

Figure 2.3: Virion and capsid structure. Adapted with permission from [Current Opinion in
Virology 1(2): 142-149, Herpesvirus capsid assembly: insights from structural analysis]. Copyright
(2011) Elsevier.

Three structurally similar but morphologically distinct types of capsids exist in infected
cells. The three capsid types differ in the contents of the capsid cavity: A-capsids are the
abortive result of failed DNA packaging and are empty, B-capsids contain scaffolding protein
but no viral DNA and are likely also dead end byproducts of the capsid assembly process, while
C-capsids contain viral DNA and no scaffolding protein and are the capsids ultimately found in
mature infectious virions (137, 184). Another distinguishing feature of C-capsids is the presence
of rod-shaped structures called C-capsid specific components (CCSCs) near capsid vertices that
have been shown to interface with the tegument by binding to the UL36 protein. CCSCs are
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attached to viral capsids in the nuclei of infected cells upon completion of DNA packaging, and
each CCSC is made up of one copy of pUL25 and one copy of pUL17. Five CCSCs extend radially
outward from each capsid vertex, presumably helping to brace neighboring pentons against
internal capsid pressure in DNA-loaded C-capsids (Figure 2.4) (35). This pressure occurs because
the confined HSV-1 genome is subjected to bending stress in addition to repulsive hydration
and electrostatic forces. The internal pressure of HSV-1 capsids is approximately 18
atmospheres, which is roughly comparable to the ~25 atmosphere internal pressure in
bacteriophage λ. This high internal capsid pressure likely contributes to successful ejection of
the HSV genome into the nucleus upon docking with the nuclear pore complex (25).

Figure 2.4: Location of CCSCs on the capsid. CCSCs are colored green and visualized on the entire
capsid at left and magnified at right. Adapted with permission from [Current Opinion in Virology
1(2): 142-149, Herpesvirus capsid assembly: insights from structural analysis]. Copyright (2011)
Elsevier.
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HSV-1 tegument
The tegument is a proteinaceous matrix that surrounds the capsid and links the capsid
to the viral envelope. The tegument plays a variety of roles in addition to being a structural
component of the virion. Tegument components are involved in regulation of gene expression,
immune modulation, capsid transport within the cell, and both primary and secondary
envelopment steps in the viral life cycle (97, 160).
The tegument of HSV-1 is currently believed to consist of 24 proteins, including pUL7,
pUL11, pUL13, pUL14, pUL16, pUL21, pUL23, pUL36 (VP1/2), pUL37, pUL41, pUL46 (VP11/12),
pUL47 (VP13/14), pUL48 (VP16), pUL49 (VP22), pUL50, pUL51, pUL55, pUS2, pUS3, pUS10,
pUS11, ICP34.5, ICP0 and ICP4 (Table 2.3). The most abundant of these proteins are pUL46
(VP11/12), pUL47 (VP13/14), pUL48 (VP16) and pUL49 (VP22). These four proteins are present
at more than 1000 copies per virion and together make up the majority of tegument volume
(160). By contrast, the tegument proteins pUL36 and pUL37 are present in ~120 copies per
virion (232). The only tegument proteins shown to be essential for growth in cell culture are
pUL36 (VP1/2), pUL37, pUL48 (VP16) and ICP4 (160). In fact, a mutant PRV lacking all of the
hyper-abundant tegument proteins pUL46, pUL47, pUL48 and pUL49 is able to survive in vitro,
suggesting a certain amount of redundancy in the structural and functional contributions of
most tegument proteins (107).
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Table 2.3: Properties of HSV-1 tegument proteins. Adapted with permission from [Virus Research
145(2): 173-186, Functional roles of the tegument proteins of herpes simplex virus type 1].
Copyright (2009) Elsevier.
Tegument
protein
pUL7
pUL11
pUL13

Predicted Essential (E) or
Mwt (kDa) nonessential (NE)
in cell culture
33.1
NE
10.5
NE
57.2
NE

pUL14

23.9

NE

pUL16
pUL21

40.4
57.6

NE
NE

pUL23
pUL36
(VP1/2)
pUL37

41.0
335.9

NE
E

120.6

E

pUL41

54.9

NE

pUL46
(VP11/12)
pUL47
(VP13/14)
pUL48
(VP16)
pUL49
(VP22)
pUL50
pUL51
pUL55
pUS2
pUS3

78.2

NE

73.8

NE

54.3

E

32.3

NE

39.1
25.5
20.5
32.5
52.8

NE
NE
NE
NE
NE

pUS10
pUS11
ICP34.5

34.1
17.8
26.2

NE
NE
NE

ICP0
ICP4

78.5
132.8

NE
E

Functions

Regulates mitochondrial function
Secondary envelopment
Protein kinase, tegument dissociation, regulates
apoptosis and pUS3, inhibits IFN response
Nuclear import, regulates apoptosis, nuclear
targeting of capsids
Secondary envelopment
Secondary envelopment, regulates microtubule
assembly
Thymidine kinase, viral DNA replication
Capsid transport, secondary envelopment,
release of viral DNA, deubiquitinating activity
Secondary envelopment, regulates viral
transcription
Regulates host/viral translation and immune
response
Secondary envelopment, regulates pUL48dependent transcription
Secondary envelopment, regulates pUL48dependent transcription
Secondary envelopment, regulates viral
transcription
Secondary envelopment, regulates microtubule
assembly
dUTPase, viral DNA replication
Unknown
Unknown
Unknown
Protein kinase, primary deenvelopment,
tegument dissociation, regulates actin assembly
Unknown
Regulates host translation, capsid transport
Regulates host translation, viral DNA replication
and immune response
Regulates viral transcription
Regulates viral transcription
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Mounting evidence suggests that the tegument is not an amorphous mass as described
in older literature. Cryo-electron tomography of mature HSV-1 virions revealed the tegument to
be asymmetrical with a tendency to congregate on one side of the capsid, forming a cap-like
structure and resulting in the capsid being pushed off-center and closer to the envelope on the
side opposite the bulk of the tegument "cap" (Figure 2.5B). The tegument appears as a dense
particulate layer interspersed with filaments ~7 nm in width and up to ~40 nm in length
consistent with actin (122). Actin filaments have been detected in several viruses that undergo
membrane budding during egress, including in the alphaherpesvirus pseudorabies virus (PRV),
suggesting the same may be true in HSV-1 (122, 284, 314). The tegument contains ~40% of the
total protein mass of the virion and occupies the majority of internal space within the envelope,
accounting for two-thirds of the volume with the capsid making up the remaining one-third
(122, 184).
Intriguingly, tegument in cell-associated virus is uniformly distributed around the capsid.
The asymmetric distribution of the tegument appears to be the end result of a maturation
process that occurs over the course of approximately 40 hours. During this process, the
tegument becomes more asymmetric and gains increasing resistance to removal by Triton X100. This suggests that the tegument becomes more tightly associated with the capsid in
mature virions, possibly as an adaptation to preserve structural integrity and infectivity during
prolonged exposure to the extracellular environment (232).
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Figure 2.5: Three-dimensional rendering of an HSV-1 virion from cryo-electron tomography. (A)
External view, showing distribution of glycoprotein spikes colored in yellow protruding from the
membrane colored in blue. (B) Cutaway view, showing the capsid in light blue and the tegument in
orange. pp: proximal pole, dp: distal pole, scale bar: 100 nm. Adapted with permission from
[Science 302(5649): 1396-1398, Three-dimensional structure of herpes simplex virus from cryoelectron tomography]. Copyright (2003) American Association for the Advancement of Science.

Most tegument is accumulated on the capsid in the cytoplasm, particularly during
secondary envelopment when partly tegumented capsids bud into tegument-coated regions of
trans-Golgi derived vesicles enriched with viral membrane proteins (97, 232). Interactions
between tegument proteins and membrane-associated proteins are crucial for secondary
envelopment. However, interactions between the capsid and the tegument are not strictly
required for the successful assembly and structural integrity of the tegument layer or for
subsequent envelopment in the cytoplasm, as evidenced by the existence of "light particles" or
L-particles which are composed of enveloped tegument proteins without a capsid (205, 303).
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Tegument proteins can be categorized into the inner tegument proteins consisting of
pUS3, pUL36 and pUL37 which remain associated with the capsid after entry into the host cell,
and the outer tegument proteins which detach from the capsid after entry in order to prime the
cell for infection (216, 231). The inner tegument protein pUL36 binds directly to the capsid via
documented interactions with the capsid proteins VP5 and pUL25 and serves as the bridge
between the capsid and the outer tegument (37, 61). In turn, it has been proposed that the
outer tegument protein pUL48 functions as an adaptor that links the capsid-associated inner
tegument to the membrane-associated outer tegument (216). Yeast two-hybrid assays have
shown that pUL48 physically interacts with pUL36 and with the outer tegument proteins pUL41,
pUL46, pUL47 and pUL49 (232, 303). Moreover, virions lacking pUL48 are dispersed throughout
the cytoplasm and are unable to localize to TGN membranes or undergo secondary
envelopment (221). Interactions between pUL48 and the capsid proteins pUL19 (VP5), pUL38
(VP19C) and pUL35 (VP26) have also been detected, but these interactions are not believed to
be biologically relevant because pUL48 is unable to bind to capsids of mutant HSV-1 lacking
pUL36 (171). In addition to directly binding to the outer tegument, pUL36 indirectly interacts
with the viral envelope via its binding partner pUL37 which has been shown to directly interact
with the envelope proteins gK and pUL20 (145, 219). The presence of pUL36 and pUL37 is
critical for the successful construction and organization of the tegument as well as for the
cytoplasmic envelopment and maturation of HSV-1. The importance of pUL36 and pUL37 is
further reinforced by their status as the most highly conserved tegument proteins across all
herpesvirus subfamilies (215).
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UL36 protein. Weighing in at 335.9 kD, the 3164 aa protein pUL36 (VP1/2) is nearly
three times more massive than any other tegument protein (160). pUL36 is phosphorylated on
serine residues and is expressed late during infection, only becoming detectable approximately
8 hours post infection (207, 208). pUL36 is present at 100-150 copies per virion and is an
important structural component of the tegument (231). Highly conserved among all
herpesviruses, pUL36 plays important roles both at the start of infection and during
tegumentation and secondary envelopment in the cytoplasm (81, 208, 260).
pUL36 is recruited to cytoplasmic capsids that later colocalize with TGN membranes and
membrane proteins at sites of secondary envelopment (273). Although other tegument
proteins such as pUL16, pUL46 (VP11/12) and pUL48 (VP16) have been shown to reversibly bind
to capsids, pUL36 is thought to be the key link between the capsid and the tegument (171, 210,
216, 226). pUL36 forms filamentous structures attached to capsid pentons that extend outward
through the tegument, possibly serving as a flexible scaffold for the direct or indirect binding of
other tegument proteins (43, 231). Attachment of pUL36 to the capsid is accomplished by
binding to the major capsid protein VP5 and by a noncovalent interaction between the carboxyl
terminus of pUL36 and the C-capsid specific component protein pUL25 (37, 61, 232). pUL36
contains two binding sites for the capsid protein pUL25, one located in the region
encompassing aa 2430-2893, and the other located in the C-terminal 167 aa portion. The Cterminal 167 residues of pUL36 are needed to retain pUL36 on incoming capsids during entry,
but not required for successful targeting of cytoplasmic capsids to sites of viral assembly at TGN
membranes as determined by colocalization experiments. However, HSV-1 with a C-terminal
truncation of 735 aa from pUL36 encompassing both putative pUL25 binding sites was unable
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to recruit pUL36 to capsids in the cytoplasm and did not colocalize with membrane proteins,
suggesting that the pUL25 binding site spanning residues 2430-2893 is sufficient for
recruitment of pUL36 onto capsids in the cytoplasm and for targeting capsids to glycoproteinenriched cytoplasmic TGN membranes as determined by immunofluorescence (273).
Characterization of an HSV-1 mutant virus lacking the entire pUL36 protein did not show any
significant defects in primary envelopment, but secondary envelopment was severely impaired,
with numerous unenveloped DNA-filled capsids accumulating in the cytoplasm (81). Further
experiments demonstrated that the presence of pUL36 is crucial for successful virus assembly
and localization to sites of cytoplasmic envelopment both in vitro and in vivo (160, 273).
pUL36 forms the inner tegument layer along with its binding partner pUL37 (303). The
interaction between pUL36 and pUL37 has been confirmed in PRV in addition to HSV-1, and is
mediated by residues F593 and E596 of pUL36 (168, 219). The outer tegument is thought to be
connected to the inner tegument primarily via interactions between the amino terminus of
pUL36 and pUL48 (216, 273). During entry, pUL36 releases the outer tegument from the
incoming capsid while remaining tightly bound to the capsid along with the other inner
tegument proteins pUL37 and pUS3 (231, 273). In turn, pUL48 has been shown to interact with
a variety of other tegument proteins using yeast two-hybrid assays, including pUL41, pUL46,
pUL47 and pUL49 (232, 303). The presence of pUL36 is required for the successful
incorporation of pUL37 and pUL48 onto capsids (171). Both pUL36 and pUL37 are also present
in L-particles, presumably due to interactions with each other and with outer tegument
proteins such as pUL48, showing that interactions between pUL36 and the capsid are not
required for the incorporation of pUL36 into tegument (292).
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The presence of pUL36 and pUL37 is critical for the assembly and release of infectious
virions. Viruses unable to express either one of these genes cannot form enveloped virions due
to the block in cytoplasmic envelopment and accumulate unenveloped capsids in the
cytoplasm. In order to study the role these proteins play during the earliest stages of infection,
researchers fused adjacent cells to form syncytia and allow direct capsid transfer to uninfected
cells, entirely bypassing the typical entry steps at the plasma membrane. Mutant virus lacking
pUL37 was able to infect other nuclei within the syncytia while virus lacking pUL36 was not,
thus showing that pUL36 plays an important role at the start of infection in addition to its role
in virion assembly while pUL37 is not required for initiation of infection (260). Impairment of
pUL36 function during infection by the use of a temperature-sensitive pUL36 mutant (tsB7)
results in the abrogation of DNA release from capsids and the accumulation of capsids at
nuclear pores (24). After the capsid docks to the nuclear pore complex, cleavage of pUL36 is
necessary for the successful release of viral DNA into the host cell nucleus, suggesting that
pUL36 may serve to plug the portal vertex after viral DNA is packaged into the capsid (153).
The amino terminal region of pUL36 contains a functional nuclear localization signal and
pUL36 has been detected in both the nucleus and cytoplasm of infected cells (1, 208). However,
analysis of purified nuclear capsids of HSV-1 has yielded mixed results, with one study detecting
and one failing to detect any associated pUL36 (38, 297). Additional experiments with PRV
virions isolated from the perinuclear space following primary envelopment failed to recognize
any bound pUL36 using immunogold analysis (168). Nuclear pUL36 may be involved in cleavage
and packaging of viral DNA and in late gene expression, as determined by experiments with a
temperature-sensitive pUL36 mutant virus (2, 24, 51).
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The amino terminus of pUL36 also encodes a 420 aa ubiquitin-specific cysteine protease
with the active site located at Cys65. This domain may be involved in the deubiquitination of
viral proteins to avoid proteasomal degradation, and possibly in cytoplasmic envelopment, due
to ubiquitination being implicated in membrane trafficking and multivesicular body formation
(156). The ubiquitin-specific protease domain of pUL36 has also been shown to function in
evasion of interferon-mediated innate immunity by deubiquitinating TRAF3, resulting in
downregulation of beta interferon (IFN-β) production (306). The deuibiquitinating activity of
pUL36 is highly conserved, as evidenced by the presence of equivalent deuibiquitinating activity
in pUL36 homologues encoded by the betaherpesvirus murine cytomegalovirus (MCMV) and
the gammaherpesvirus Epstein-Barr virus (EBV), both of which retain the conserved catalytic
cystein residue at the active site despite having less than 15% sequence identity with HSV-1.
Portions of pUL36 corresponding to N-terminal 1-285 aa of MCMV and 1-205 aa of EBV also
displayed deubiquitinating activity (274). Abolishing the deubiquitinating activity of pUL36 by
mutating the catalytic cysteine residue at the active site to a serine in PRV did not abrogate
binding to pUL37 but resulted in ~25 fold viral titer reduction and ~40% plaque size reduction
compared to wild type virus, with increased accumulation of unenveloped capsids in the
cytoplasm and reduced neurovirulence in mice (30). Another study has provided evidence for
autocatalytic activity in the deubiquitinating domain of pUL36, suggesting that it can act on
itself to influence the stability of the pUL36 protein. (29).
Viral capsids depend on the action of microtubule motors for both retrograde and
anterograde transport within the host cell. Retrograde transport toward the cell body is
mediated by the inbound motor dynein and its cofactor dynactin, while anterograde transport
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toward the cell periphery is mediated by the outbound motor kinesin. Using differentially
tegumented capsids in a mammalian cell-free system designed to replicate an intact
microtubule network with the associated motors, researchers have shown that capsids with
exposed inner tegument proteins such as pUS3, pUL36 and pUL37 were able to recruit dynein
and its cofactor dynactin, as well as both kinesin-1 and kinesin-2. In contrast, capsids lacking
either just the inner tegument or all tegument were not able to recruit microtubule motors
(253). Another study using a microchamber system to reconstitute viral trafficking along
microtubules in vitro showed that pUL36 is required for successful anterograde capsid transport
along microtubules (279).
UL37 protein. The UL37 gene of HSV-1 encodes a large 1123 aa (120.6 kD) highly
conserved tegument protein that is essential for viral growth in cell culture and is crucial for
viral assembly and secondary envelopment in the cytoplasm (37, 160, 215). The UL37 protein is
expressed late in the infection cycle and is stably phosphorylated soon after translation of the
UL37 gene. Phosphorylation of pUL37 is likely performed by a cellular kinase and is not
dependent on the presence of any known HSV-1 binding partner because pUL37 expressed by a
recombinant vaccinia virus is also phosphorylated (5). The quantity of pUL37 loaded onto
mature virions is tightly regulated, since overexpression of pUL37 does not increase the amount
of pUL37 detected in virions (203).
The UL37 protein encodes a variety of functional domains (Figure 2.6). Coimmunoprecipitation experiments revealed that pUL37 domains spanning residues 1-300 and
568-1123 are involved in self-association in the absence of its binding partner pUL36 (37). The
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amino terminus contains an alanine-rich region (ARR) spanning residues 44-80, a leucine zipper
motif covering residues 203-224 and a leucine-rich nuclear export signal (NES) encompassing
residues 263-272 (37, 307). The carboxyl terminus contains a domain spanning residues 10991104 involved in binding TNF receptor-associated factor 6 (TRAF6) to activate NF-kappaB
signaling (37, 187). The C-terminal 578-899 aa of pUL37 can interact with a spectraplakin
protein called dystonin/BPAG1 known as a cytoskeletal cross-linker that is involved in
microtubule stabilization and transport. Viral replication and cytoplasmic capsid mobility during
egress from infected cells is impaired in dystonin-depleted cells, suggesting that pUL37 may
play a role in capsid trafficking along microtubules (246). The C-terminus of pUL37 is also
responsible for binding to pUL36 (37, 161). Scanning alanine mutagenesis of pUL37 revealed
that residue D631 of pUL37 mediates binding to pUL36. Knocking out this residue resulted in
significantly decreased ability of the virus to replicate, with mutant viral titers approximately 2
logs lower than those of wild type virus (161). Trans-complementation experiments using a
plasmid encoding the C-terminal portion of pUL37 spanning residues 568-1123 that includes
the putative pUL36 interaction site showed that the plasmid is sufficient to partially rescue a
virus unable to express pUL37 (37).

Figure 2.6: Functional domains of the UL37 protein.
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The function of the central portion of pUL37 spanning aa 301-567 is not well defined. A
mutant HSV-1 with a 12 aa protein C epitope tag inserted in-frame after residue 480 of pUL37
exhibited a severe defect in cytoplasmic envelopment, but was partially complemented for
replication and spread when grown on cells expressing pUL20. Two-way interactions between
pUL37 and the membrane proteins pUL20 and gK were confirmed using coimmunoprecipitation and proximity ligation assays, thus providing the first direct link between
the inner tegument and the envelope, although the exact locations of the relevant binding sites
remain unknown (145). pUL20 and gK are known to be among the most important mediators of
secondary envelopment, and their interactions with pUL37 may serve to facilitate the process
of cytoplasmic virion envelopment (52, 145).
pUL37 forms a complex with pUL36, and this interaction is conserved across all three
subfamilies of the Herpesviridae. Interactions between proteins homologous to pUL36 and
pUL37 have been documented in the alphaherpesviruses HSV-1, PRV and VZV, in the
betaherpesvirus HCMV and in the gammaherpesvirus KSHV (26, 168, 181, 219, 268, 300, 303).
The presence of pUL36 is necessary for incorporation of pUL37 onto capsids (171). pUL37 is
likely added to capsids after pUL36, since pUL36 is still detected on both HSV-1 and PRV capsids
in mutants lacking pUL37 (80, 170). Along with pUL36, pUL37 may be involved in the
organization of tegument structure. pUL37 attaches to capsid-bound pUL36 at the vertices,
together forming thin flexible strands ranging from 15 to 70 nm in length that extend
throughout the tegument, possibly providing a scaffold for the rest of the tegument (231).
Deletion of either pUL36 or pUL37 prevents the acquisition of appreciable amounts of
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tegument in the cytoplasm and blocks cytoplasmic envelopment in HSV-1, resulting in
cytoplasmic accumulation of unenveloped capsids (80, 81, 260).
The role of the interaction between pUL36 and pUL37 in secondary envelopment is still
unclear. A PRV mutant virus engineered to remove the pUL36 domain responsible for
interacting with pUL37 exhibits impaired cytoplasmic envelopment (109). The lack of a
complete block in secondary envelopment after disruption of pUL36-pUL37 binding may be due
to decreased importance of pUL37 for secondary envelopment in PRV. Complete deletion of
the PRV version of pUL37 disrupts cytoplasmic envelopment to a lesser extent than pUL37
deletion in HSV-1 (170, 260). The phenotype of HSV-1 pUL37-null mutants is characterized by
unenveloped capsids distributed throughout the cytoplasm that do not colocalize with TGN
vesicles, suggesting that pUL37 may play a role in directing capsids to secondary envelopment
sites (245). Trafficking of pUL37 to putative sites of secondary envelopment at TGN membranes
in HSV-1 infected cells is dependent on the presence of pUL36, and occurs even in the absence
of capsids (79).
Interaction between pUL37 and the capsid proteins pUL35 and pUL38 has been
documented by yeast two-hybrid screens in HSV-1 (181). However, pUL37 is only recruited to
capsids in the presence of pUL36, implying that direct interactions between the capsid and
pUL37 are not an important determinant for the accretion of pUL37 onto capsids (271). Both
pUL36 and pUL37 are also present in L-particles, further indicating that interactions with capsid
proteins are not strictly required for their incorporation into tegument (204, 292). Successful
incorporation of either pUL36 or pUL37 into L-particles is dependent on the presence of the
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other, reflecting their close association (260). Integration of pUL36 and pUL37 into L-particles is
probably mediated by interactions with outer tegument proteins (106). Interactions between
pUL36 and pUL48, as well as between pUL37 and pUL46, have been documented by yeast twohybrid screening (181, 303). Surprisingly, the presence of pUL36 or pUL37 is not required to
form L-particles, suggesting that they are not needed for outer tegument assembly or for the
membrane invagination process during budding at sites of secondary envelopment (109, 170,
260). However, L-particles lack capsids and are not infectious, with a tegument structure
dissimilar to that of normal virions. pUL36 and pUL37 likely influence tegument organization
and act as a link between the capsid and the outer tegument and envelope, thus performing a
crucial role during secondary envelopment (145, 170, 251, 260).
Although early work with a pUL37 deletion mutant hinted at a role for pUL37 in capsid
egress from the nucleus, follow-up research suggested that the observed overabundance of
capsids in nuclear fractions was due to large clusters of cytoplasmic capsids precipitating with
the nuclei (80, 260). pUL37 has been detected on purified intranuclear capsids along with
pUL36, but neither one is required for translocation of capsids from the nucleus to the
cytoplasm in both HSV-1 and PRV (38, 109, 183, 260). Transport of pUL37 to the nucleus in
infected cells is possibly due to cytoplasmic interaction with the DNA-binding protein ICP8 (280,
281). Modulation of NF-kappaB signaling by binding to TRAF6 and interaction with known DNAbinding proteins such as ICP8 suggest a potential role for pUL37 in transcriptional regulation of
immediate early genes (6, 187, 280).
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In vitro experiments have shown that inner tegument proteins such as pUL37 and its
binding partner pUL36 are required for the successful recruitment of microtubule motors such
as kinesin, dynein, and the dynein cofactor dynactin onto capsids and for the transport of viral
capsids along microtubules (253, 273). pUL37 is added to capsids in the cytoplasm along with
pUL36, and the presence of both is required for efficient transport of viral capsids to sites of
secondary envelopment at the TGN (271). pUL36 and pUL37 remain bound to capsids during
infection and entry into host cells and promote nucleus-directed capsid mobility along
microtubules, likely by binding to dynein (4, 63, 313). However, pUL37 deletion mutants in both
HSV-1 and PRV show that it is not strictly required for localization of incoming capsids to the
nucleus (174, 260).
The recently published crystal structure of the amino terminal half of pUL37 in the HSVrelated alphaherpesvirus PRV provides a compelling structural argument for a role of pUL37 in
viral trafficking. The N-terminus of PRV pUL37 encompassing residues 1 to 479 is an elongated
structure rich in alpha helices that is structurally similar to members of the complexes
associated with tethering containing helical rods (CATCHR) family of eukaryotic cellular
multisubunit tethering complexes (MTCs) involved in vesicular transport (Figure 2.7). This
similarity is presumably due to convergent evolution because sequence identity between the
pUL37 N-terminus and MTC subunits is less than 10%. Structural stability of the pUL37 Nterminus in PRV is maintained by the internally located conserved residue W477, as
demonstrated by the construction of a shorter N-terminal construct spanning residues 1-476.
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Figure 2.7: Structure and organization of the PRV N-terminal 1-479 aa of pUL37. (A) Secondary
structure of individual domains. Domain I components are shown in different shades of green.
Domain II subdomains are shown in blue and purple. The nuclear export signal (NES) portion of
domain II is shown in teal. Domain III is shown in red. (B) Organization of helices within each
domain. (C) Crystal structure of the entire PRV pUL37 N-terminus encompassing residues 1-479.
(D) Magnified view of the region surrounding residue W477. Adapted with permission from
[Journal of Virology 88(10): 5462-5473, Crystal structure of the herpesvirus inner tegument
protein UL37 supports its essential role in control of viral trafficking]. Copyright (2014) American
Society for Microbiology.
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Mutagenesis of conserved surface-exposed regions selected by evolutionary trace analysis
(ETA) in conjunction with the 3D structural data revealed a cluster of residues important for
spread between infected cells. Mutation of the domain III residues Q324, D362, R365, H421,
H425 to alanine impaired cell-to-cell spread without reducing the rate of viral production,
suggesting a role for pUL37 in transporting mature virions to cell junctions for infection of
adjacent cells (251).
The multifunctional UL37 protein also undoubtedly plays a variety of as yet
undiscovered roles in viral replication by interacting with a plethora of host cell proteins. Yeast
two-hybrid screening of human brain cDNA libraries revealed potential interaction between
pUL37 and a number of host cell proteins, including the Iκβ kinase complex associated protein
(IKAP), the 20S proteasome subunit beta type 5 (PSMB5), the autophagy regulator Beclin1
(BECN1), the serine threonine kinase thousand and one kinase 3 (TAOK3), the NIF3L1 binding
protein THO complex 7 homolog (THOC7), the nuclear RNA helicase DEAD box protein 5 (DDX5),
the molecular chaperonin containing TCP1 subunit 3 (CCT3), the mitochondrial protein
asparaginyl-tRNA synthetase 2 (NARS2), and the transcriptional repressors GTPase activating
Rap/RanGAP domain-like 1 (GARNL1) and zinc finger protein 350 (ZNF350) (159).
HSV-1 envelope
The envelope contains at least 12 glycoproteins in addition to several other membraneassociated viral proteins. The glycoproteins include pUL1 (gL), pUL10 (gM), pUL22 (gH), pUL27
(gB), pUL44 (gC), pUL49.5 (gN), pUL53 (gK), pUS4 (gG), pUS5 (gJ), pUS6 (gD), pUS7 (gI) and pUS8
(gE). The non-glycosylated membrane proteins include pUL20, pUL24, pUL43, pUL45, pUL56
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and pUS9 (42, 264). While pUL34 is also technically a membrane-associated protein, it is not
present on the envelope of extracellular virions. Instead, pUL34 localizes to the inner nuclear
membrane and acts in concert with pUL31 to mediate primary envelopment (264). The various
envelope proteins play important roles in both virus entry and egress from infected cells.
During entry, membrane proteins are involved in binding to cellular receptors and in the
initiation and regulation of membrane fusion, while during egress they play crucial roles during
envelopment and infectious virus production via interactions with the tegument (97).
Unlike the capsid, both the tegument and the envelope are pleiomorphic structures. The
envelope is a host-derived lipid bilayer ~5 nm thick with an average diameter of ~186 nm that
increases to ~225 nm when the protruding viral glycoprotein spikes are included. Cryo-electron
tomography of mature enveloped virions reveals 600-750 nonrandomly distributed
glycoprotein spikes of highly variable morphology embedded in the viral envelope (Figure 2.5A).
The tegument appears to be in contact with the internal portions of adjacent envelope
glycoprotein spikes and may serve to anchor the glycoproteins, as evidenced by increased spike
cluster density in the membrane overlying the thickened "cap" portion of the asymmetrical
tegument (122). Accordingly, a number of direct interactions between envelope glycoproteins
and outer tegument proteins have been documented in HSV-1. The tegument protein pUL48
(VP16) binds to the cytoplasmic tails of gB, gD and gH (119, 154, 325). Co-immunoprecipitation
experiments indicate that the tegument proteins pUL11 and pUL49 (VP22) interact with the
cytoplasmic portions of gD and gE (49, 93, 239). The PRV version of pUL49 (VP22) has been
shown to interact with the carboxyl terminal domains of gE/gI and gM (108). Interaction
between pUL49 and the cytoplasmic portion of the membrane protein pUS9 has also been
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detected (181). Most recently, the membrane proteins gK and pUL20 have been reported to
bind to pUL37, marking the first documented interaction between envelope proteins and the
inner tegument (145).
Glycoprotein B. Glycoprotein B (gB) is a 904 residue glycosylated transmembrane
protein encoded by the UL27 gene of HSV-1. gB is the most conserved component of the viral
entry and fusion machinery composed of gB, gD and the gH/gL heterodimer. A crystal structure
of the gB ectodomain revealed a trimeric structure strikingly similar to vesicular stomatitis virus
glycoprotein Gr, a known fusion protein. The gB structure reflects aspects of both class I and
class II fusion proteins and suggests that fusogenic activity of gB is mediated by a reversible
conformational change between an "open" and "closed" orientation of the trimeric gB complex
(Figure 2.8) (130). This conformational rearrangement to initiate fusion is presumably mediated
by interactions with gD and the gH/gL heterodimer, but may also be assisted by the
documented direct binding of gB to cellular receptors such as the paired immunoglobulin-like
type-2 receptor alpha (PILR-alpha), myelin-associated glycoprotein (MAG) and non-muscle
myosin heavy chain IIA (NMHC-IIA) (12, 56, 62, 272, 291). gB-mediated fusion is further
influenced by direct interactions with the membrane proteins pUL20 and gK (54, 102, 213).
Recently, deletion of gM and the membrane-associated tegument protein pUL11 has been
shown to affect membrane fusion events, presumably due to interactions with members of the
viral fusion complex. Indeed, interaction between gM and pUL20 was detected by two-way coimmunoprecipitation experiments (163).
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Figure 2.8: Schematic model of gB illustrating predicted conformational change between a
“closed” (A) and “open” (B) state. Domains of gB are shown in different colors. Adapted with
permission from [Science 313(5784): 217-220, Crystal structure of glycoprotein B from herpes
simplex virus 1]. Copyright (2006) American Association for the Advancement of Science.

Glycoprotein K. Glycoprotein K is a 338 residue glycosylated transmembrane protein
encoded by the UL53 gene of HSV-1 and is conserved in all alphaherpesviruses. gK contains four
hydrophobic transmembrane domains, a 30 residue signal sequence and two N-linked
glycosylation sites at residues 48 and 58 (Figure 2.9) (254). The presence of gK is critically
important for successful cytoplasmic virion envelopment and infectious virus production. gK
deletion mutants are unable to egress and accumulate in the cytoplasm as unenveloped virions
58

(101, 142, 143, 147, 254). gK exists as a complex with the membrane protein pUL20 in infected
cells. Studies indicate that transport of gK to the plasma membrane and to sites of secondary
envelopment at TGN membranes is mediated by the presence of pUL20 (100, 103, 212).

Figure 2.9: Schematic illustration of glycoprotein K. The four transmembrane regions, the 30 aa
N-terminal signal peptide, the two N-linked glycosylation sites, and the locations of known
syncytial mutations are shown.

Studies using a variety of deletion, truncation and syncytial mutants of gK have
illustrated the importance of gK in mediating virus-induced cell fusion (16, 17, 53, 142, 213). A
number of gK mutations, primarily within the amino terminus of gK, have been identified that
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promote formation of syncytia in infected cell monolayers (252, 269). The recent detection of a
direct interaction between the gK amino terminus and the extracellular portion of the key
fusion protein gB suggests that the prevalence of syncytial mutations in the amino terminus of
gK is not coincidental (54).
Overexpression of gK was correlated with an increase in the number of enveloped
virions in the perinuclear space, suggesting a role in gB-mediated de-envelopment at the outer
nuclear membrane (143). However, simultaneous deletion of both gB and gK as well as both gB
and pUL20 did not prevent capsids from accumulating in the cytoplasm, indicating that pUL20,
gB and gK do not function in a redundant manner for de-envelopment (213).
Virus lacking either the entire gK or merely the amino terminus of gK enters cells at a
slower rate than wild-type virus (104, 146). The amino terminus of gK appears to be required
for efficient virus entry into cells via the gB-associated paired immunoglobulin-like type-2
receptor alpha (PILRα) (55). Virus lacking gK is unable to enter neurons via their axonal termini,
illustrating the further importance of gK as a determinant of neurovirulence (73, 222). gK may
also play a role in immunomodulation due to the presence of a T cell epitope within its amino
terminal signal domain (241).
UL20 protein. The UL20 protein is a 222 residue nonglycosylated hydrophobic
transmembrane protein that is conserved in all alphaherpesviruses (Figure 2.10) (194). pUL20 is
an important mediator of virus-induced cell fusion and cytoplasmic virion envelopment, with
pUL20 deletion mutants characterized by accumulation of unenveloped virions in the cytoplasm
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(17, 21, 102, 211). Virus-induced cell fusion was also prevented in recombinant viruses unable
to express pUL20 that contained syncytial mutations in gB or gK (102).
pUL20 forms a complex with gK, and expression of pUL20 is important for intracellular
transport of gK to the cell surface and to TGN membranes (100, 212). Both pUL20 and gK
directly interact with gB and function as regulators of gB-mediated fusion (54, 102, 149, 213).
Interaction between pUL20 and gM has also been reported (163). The pUL20 domains involved
in virus-induced cell fusion and cytoplasmic virion envelopment are functionally independent,
as evidenced by pUL20 mutants which abrogate cytoplasmic envelopment without inhibiting
virus-induced cell fusion or transport of pUL20 and gK to the cell surface and to TGN
membranes (211, 212).

Figure 2.10: Schematic illustration of the UL20 protein. The four transmembrane regions and five
predicted domains are shown.
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Life Cycle of Herpes Simplex Virus
HSV infects the host at mucocutaneous surfaces and replicates before invading local
sensory nerves and propagating via neurons to sensory ganglia, specifically the trigeminal
ganglia for ocular and oral herpes and sacral ganglia for genital herpes, where it establishes
lifelong latency. In order to initiate infection, the DNA-containing capsid is deposited in the
cytoplasm of a targeted cell either by fusion of the viral envelope with the plasma membrane or
by endocytosis followed by fusion of the viral envelope with the membrane of the endocytic
vesicle. This process is mediated by the action of a subset of viral envelope glycoproteins that
bind to a variety of cellular receptors. The deenveloped virion is then transported to nuclear
pore complexes to release viral DNA into the nucleus, leading to either the start of another viral
replication cycle or the establishment of latency. New capsids are assembled in the nucleus and
loaded with viral DNA. Capsids travel to the cytoplasm by moving across the nuclear membrane
in a process called primary envelopment. In the cytoplasm, capsids acquire tegument and
undergo secondary envelopment by budding into TGN-derived vesicles enriched with viral
membrane proteins in a process that is thought to be largely mediated by interactions between
tegument proteins and the cytoplasmic tails of TGN-embedded viral glycoproteins. Enveloped
virions are then transported inside the vesicles to the plasma membrane for release into the
extracellular environment (97, 303).
Virus entry
In order to initiate infection, virus must first attach to the host cell membrane. HSV
attachment is mediated primarily by binding of the envelope glycoprotein gC to
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glycosaminoglycans (GAGs) on the cell surface, although gB has also been implicated in
attachment (42, 131, 132). The dominant cell surface receptors involved in viral attachment are
the widely expressed heparan sulfate and chondroitin sulfate GAGs, which are beleived to bind
the amino terminal portion of gC (295). Surprisingly, deletion of gC does not impair viral
attachment in every tested HSV-1 strain, suggesting that other viral proteins such as gB are
involved (118). Deletion of heparan sulfate and chondroitin sulfate is significantly more
deleterious to viral infectivity, but does not prevent infection from happening (121). Viral
attachment is reversible and functions separately from fusion, as evidenced by the retention of
unfused viral envelopes and subsequent infectivity in detached virus(42).
Entry of HSV into cells typically occurs by fusion of the viral envelope to the host cell
plasma membrane, although attached virus may also enter via endocytosis and fusion of the
viral envelope to the surrounding endocytic vesicle (235). Entry is primarily mediated by binding
of the gD ectodomain to cellular receptors, initiating a conformational change which triggers
fusion by activating the gB, gH/gL fusion complex (59). In addition, virus entry is facilitated by
binding of gB to cellular receptors including the paired immunoglobulin-like type-2 receptor
alpha (PILR-α), myelin-associated glycoprotein (MAG) and non-muscle myosin heavy chain IIA
(NMHC-IIA) (12, 56, 272, 291).
The transmembrane and cytoplasmic domains of gD serve to anchor gD in the viral
envelope and do not appear to play a role in entry (36). gD binds to three families of cellular
entry receptors: nectins, tumor necrosis factor (TNF) receptors, and modified heparan sulfate
receptors (42). Nectins are a group of immunoglobulin-type intercellular adhesion molecules

63

that can dimerize with other nectins and are commonly found at cadherin-based cell junctions
(294). Nectins are widely expressed in human tissues and are divided into four subtypes (41).
Nectin 1 is utilized for HSV-1 entry, while HSV-2 is able to exploit both nectin 1 and nectin 2
(42). TNF receptors are involved in signal transduction pathways regulating cell differentiation,
proliferation and apoptosis. gD binds to a TNF receptor dubbed herpesvirus entry mediator
(HVEM) that is primarily expressed on cells of the immune system such as B and T lymphocytes
and monocytes, as well as in epithelial cells and a number of other tissues, excluding neurons
(176, 287). 3-O-sulfated heparan sulfate is the third type of gD receptor and is expressed in
neurons in addition to a variety of other tissues (42). Variations in the distribution of cellular gD
receptors across cell types likely affect HSV tissue tropism, and the preferential distribution of
HVEM on immune system components that are not commonly targeted ty HSV infection
suggests a possible role for the HVEM-gD interaction in immune evasion (42, 177).
Fusion activity in HSV is executed by a highly conserved multipartite system of viral
glycoproteins composed of gB and the gH/gL heterodimer (42). The crystal structure of gB
revealed a trimeric protein that bears a close resemblance to the known fusion protein
vesicular stomatitis virus G protein, while gH exhibits properties similar to those of class 1
fusion glycoproteins (116, 130). Both gB and the gH/gL heterodimer are required for fusion to
proceed (39, 99, 267). Absence of gL is prevents incorporation of gH into viral particles and
abrogates entry into cells (267). It has recently been suggested that gB is the sole fusogenic
protein, with gD and gH/gL merely serving to trigger a conformational change in gB to initiate
fusion (62).
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Presence of gD in addition to gB and gH/gL is necessary and sufficient for successful
entry into host cells (42, 236). Transfection of plasmids expressing gD, gB, gH and gL into cells
leads to reconstitution of a functional fusogenic complex in the presence of a suitable gD
receptor, suggesting that no additional viral proteins are strictly required for membrane fusion
(114, 298).
The fusogenic action of gB is regulated by direct or indirect interactions with other viral
glycoproteins. Studies utilizing HSV-1 mutants with a tendency to fuse adjacent infected cells to
create multinucleated giant cells called syncytia have indicated that pUL20, gK, gM and pUL11
perform regulatory roles in virus-induced fusion. Additionally, both pUL20 and gK have been
shown to directly interact with gB, while gM may in turn interact with pUL20 (54, 102, 163,
213).
Capsid transport to the nucleus
After fusion with the host cell membrane, tegumented viral capsids are deposited into
the cytoplasm. Capsids are propelled to the nucleus along microtubules by dynein motors.
Experiments designed to replicate viral transport along the microtubule network in vitro have
shown that the presence of inner tegument proteins such as pUS3, pUL36 and pUL37 on the
capsid is required to recruit the microtubule motors responsible for both retrograde (dynein
and dynactin) and anterograde (kinesin) transport (253). However, microtubule interactions do
not completely account for intracellular capsid mobility since disruption of the microtubule
network by nocodazole treatment does not completely abrogate HSV-1 infection (286).
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As capsids travel towards the nucleus to deposit viral DNA through nuclear pore
complexes (NPCs), outer tegument proteins such as pUL41, pUL47 and pUL48 (VP16)
disassociate from the capsids to prime the host cell for viral gene expression and production of
progeny virus (184, 216). The UL41 gene encodes the 58 kD virion host shutoff (vhs) protein.
vhs dissassociates from the tegument during infection and travels to the nucleus where it
degrades mRNA, shutting down gene expression and protein synthesis in the host cell (91). vhs
also degrades viral mRNA and may contribute to the switch to late gene expression by
degrading transcripts of immediate-early and early genes (240). Downregulation of vhs activity
in the later stages of infection may be accomplished by the documented interaction of vhs with
the tegument protein pUL48 (275, 283). pUL48, also known as the alpha trans-inducing factor
(αTIF), is major structural component of the tegument. pUL48 travels to the nucleus after
infection and forms a complex with the cellular protein Oct-1 to initiate the viral gene
expression cascade by starting the transcription of immediate-early genes (232). pUL47 also
localizes to the nucleus after infection and may be involved in regulating pUL48-mediated
expression of immediate-early genes (303).
Upon capsid docking to the nuclear pore complex (NPC) (Figure 2.11), cleavage of the
attached inner tegument protein pUL36 is necessary to release viral DNA into the nucleus,
suggesting that pUL36 acts as a sort of plug to retain the packaged viral DNA (153). The highly
pressurized viral DNA is released from the capsid portal as a single linear strand, which is
quickly condensed upon entering the nucleus by host intranuclear proteins into DNaseinsensitive rod-like structures (25, 218).
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Figure 2.11: Artificially colored electron micrograph of empty HSV-1 capsid shortly after
releasing viral DNA through the nuclear pore complex (NPC). Adapted with permission from
[Journal of the American Chemical Society 135(30): 11216-11221, Herpes virus genome, the
pressure is on]. Copyright (2013) American Chemical Society.

Viral gene expression and DNA replication
Freshly injected linear viral DNA rapidly circularizes due to the actions of the DNA repair
protein XRCC4 and DNA ligase IV and serves as a template for subsequent replication (227).
Immediate early (IE or alpha) genes encoding ICP0, ICP4, ICP22, ICP27, ICP47 and pUS1.5 are
expressed very soon after infection, prior to replication of viral DNA. alpha gene expression is
stimulated by pUL48 (αTIF), and the alpha gene products themselves modulate further gene
expression, stimulating expression of early (beta) genes which encode components of the viral
DNA replication machinery (97). The origin-binding protein pUL9 initiates replication by loading
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the viral replisome complex onto origins of replication in the viral genome. The replisome
consists of a virally encoded DNA polymerase composed of pUL30 and pUL42, a helicaseprimase composed of pUL5, pUL8 and pUL52, and the single-stranded DNA-binding protein
pUL29 (ICP8) (228). Viral DNA replication proceeds using a rolling circle mechanism, and newly
synthesized viral DNA is used as the template for transcription of late (gamma) genes primarily
encoding structural proteins that are utilized for the formation of progeny virus. Viral gene
transcription is handled by the host RNA polymerase II, and viral proteins are synthesized in the
cytoplasm (66, 228).
In latently infected neurons, viral DNA persists in the nucleus as a circular episome and
normal lytic gene expression does not occur. Instead, the virus expresses latency-associated
transcripts (LATs) which silence viral gene expression and have been implicated in protecting
neurons from apoptosis (250). LAT transcript levels decrease upon viral reactivation, triggering
alpha, beta and gamma gene expression and allowing viral replication to proceed (97).
Capsid assembly
HSV-1 capsids are assembled in the nuclei of infected cells in large nuclear inclusion
bodies that form approximately four hours after initial infection and persist for the duration of
infection (Figure 2.12) (35). At the start of assembly, VP5 forms complexes with the scaffolding
proteins VP21 and VP22a which are cleaved from the overlapping UL26 and UL26.5 gene
products (97). These complexes congregate to form 125 nm spherical procapsids, with the
portal vertex being incorporated during initiation of procapsid assembly (35, 233). DNA transfer
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Figure 2.12: Diagram of HSV assembly and egress. (1-3) Intranuclear capsids assemble in the
nucleus. (4) Capsids are packaged with viral DNA. (5) Capsids travel to the inner nuclear
membrane. (6) Capsid budding into the inner nuclear membrane. (7) Enveloped capsid in the
perinuclear space. (8) Fusion of envelope with the outer nuclear membrane and de-envelopment.
(9) Tegument proteins assemble on the capsid. (10) Viral membrane proteins and additional
tegument proteins gather at sites of secondary envelopment. (11) Capsids bud into TGN-derived
membranes to acquire envelope. (12) Enveloped virion fully enclosed in cytoplasmic vesicle. (13)
Mature virions are transported to the plasma membrane for release. (10a-13a) Formation of Lparticles consisting of enveloped tegument proteins without a capsid. Adapted with permission
from [Current Opinion in Microbiology 9(4): 423-429, Herpesvirus assembly: a tale of two
membranes]. Copyright (2006) Elsevier.

into the capsid through the portal vertex is mediated by interactions between the portal and
the tripartite terminase complex consisting of the viral proteins pUL15, pUL28 and pUL33 which
is involved in cleaving concatemeric DNA into monomers during packaging. The pUL15, pUL28
and pUL33 protein complex initially forms in the cytoplasm and is eventually translocated to the

69

nucleus, aided by the presence of a nuclear localization signal (NLS) in pUL15 (97, 318). During
DNA packaging, the capsid angularizes to its mature polyhedral shape as the scaffolding protein
exits the still-leaky procapsid and is cleaved away by the viral maturational protease VP24
encoded by the UL26 gene (35). Following angularization, the minor structural capsid protein
VP26 is recruited to the maturing capsids in an ATP-dependent manner (50). The tegument
protein VP1-2 (pUL36) encoded by the UL36 gene likely serves to plug the portal after DNA
packaging, as evidenced by research showing that cleavage of pUL36 after the capsid attaches
to the nuclear pore complex is required to release viral DNA into the nucleus during infection
(153).
Primary envelopment
In order to leave the nucleus, newly constructed DNA-filled capsids bud into the inner
nuclear membrane, forming enveloped particles in the perinuclear space that subsequently
undergo de-envelopment at the outer nuclear membrane to release the capsid into the
cytoplasm (Figure 2.12). Although the nucleus contains pores that allow for the passage of
certain proteins, HSV-1 capsids generally do not use this route for egress from the nucleus due
to the relatively large 125 nm diameter of the capsid. Further evidence for the envelopment
and de-envelopment pathway for nuclear egress is provided by observations indicating that
nuclear pores are not disrupted during capsid translocation to the cytoplasm (134, 149).
Primary envelopment at the inner nuclear membrane requires the action of a nuclear
envelopment complex (NEC) composed of pUL31 and pUL34 (258, 266). pUL34 is a type II
integral membrane protein that is anchored within the inner nuclear membrane (282). pUL31 is
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a phosphoprotein that has been shown to associate with the C-capsid specific components
(CCSCs) at capsid vertices. pUL31 preferentially binds to the pUL25 component of CCSCs, but is
also able to interact with the pUL17 CCSC component in the absence of pUL25. Interaction of
the NEC with CCSCs may drive the preferential selection of DNA-containing capsids for primary
envelopment (319).
The capsid-associated pUL31 is thought to bind to pUL34 at the inner nuclear
membrane to initiate budding into the perinuclear space (259). Interactions with the capsid are
further supported by the detection of both pUL31 and pUL34 within enveloped perinuclear
virions, although they are not found within mature virions (110, 259). Surprisingly, the presence
of capsids is not strictly required to initiate budding into the perinuclear space due to the fact
that transient expression of only pUL31 and pUL34 of PRV is sufficient to form perinuclear
vesicles (169).
Before capsids can even reach the inner nuclear membrane, they must first penetrate
the nuclear lamina. The lamina is a dense filamentous layer composed of lamins A, B and C that
coats the inner nuclear membrane (77). The NEC mediates localized disassembly of the lamina
by recruiting protein kinase Cα and protein kinase Cδ to phosphorylate lamin B, while the
capsid-associated kinase pUS3 phosphorylates lamin A and lamin C (178, 223, 244). The NEC
also disrupts the lamina by binding to lamin A and lamin C, possibly due to competitive
inhibition of interactions between the lamins (224, 257).
Tegument proteins are not necessary for primary envelopment, although perinuclear
virions are already coated with a thin layer of tegument composed of pUL11, pUL36, pUL37,
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pUL41, pUL48, pUL49 and pUS3 (18, 215, 217, 229, 243, 255, 259). The remainder of the
tegument is added before and during secondary envelopment in the cytoplasm (149). Viral
glycoproteins including gB, gD, gH, gL and gM have been detected in perinuclear virions as well
as in the inner and outer nuclear membranes (22, 94, 289). gD and gM are actively recruited by
the NEC to the inner nuclear membrane and gD has even been shown to bind to pUL34, but the
role of viral glycoproteins in primary envelopment is unclear (310).
Perinuclear virions are released into the cytoplasm by fusion of the perinuclear
envelope with the outer nuclear membrane in a process called de-envelopment. This fusion is
presumably mediated by gB and the gH/gL heterodimer, which are also involved in fusion
during entry (129). Accordingly, HSV mutants lacking gB and gH show enveloped virions stuck
within the perinuclear space, unable to undergo de-envelopment and enter the cytoplasm (94).
gB is a key HSV-1 fusion protein whose action is tightly regulated to avoid runaway fusion of
intracellular membranes (130, 149). pUL20 and gK are able to physically interact with gB and
act as regulators of gB-mediated fusion (54, 102, 143, 149). Furthermore, phosphorylation of gB
by pUS3 has been shown to promote de-envelopment at the outer nuclear membrane (312,
316).
Secondary envelopment
Cytoplasmic capsids begin to acquire more tegument proteins such as pUL36 and pUL37
during their journey to sites of secondary envelopment at trans-Golgi network (TGN) derived
vesicles and endosomes (Figure 2.12) (271). Additional tegument is bound to the cytoplasmic
surface of TGN membranes and is added to the capsids during secondary envelopment (34,
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149). The inner tegument proteins pUL36 and pUL37 mediate the transport of viral capsids to
TGN membranes via interactions with the microtubule-based transport machinery (192, 271).
pUL36 and pUL37 interact with viral capsids and with each other to form filaments attached to
capsid vertices, and their presence is necessary for acquisition of the outer tegument and for
cytoplasmic envelopment (80, 81, 231, 260).
The process of secondary envelopment in the cytoplasm involves a complex web of
interactions between the capsid, the tegument and the cytoplasmic tails of envelope
glycoproteins embedded in TGN membranes (Figure 2.13) (149, 216). Capsids coated with the
inner tegument proteins pUL36 and pUL37 are connected to the outer tegument via the
documented interactions between pUL36 and pUL48 and between pUL37 and pUL46 (181,
303). pUL48 acts as a sort of hub within the outer tegument and interacts with the tegument
proteins pUL41, pUL46, pUL47 and pUL49 (88, 232, 283, 303). Another interaction between
outer tegument proteins is the binding of pUL21 to pUL16, verified in both HSV-1 and in PRV
(127, 167). In turn, pUL16 binds to the membrane-associated tegument protein pUL11 (189,
321). pUL11 interacts with the membrane proteins gD and gE and has been proposed as a
bridge between the tegumented capsid and the envelope during secondary envelopment (93,
209, 321). Indeed, mutant viruses lacking expression of pUL11 exhibit mild impairment of
cytoplasmic envelopment and infectious virus production, but not nearly to the same extent as
mutants lacking pUL20 or gK (20, 52, 213).
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Figure 2.13: Diagram of viral protein interactions during secondary envelopment. Yellow
rectangles denote tegument proteins.

Viral glycoproteins such as gB, gD, gE/gI are sorted to TGN membranes due to
modification with mannose-6-phosphate (M6P) and to the presence of encoded sorting
domains, including di-leucine motifs, tyrosine motifs and acidic clusters, that are similar to
those found on host TGN proteins (27, 123, 206). Interactions with these targeted glycoproteins
enable viral proteins that lack such domains to still be recruited to TGN membranes for
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incorporation into mature virions (69). The cytoplasmic domains of viral membrane proteins
embedded in TGN vesicles interact with tegument proteins to anchor them onto the
membrane, and both the membrane proteins and the membrane-bound tegument proteins
also interact with the incoming partially tegumented capsids to promote budding and
subsequent envelopment (149, 217).
In addition to the interaction between pUL11 and glycoproteins D and E, a variety of
other links between membrane glycoproteins and tegument proteins have been identified (93).
The tegument-associated protein kinase pUL13 has been shown to phosphorylate both gE and
pUL49, in addition to modulating the function of pUL41 (67, 234, 242). Pulldowns and chemical
cross-linking experiments have shown that the outer tegument protein pUL48 (VP16) is able to
bind to the cytoplasmic tails of gB, gD and gH (119, 154, 325). The tegument proteins pUL11
and pUL49 (VP22) interact with the cytoplasmic portions of gD and gE (49, 93, 239, 290). The
PRV version of pUL49 can interact with the carboxyl terminal domains of gE/gI and gM (108).
Interaction between pUL49 and the cytoplasmic portion of the membrane protein pUS9 has
been detected via yeast two-hybrid screening (181). The absence of pUL49 also has a negative
impact on the incorporation of gD, gE/gI and ICP0 into virions, although incorporation of the
ICP0 binding partner ICP4 is unaffected (86, 87, 320). Interactions between the membrane and
the inner tegument or capsids have also been reported. The membrane proteins pUL20 and gK
have been shown to bind to the inner tegument protein pUL37 via co-immunoprecipitation and
proximity ligation assays, which may provide an explanation for the relative importance of
pUL20 and gK in facilitating cytoplasmic virion envelopment. (52, 101, 145). Furthermore, the
cytoplasmic tail of gD is reportedly able to directly bind capsids (49).
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Single glycoprotein deletions in HSV-1, with the notable exception of gK, do not have a
significant effect on secondary envelopment (52, 101, 149). It has been suggested that gD, gE
and gM are essential mediators of secondary envelopment in the cytoplasm and act in a
redundant manner, which would explain why single deletions of these glycoproteins do not
significantly perturb cytoplasmic envelopment (92, 149, 217). Early studies indicated that HSV-1
mutants lacking both gD and the gE/gI heterodimer showed nearly complete abrogation of
cytoplasmic envelopment (92). A similar phenotype was observed for PRV mutants lacking gM
and gE/gI (32). However, follow-up analysis of HSV-1 mutants lacking gE, gM, or the cytoplasmic
portion of gD, either alone or in combination, did not show significantly impaired cytoplasmic
envelopment and infectious virus production even in the absence of all three simultaneously,
suggesting that these proteins are not essential and do not function in a redundant manner for
cytoplasmic envelopment (52, 180). A recombinant HSV-1 lacking both gM and pUL11 did
exhibit impaired secondary envelopment, but not to the same extent as mutants unable to
synthesize gK or the non-glycosylated membrane protein pUL20, thus illustrating the
preeminent role pUL20 and gK play in the secondary envelopment process (52, 101, 182). It is
theoretically possible that lack of pUL20 or gK does not actually prevent cytoplasmic
envelopment from occurring. pUL20 and gK are known fusion modulators, and their absence
may cause the newly enveloped virions to immediately undergo de-envelopment back into the
cytoplasm due to fusion of the virion envelope with the surrounding TGN vesicle. However, this
possibility is yet to be thoroughly investigated (54, 102, 143, 149, 212, 213).
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Impaired virion egress was recently noted using an HSV-1 double mutant lacking gB and
gD, leaving open the possibility that gB may cooperate with gD to facilitate cytoplasmic
envelopment (40, 151). Glycoprotein B is primarily responsible for fusion of the viral envelope
to the host cell membrane during entry (130). gB-mediated fusion is modulated by interactions
between gB and other membrane proteins, including gD, gH, gK and pUL20 (13-15, 54, 62, 114).
pUL20 forms a complex with gK and has also been shown to interact with gM (100, 163).
Deletion of one or more viral proteins may lead to defects in secondary envelopment by
directly or indirectly affecting the stability and function of other viral proteins due to disruption
of the complex tangle of interactions among tegument proteins and viral glycoproteins (52).
Host cell proteins are likely also involved in secondary envelopment. ESCRT proteins in
particular may facilitate membrane curvature during the budding process. This is supported by
experiments with dominant-negative forms of ESCRT component proteins that show abrogation
of secondary envelopment in both HSV-1 and HCMV (247, 296). Viral proteins likely interact
with ESCRT components to recruit ESCRT machinery to sites of cytoplasmic envelopment at
TGN membranes. Sequence-based screening of HSV-1 proteins for potential ESCRT-binding
partners revealed a putative ESCRT-binding motif in gK that is similar to retroviral motifs called
late domains which promote ESCRT recruitment (247).
Egress to extracellular spaces
After undergoing secondary envelopment by budding into cytoplasmic membranes
derived from the trans-Golgi network (TGN) and endosomes, enveloped virions enclosed within
cellular vesicles are translocated to the plasma membrane for release by co-opting the cell's
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exocytic machinery (Figure 2.12) (149, 215, 217). These doubly-enveloped virions are
morphologically identical to extracellular virions, but show significant differences from
enveloped virions found in the perinuclear space (117). Transport of TGN-derived vesicles
containing enveloped virions to the plasma membrane is assisted by the action of cellular
serine-threonine protein kinase D, which is involved in fission of cargo-laden TGN vesicles and
regulation of their transport towards the basolateral plasma membrane (256). HSV is also
known to utilize myosin Va to translocate enveloped virion-containing vesicles to the plasma
membrane along cortical actin filaments (262). Upon reaching the plasma membrane, TGNderived transport vesicles fuse with the plasma membrane to release their enveloped virion
cargo into the extracellular space. This fusion is unlikely to be mediated by the viral fusion
machinery utilized during entry because the viral glycoproteins embedded in the transport
vesicles are incorrectly oriented. As tegumented capsids bud into TGN-derived vesicles to
acquire an envelope, they are in contact with the cytoplasmic portions of viral glycoproteins
embedded in TGN membranes. Therefore, the portions of viral glycoproteins that were located
inside the TGN-derived vesicles are oriented to the outside surface of the final enveloped
virion, with the formerly cytoplasmic portions facing inside the virion (149).
In polarized epithelial cells, progeny virions are often sorted to cell-cell junctions instead
of simply being released into the extracellular space. This sorting is presumably mediated by
viral proteins attached to or incorporated into the TGN-derived vesicles containing mature
enveloped virions (149). Studies have implicated the gE/gI membrane protein complex and the
inner tegument protein pUL37 in mediating transport of progeny virions to cell-cell junctions
(150, 251). Trafficking to cell-cell junctions provides important benefits for the virus. Placing
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virions in close proximity to adjacent cells facilitates the spread of infection. Minimizing
exposure to the extracellular space also allows virions to avoid elements of the host immune
response such as antibodies and components of the complement cascade (149). Immune
system exposure is further reduced by the propensity of HSV to cause fusion between cell
membranes of adjacent cells in vivo. The plasma membranes of infected cells are enriched with
viral glycoproteins, including members of the fusion complex involved in fusion of the viral
envelope with the plasma membrane during entry. Viral entry fusion machinery is thus
repurposed to create large multinucleated cells called syncytia (97, 135). These factors help
explain why titers of neutralizing antibodies in HSV-infected patients frequently do not
correlate with disease severity or frequency of recurrence (64, 65).
HSV-1 egress in neurons: “married” vs. “separate” models
HSV-1 shares with other alphaherpesviruses the ability to invade neurons and establish
a life-long latent infection. After replicating at the initial site of infection, HSV-1 enters sensory
neurons via their axon termini by fusion of the viral envelope with the neuronal plasma
membrane. The viral capsid, along with associated inner tegument proteins, is then transported
in a retrograde fashion from the periphery of the neuron to the cell body where viral DNA is
deposited in the neuronal nucleus for replication or establishment of latency. This retrograde
transport is mediated by dynein motors associated with the neuron’s internal microtubule
network (7, 82). In neurons, the minus-ends of microtubules are anchored in the neuronal cell
body while the growing plus-ends are located at the axon termini. Dynein, along with its
cofactor dynactin, are large protein complexes involved in the ATP-dependent movement of
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bound cargo towards microtubular minus-ends. In HSV-1, the essential inner tegument protein
pUL36 and its binding partner pUL37 remain associated with the capsid after entry and have
been hypothesized to play a role in retrograde transport by interacting with the
dynein/dynactin complex, possibly in a redundant fashion with other viral capsid or inner
tegument proteins. The outer capsid protein VP26, as well as the viral proteins pUL34 and
pUL9, has been shown to bind to dynein in vitro, but recent studies with VP26-null mutant virus
showed no defect in dynein-mediated retrograde capsid transport. The pUL34 and pUL9
proteins are not present in mature virions and are not involved in retrograde transport (71, 82).
Also, in vivo models have shown the membrane protein gE to be important for retrograde
spread in HSV-1 but not in PrV (202).
Upon reactivation from latency in neurons, HSV-1 assembly and egress directly from the
neuronal cell body proceeds in much the same way as in non-neuronal cells. However, neurons
are highly polarized cells and a subset of newly constructed HSV-1 particles undergoes
anterograde transport driven by microtubule-dependent kinesin motors whereby the viral
particles travel along the axon from the neuronal cell body toward the plus-ends of
microtubules at the axon terminus, leading either to reinfection of the innervated region and
virus shedding or to further invasion of the central nervous system by infection of other
neurons (82, 230). Two competing models exist for the anterograde transport of HSV-1 that
occurs during viral egress from infected neurons. In the “married” model, the secondary
envelopment step (where the tegumented viral capsid acquires its final envelope by budding
into cytoplasmic vesicles enriched with viral glycoproteins and other membrane-associated
proteins) occurs within neuronal cell bodies and the resulting mature enveloped virions are
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transported within secretory vesicles toward the axon termini for release. In the “separate”
model, unenveloped viral capsids coated with inner tegument proteins are transported along
the axons separately from axonal vesicles containing the viral glycoproteins and other
membrane-associated proteins, with the secondary envelopment step and subsequent viral
release by exocytosis occurring at the axon termini (82, 149, 230).
Kinesins are a large group of molecular motor proteins that typically use ATP hydrolysis
to move cargo toward the plus-ends of microtubules. One or more different types of kinesin
may be involved in viral transport, possibly based on changes in the composition of viral cargo
(82). The prototypical kinesin-1 is a tetramer consisting of two identical heavy chains and light
chains with a “tail” region that binds cargo and two “heads” with ATPase activity that bind and
“walk” along microtubules by stepping past one another hand-over-hand (322). The tail region
is composed of both heavy and light chains, both of which are capable of interacting with cargo
either directly or via adaptor proteins. The “separate” and “married” models for HSV-1
anterograde transport have direct implications for elucidating the mechanism and binding
partners of kinesin in viral anterograde transport. If the “separate” model is valid, kinesin’s
cargo would consist of tegumented capsids and kinesin could be expected to interact with some
of the exposed capsid or inner tegument proteins (82). In fact, interaction between the carboxyl
terminus of the HSV-1 tegument protein pUS11 and a kinesin-1 cargo-binding domain has been
documented, but HSV-1 virions lacking pUS11 were still capable of binding kinesin-1, suggesting
a level of redundancy in kinesin-virion interactions (82, 85). The major tegument protein pUL36
has also been proposed to play a role in kinesin binding and anterograde transport in both HSV-
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1 and PrV. A recent study showed decreased microtubule binding and motility in an in vitro
microchamber assay using a mutant HSV-1 expressing a partially deleted pUL36 protein (279).
On the other hand, if the “married” model is valid and enveloped virions are transported
within secretory vesicles containing embedded viral glycoproteins then kinesin could be
expected to interact with either cellular receptors or viral glycoprotein cytoplasmic tails located
on the outer vesicle. Such an interaction has been documented between kinesin and the
cellular receptor amyloid precursor protein, which associates with vesicles containing
enveloped HSV-1 during neuronal egress (82, 85). Direct interaction has also been documented
between kinesin and the HSV-2 membrane-associated protein pUL56 (82). Furthermore, while
studies in various alphaherpesviruses such as PrV and BHV-5 have indicated that the viral
envelope proteins gE/gI and pUS9 are critical for anterograde neuronal transport, in HSV-1 only
gE/gI are essential for anterograde spread while pUS9 is dispensable (57, 202). It has also been
postulated that the possible interactions between kinesin and tegument proteins such as pUS11
and pUL36 may be amenable to interpretation under the “married” model by considering the
transport of partially enveloped virions where some of the tegument proteins are exposed and
may bind to kinesin. Alternatively, there is some evidence that pUL36 may bind to the surface
of the cytoplasmic organelles which enclose the enveloped virions, allowing for direct
interactions between pUL36 and kinesin (279). However, the fact that HSV-1 lacking gE/gI
cannot undergo anterograde neuronal transport means that any putative interactions between
kinesin and pUL36 or pUS11 are insufficient to rescue this critical function in the absence of
gE/gI.
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In contrast to pseudorabies virus (PrV), where the “married” model for anterograde
neuronal transport has seen wide acceptance after numerous studies utilizing electron
microscopy and live-cell imaging of fluorescently labeled PrV, the picture for HSV-1 has been
less clear (82, 186, 197). Earlier studies with HSV-1 lent support to the “separate” model by
observing unenveloped nucleocapsids in the axons of infected neurons by electron microscopy
and a lack of colocalization between fluorescently labeled capsids and envelope proteins in
neuronal axons while also observing some colocalization of labeled capsid, tegument and
envelope proteins in neuronal growth cones at axon termini, presumably due to secondary
envelopment at axon termini (82, 136, 285). However, many of these studies suffered from
flaws, such as the assumption that the motionless unenveloped virus particles observed in the
axon after fixation for electron microscopy or conventional fluorescent microscopy were
undergoing anterograde transport to the axon terminus instead of retrograde transport to the
neuronal cell body after secondary infection, a problem often exacerbated by the high MOIs (up
to 1000 PFU/neuron) used in the experiments (311). EM experiments are further complicated
by the significantly lower quantities of virus found in the axons of neurons infected with HSV-1
compared to neurons infected with PrV (230).
More recent experiments provide solid evidence for the “married” model for HSV-1
anterograde neuronal transport. In a high-resolution electron microscopy study of explanted
primary neurons from rat superior cervical ganglia, approximately 75% of observed intraaxonal
HSV-1 virus particles were enveloped, supporting the “married” model (230). Another EM study
using both rat and mouse primary neurons from superior cervical ganglia in Campenot neuronal
growth chambers also reported a majority of enveloped HSV-1 particles in neuronal axons
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(139). Also, a recent study that used live-cell imaging to evaluate anterograde transport in chick
embryo and rat dorsal root ganglion-derived neurons by a recombinant HSV-1 simultaneously
expressing both an RFP-tagged capsid protein (VP26) and a GFP-tagged membrane protein (gB)
showed that up to 70% of virus particles were enveloped during anterograde axonal transport
(8). Furthermore, a similar recent live-cell imaging study using a recombinant HSV-1 expressing
YFP-tagged VP26 and RFP-tagged gB in human SK-N-SH neuroblastoma cells and rat superior
cervical ganglion neurons in microfluidic chambers showed clear evidence of both enveloped
and unenveloped viral capsids in anterograde transport. Caveats include the smaller proportion
of enveloped particles in the axons of human neurons compared to rat neurons, which may be
explained in part by differences between the human and rat anterograde transport machinery,
and the possibility that adding bulky fluorescent proteins to the HSV-1 capsid and envelope
could impact the ratios of enveloped and unenveloped particles in axons. Thus, it is possible to
find varying degrees of evidence for both the “separate” and “married” models for HSV-1
anterograde transport, depending on the type of neuron used for the experiment and the
imaging method employed (311). Although there is little doubt now that anterograde transport
of fully enveloped virions can occur in HSV-1, it is also true that some portion of exiting HSV-1
virions are transported as tegumented capsids, suggesting the two mechanisms could coexist in
HSV-1 to a greater extent than in PrV.
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CHAPTER III: FUNCTIONAL HIERARCHY OF HERPES SIMPLEX VIRUS 1 VIRAL
GLYCOPROTEINS IN CYTOPLASMIC VIRION ENVELOPMENT AND EGRESS*
Introduction
Herpes simplex virus 1 (HSV-1) virion assembly begins in the nucleus with the
construction of viral capsids, which acquire certain tegument proteins and then bud through
the inner nuclear membrane, forming enveloped virions within the perinuclear space (primary
envelopment). Enveloped virions fuse with the outer nuclear membranes, allowing capsid
deposition in the cytoplasm of cells (10, 45, 47); reviewed in reference (42). In the cytoplasm,
viral capsids are coated with tegument proteins and acquire final viral envelopes by budding
into glycoprotein-enriched regions of the trans-Golgi network (TGN) membranes (secondary
envelopment) (17, 51, 54, 56). This final virion morphogenesis step delivers fully enveloped
virions into cytoplasmic vesicles, which are ultimately transported out of the cell (33).
Secondary envelopment of cytoplasmic capsids is facilitated by interactions between tegument
proteins and the cytoplasmic domains of viral glycoproteins and other membrane proteins
anchored in TGN-derived membranes (17, 51, 54, 56); reviewed in references (32, 42).

*

This chapter previously appeared as D.V.Chouljenko, I.J.Kim, V.N.Chouljenko,
R.Subramanian, J.D.Walker, K.G.Kousoulas, Functional hierarchy of herpes simplex virus 1
viral glycoproteins in cytoplasmic virion envelopment and egress, Journal of Virology, April
2012, 86(8): 4262-4270. It is reprinted by permission of the American Society for
Microbiology.
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Deletion or forced retention of either gD or gH within the endoplasmic reticulum does
not cause drastic defects in cytoplasmic virion envelopment and egress, although both
glycoproteins are essential for viral infectivity (7, 19, 38, 55). Similarly, gB is not required for
cytoplasmic envelopment and egress, inasmuch as gB-null viruses acquire envelopes and can be
rendered infectious after treatment with the fusogen polyethylene glycol (8, 41). However,
partial deletion of the carboxyl terminus of gB was reported to cause substantial reductions in
cytoplasmic virion envelopment and egress (9), suggesting that truncated gB may cause a
dominant negative effect. Recently, a gB-gD double mutant but not a gD-null virus exhibited
substantial defects in late stages of virus egress, indicating that gB may cooperate with gD in
facilitating virion envelopment (34). Single or simultaneous deletion of HSV-1 gE and gM genes
did not cause any appreciable defects in cytoplasmic virion envelopment and infectious virus
production (6). Similarly, lack of either gD or gE expression caused a mild (2- to 3-fold)
reduction in enveloped virions. However, simultaneous deletion of HSV-1 gD and gE or gD, gE,
and gI genes caused drastic accumulation of unenveloped capsids in the cytoplasm. Because
neither of these gene deletions alone caused similar defects, it was concluded that gD and gE
function in a redundant manner in cytoplasmic virion egress (16). Deletion of the UL11 gene
produced mild defects in cytoplasmic virion egress (27), while deletion of either the gK or UL20
gene or specific mutations within these two genes caused drastic inhibition of cytoplasmic
virion envelopment (23, 31, 41). Also, it was reported that simultaneous deletion of HSV-1 UL11
and gM caused drastic inhibition of cytoplasmic virion envelopment (37). Together, these
results suggest that there are multiple cooperative relationships among viral glycoproteins and
membrane proteins facilitating cytoplasmic virion envelopment.
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We have reported that gK and UL20 have distinct functions in virus-induced cell fusion
and cytoplasmic virion envelopment. These functions are genetically separable, since mutations
in UL20 that drastically inhibit virion envelopment do not affect virus-induced cell fusion (24,
40). UL20 and gK function in virus-induced cell fusion by physically binding to gB and gH in
infected cell surfaces (12, 13). Their roles in cytoplasmic envelopment and egress are not
defined, but it is likely that they interact with other viral glycoproteins and tegument proteins
to facilitate virion envelopment. Infectious virus production is directly dependent on the ability
of viruses to assemble in the cytoplasm mature virions containing fully glycosylated
glycoproteins and spread from infected to uninfected cells. Moreover, there are no known
glycoprotein mutations that inhibit virion egress without affecting cytoplasmic envelopment. In
the study described in this report, we determined particle-to-PFU ratios, relative plaque size
(indicative of relative virus spread), and kinetics of virus growth and conducted ultrastructural
visualization of glycoprotein-deficient mutant and wild-type virions in the same HSV-1(F)
genetic background to gain an understanding of the relative contribution of individual viral
glycoproteins in infectious virion morphogenesis and egress. The results show that UL20 and gK
are the most important viral determinants for cytoplasmic virion envelopment, egress, and
infectious virus production in comparison to gM, gD with deletion of the carboxyl-terminal 29
amino acids (gDΔct), gE, and UL11 alone or in various combinations.
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Materials and Methods
Cells and antibodies
African green monkey kidney (Vero) cells were obtained from the American Type
Culture Collection (Manassas, VA). Cells were maintained in Dulbecco’s modified Eagle’s
medium (Gibco-BRL, Grand Island, NY), supplemented with 10% fetal calf serum and antibiotics.
Antibodies used include anti-HSV-1 gE monoclonal antibody (Virusys, Sykesville, MD) and Alexa
Fluor 488-conjugated goat anti-mouse IgG monoclonal antibody (Invitrogen-Molecular Probes,
Carlsbad, CA) for the indirect immunofluorescence assays (IFAs), as well as anti-HSV-1 gD, antiHSV-1 gB, anti-HSV-1 gC monoclonal antibodies (Virusys, Sykesville, MD), rabbit anti-gM
antibody (a gift from Joel Baines, Cornell University, Ithaca, NY), and rabbit anti-UL11 antibody
(a gift from John Wills, Pennsylvania State University, Hershey, PA) for the Western immunoblot
assays.
Construction of HSV-1 mutant viruses
Mutagenesis was accomplished in Escherichia coli using the markerless two-step RED
recombination mutagenesis system and synthetic oligonucleotides (36, 53) (Table 3.1)
implemented on the bacterial artificial chromosome (BAC) plasmid pYEbac102 carrying the
HSV-1(F) genome (52) (a kind gift from Y. Kawaguchi, University of Tokyo, Tokyo, Japan).
Construction of the HSV-1 mutants gDΔct (US6), ΔgE (US8), ΔUL20, ΔgM1, ΔgE+gDΔct, and
ΔgE+ΔgM1 was described previously (36). The ΔgM2 recombinant virus was constructed by
altering two potential initiation codon sites (from ATG to CTG and ATG to ATT, respectively)
located 57 bp apart at the beginning of the UL10 open reading frame (ORF) (5) (Figure 3.1,
Table 3.1). The ΔUL11 virus was constructed by changing the initiation codon from ATG to CTG.
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Table 3.1: RED recombination primers.

Figure 3.1: Genomic map of mutated genes. (a) Prototypic arrangement of the HSV-1 genome with
the unique long (UL) and unique short (US) regions flanked by the terminal repeat (TR) and internal
repeat (IR; L, long; S, short) regions; (b) expanded genomic regions of the UL10, UL11, UL20, US6,
and US8 ORFs; (c) effect of ATG mutagenesis on gM, gE, UL11, and UL20 gene expression (hatched
regions), as well truncation of gD after gDΔct mutagenesis (hatched gD region).
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The ΔgE+gDΔct recombinant virus was used as the backbone for construction of the
ΔgE+gDΔct+ΔgM2 triple mutant by altering the two potential initiation codon sites in gM, as
described above for ΔgM2 virus. The ΔgM2+ΔUL11 double mutant was constructed by altering
the initiation codon of UL11 from ATG to CTG in the ΔgM2 virus.
Confirmation of the targeted mutations, recovery of infectious virus and marker-rescue
experiments
HSV-1 BAC DNAs were purified from 50 ml of overnight BAC cultures with a Qiagen
large-construct kit (Qiagen, Valencia, CA). Using PCR test primers designed to lie outside the
target mutation site(s), all mutated DNA regions were sequenced to verify the presence of the
desired mutations in BACs. Similarly, viruses recovered from infected Vero cells were
sequenced to confirm the presence of the desired mutations. Viruses were recovered from cells
transfected with BACs as we have described previously (36). To determine whether the
ΔUL11+ΔgM2 mutant virus contained any other genomic mutations, rescue experiments were
performed with approximately 1-kbp DNA fragments spanning the UL11 and gM initiation
codon mutations. Vero cells were transfected with the DNA fragments, and 24 h later,
transfected cells were infected with the ΔUL11+ΔgM2 virus. Virus stocks were prepared 24 h
postinfection (hpi) and plated at limiting dilution on Vero cells. Approximately 10 to 15% of viral
plaques appeared to be similar to wild-type virus (data not shown). DNA sequencing of wildtype-like viral plaques confirmed the absence of the UL11 and gM mutations.
Plaque morphology of mutant viruses and relative plaque area measurements
Visual analysis of plaque morphology of mutant viruses was performed as we have
previously described (24, 27, 36, 41). Plaque area measurements and data analysis were
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essentially as described previously (36), except that photographs of viral plaques analyzed were
taken at 50x magnification and 30 randomly selected plaques were imaged for each of the
mutant and wild-type viruses under consideration.
One-step viral growth kinetics
Analysis of one-step growth kinetics was performed as we have described previously
(20, 25). Briefly, nearly confluent Vero cell monolayers were infected with each virus at 4°C for
1 h at multiplicities of infection (MOIs) of 0.2 and 3. Thereafter, plates were incubated at 37°C
in 5% CO2 and virus was allowed to penetrate for 1 h at 37°C. Any remaining extracellular virus
was inactivated by low-pH treatment (pH 3.0), and cells were incubated at 37°C in 5% CO2.
Supernatants and cell pellets were separated at different times postinfection and stored at 80°C.
SDS-PAGE, Western immunoblotting, and indirect immunofluorescence assay
Subconfluent Vero cell monolayers were infected with the indicated virus at an MOI of
3. At 24 hpi, cells were collected by low-speed centrifugation, washed with phosphate-buffered
saline (PBS), and processed as described previously (21, 36). The indirect immunofluorescence
assay for the detection of gE expression was performed as described previously (36).
Electron microscopy
The ultrastructural morphology of virions within infected cells was examined by
transmission electron microscopy essentially as described previously (22, 23, 31, 36, 41). All
infected cells processed for electron microscopy were prepared at 16 h postinfection and
visualized by transmission electron microscopy.
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Preparation of cytoplasmic and extracellular virions
Cytoplasmic virions were separated by glycerol shock treatment essentially as
previously described by Sarmiento and Batterson (46), with the following modifications.
Extracellular virions were prepared from supernatants of infected cells. Specifically, viruses
were adsorbed on wells of a 12-well plate of nearly confluent Vero cell monolayers at 4°C for 1
h at an MOI of 1. Afterwards, plates were incubated at 37°C in 5% CO2 for 1 h to allow the virus
to penetrate into cells. Any remaining extracellular virus was inactivated by low-pH treatment
(pH 3.0), and cells were incubated at 37°C in 5% CO2 for 18 h and supernatants were collected.
Infected cells were washed once with ice-cold PBS (pH 7.4), and the remaining extracellular
virus was inactivated by low-pH treatment (pH 3.0). After removing the low-pH PBS, 900 μl of
PBS (pH 7.4) was added to each well. To minimize nuclear disruption, the glycerol concentration
was gradually increased by adding 150 μl of 90% glycerol (prewarmed to 37°C) to each well,
followed by mixing and incubation at 37°C for 5 min, which was repeated three times to obtain
a final concentration of 30% glycerol. The glycerol-treated samples were centrifuged at 1200x g
for 10 min at 4°C, and supernatants were discarded. The cell pellet was suspended in 250 μl of
ice-cold lysis buffer (0.01 M Tris-HCl, pH 7.4, 1.0 mM MgCl2, and 1.0 mM CaCl) by gentle mixing.
The cell suspension was incubated on ice for 5 min and centrifuged at 700 x g for 10 min at 4°C
to separate the nuclei and cellular debris from the cytoplasmic fraction. The supernatant
(cytoplasmic fraction) was carefully transferred to new 1.5-ml tubes and used for TaqMan realtime PCR as described previously (49, 50).
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Q-PCR
Quantitative PCR (Q-PCR) was utilized to derive the number of viral genomes within
cytoplasmic and extracellular samples that remained protected after DNAase treatment, as
described previously for Kaposi’s sarcoma-associated herpesvirus (KSHV) (49, 50). Specifically,
the primers and probe (6-carboxytetramethylrhodamine [TAMRA]) for the real-time PCR were
designed to detect HSV-1 US6 (gD). Cytoplasmic and extracellular fractions were collected 18
hpi, and 100 µl of each suspension was used for the extraction of viral DNA. The cytoplasmic
and extracellular suspensions were treated with Turbo DNase I (Ambion, Inc.) for 1 h at 37°C.
Viral DNA was extracted using a DNeasy blood and tissue kit (Qiagen, Inc.) as per the
manufacturer's instructions. Equal volumes of viral DNA were used for TaqMan PCR analysis.
Purified HSV-1 bacterial artificial chromosome (YE102) DNA was used to generate the standard
curve. Samples were also tested, and genome numbers were determined using validated
standards provided by the Path-HSV1-genesig real-time PCR detection kit for human
herpesvirus 1 (herpes simplex virus 1) (PrimerDesign, Ltd., South Hampton, United Kingdom).
Results
Construction and molecular analysis of recombinant viruses
We showed previously that recombinant viruses carrying a deletion of the carboxyl
terminus of gD (gDΔct) and the entire gE gene or gE and gM were able to efficiently acquire
cytoplasmic envelopes (36). To compare the relative roles of UL20, gM, gE, gD, and UL11 in
cytoplasmic envelopment and virion egress, we generated additional mutant viruses lacking
expression of one or more of these genes (Figure 3.1). All mutant viruses were produced using
the two-step RED recombination mutagenesis system (53) implemented on the pYEbac102
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bacterial artificial chromosome carrying the entire HSV-1(F) genome (52), as described in
Materials and Methods. Further characterization of the gE and gM double-null virus produced
earlier (36) suggested that a second initiation codon located 19 amino acids downstream from
the first initiation codon can be utilized to produce a truncated gM (data not shown).
Therefore, to ensure a complete lack of gM expression, the mutant virus ΔgM2 was created by
altering both initiation codons, and both versions of the mutated gM genes were used to
sequentially construct the desired set of mutations. The gM and UL11 defects were readily
rescued by DNA fragments overlapping the corresponding mutations, as evidenced by the
appearance of more than 10% viral plaques that were similar to wild-type plaques. Moreover,
DNA sequencing of selected rescued viruses revealed the presence of wild-type gM and UL11
sequences (data not shown). The triple mutant virus gDΔct+ΔgM2+ΔgE was generated from the
previously characterized gDΔct+ΔgE mutant virus (36). Overall, these results suggest that there
were no spurious nucleotide changes elsewhere in the viral genomes of viruses containing the
gDΔct, gE, gM, and UL11 mutations.
Recovery and plaque morphologies of infectious viruses produced by HSV-1 BAC DNAs
To generate virus stocks from the mutant BAC genomic constructs, individual BAC
DNAs were transfected into Vero cells and initial virus stocks were recovered and characterized
as detailed in Materials and Methods. The plaque morphologies of all mutant and wild-type
viruses were examined in Vero cells. As expected, the HSV-1(F) wild-type virus produced the
largest plaques, while the ΔUL20 mutant produced the smallest plaques, consisting of less than
5 cells (Figure 3.2A). Deletion of UL11 and gM (ΔUL11+ ΔgM2 virus) caused the production of
viral plaques that were 4- to 5-fold larger than those of ΔUL20 virus. Deletion of either gE, the
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carboxyl terminus of gD (gDΔct), or gM (ΔgM2) alone did not drastically reduce the average
plaque size, while simultaneous deletion of gD (gDΔct), gM (ΔgM2), and gE (ΔgE) reduced
average plaque sizes to the same extent as deletion of UL11 alone (Figure 3.2A). To better
assess the virus plaque sizes produced by individual mutant viruses, randomly chosen viral
plaques were measured and statistically analyzed as described in Materials and Methods. This
analysis confirmed that the most drastic reduction in average viral plaque sizes was produced
by ΔUL20, followed by the ΔUL11+ΔgM2, ΔUL11+ΔgM1, ΔUL11, and gDΔct+ΔgM2+ΔgE viruses
(Figure 3.2B).

Figure 3.2A: Plaque phenotypes of wild-type and mutant viruses. Confluent Vero cell
monolayers were infected with each virus at an MOI of 0.001, and viral plaques were visualized
at 48 hpi by immunohistochemistry as described in Materials and Methods.
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Figure 3.2B: Plaque area analysis. Confluent Vero cell monolayers were infected with each virus
at an MOI of 0.001, and viral plaques were visualized at 48 hpi by immunohistochemistry as
described in Materials and Methods. Thirty different viral plaques were randomly selected,
imaged, measured, and statistically analyzed as described in Materials and Methods. Natural
log-transformed data depicted as bar graphs for each virus are shown as geometric means with
95% confidence intervals. Tukey’s test was performed after one-way analysis of variance to
examine pairwise differences between the means for each of the 14 viruses. Viruses that were
significantly different from each other (P ≤ 0.05) are labeled with different capital letters (A, B,
C, D, E, F, and G).
Replication characteristics of HSV-1 mutants
To examine the effect of the various engineered mutations on virus replication, Vero
cells were infected at an MOI of either 0.2 or 3.0 with either the wild-type or each mutant virus,
and viral titers were obtained at 24 and 48 hpi (Table 3.2). At an MOI of 0.2, ΔUL20 replicated
approximately 3 log units less efficiently at both 24 and 48 hpi than the HSV-1(F) virus. All other
mutant viruses achieved titers that were approximately 1 log unit or higher than the ΔUL20
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virus titer at 24 hpi and 48 hpi (Table 3.2). Similar results were obtained when an MOI of 3.0
was used, with the exception that all mutant viruses other than ΔUL20 virus replicated more
efficiently at the high MOI than at the low MOI, with viral titers approaching those produced by
the HSV-1(F) wild-type virus at 48 hpi (Table 3.2).
Table 3.2: Comparison of wild-type and mutant virus replication. Viral titers were
determined at different times after infection of Vero cells at an MOI of 0.2 (A) or MOI of
3.0 (B). The experiment was performed a second time and the titers obtained were
averaged, with the standard deviation calculated for each time point. Not done (ND).
A
Mutant viruses

0 hpi

24 hpi

48 hpi

1

7

5

1.67x10 ± 9.02x10

1.63x10 ± 6.11x10

1

8.67x10 ± 1.16x10

6

6

2.31x10 ± 1.35x10

1

2.88x10 ± 1.68x10

6

5

1.56x10 ± 8.72x10

1

5.67x10 ± 4.37x10

5

4

6.53x10 ± 1.12x10

1

4.27x10 ± 7.69x10

6

5

4.80x10 ± 6.11x10

1

4.07x10 ± 5.21x10

6

5

9.20x10 ± 5.03x10

1

5.73x10 ± 5.93x10

5

4

2.55x10 ± 1.55x105

1

4.53x10 ± 4.16x10

5

4

1.14x10 ± 1.44x10

1

1.13x10 ± 1.62x10

5

4

1.64x10 ± 8.00x10

1

4

2

6.13x10 ± 2.31x10

Wild-type

6.00x10 ± 28.3

ΔgE

4.00x10 ± 0.00

gDΔct

2.00x10 ± 0.00

gDΔct+ΔgE

3.00x10 ± 14.1

ΔgM2

2.00x10 ± 0.00

ΔgM2+ΔgE

1.00x10 ± 14.1

gDΔct+ΔgM2+ΔgE

3.00x10 ± 14.1

ΔUL11

1.00x10 ± 14.1

ΔUL11+ΔgM2

2.00x10 ± 0.00

ΔUL20

4.00x10 ± 28.3

3.81x10 ± 6.22x10

Mutant viruses

0 hpi

24 hpi

7

5

7

6

7

5

6

6

6

5

6

5

6

7

6

6

4

4

3

B
1.03x10 ± 8.97x10

2

1.27x10 ± 1.43x10

2

3.99x10 ± 3.15x10

2

3.40x10 ± 2.31x10

2

4.73x10 ± 5.21x10

1

7.13x10 ± 1.10x10

2

3.17x10 ± 1.89x10

2

1.99x10 ± 4.81x10

Wild-type

4.60x10 ± 84.8

ΔgE

2.50x10 ± 42.4

gDΔct

2.40x10 ± 28.3

gDΔct+ΔgE

1.80x10 ± 56.6

ΔgM2

1.60x10 ± 56.6

ΔgM2+ΔgE

7.00x10 ± 14.1

gDΔct+ΔgM2+ΔgE

1.50x10 ± 14.1

ΔUL11

3.80x10 ± 28.3

ΔUL11+ΔgM2

ND

ΔUL20

48 hpi

2

2

2.70x10 ± 14.1

7

5

7.61x10 ± 2.39x10

7

6

8.55x10 ± 3.76x10

6

5

4.40x10 ± 5.77x10

5

4

3.60x10 ± 6.43x10

6

5

4.73x10 ± 7.33x10

6

6

7.13x10 ± 8.51x10

6

5

2.43x10 ± 1.30x10

7

5

2.41x10 ± 1.33x10

ND
5

6

6

6

6

5

6

5

6

5

6

5

6

5

7

5

ND
3

1.34x10 ± 2.34x10
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6

5

3

1.61x10 ± 3.51x10

Protein expression profiles of viral mutants
To confirm that the engineered gene mutations resulted in lack of expression of the
relevant protein and to investigate whether deletion of one or more viral glycoproteins affected
the synthesis of other viral glycoproteins, all mutant viruses were tested for the expression of
gB, gC, gD, gE, gM, and UL11. As expected, all mutant viruses containing the ΔgM2 mutation
failed to express gM (Figure 3.3). The ΔgM1 virus expressed a truncated gM glycoprotein
migrating in a manner consistent with the deletion of 19 amino acids from the amino terminus
of gM, as previously reported by others (5) (data not shown). The ΔUL11 mutation caused a lack
of UL11 expression for all recombinant viruses containing this mutation. The gDΔct deletion
caused the appearance of a truncated gD migrating with the expected apparent molecular
mass, as we have reported previously (36). Mutant viruses unable to produce gM and gE or gM,
gE, and gDΔct (DME2) appeared to express substantially smaller amounts of gB than all other
viruses tested, while all viruses synthesized equivalent levels of gC. In addition, the gDΔct+gE or

Figure 3.3: Western immunoblot analysis of glycoproteins specified by mutant viruses. α-gB, αgC, α-gD, α-gM, and α-UL11 denote antibodies specific for each protein.
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gM+gE+gDΔct viruses showed substantial reductions in the relative production of the UL11
protein (Figure 3.3). The expression of gE was tested by indirect immunofluorescence, since the
available antibody did not react strongly enough in immunoblots. IFA results showed that gE
was not expressed in cells infected with viruses specifying the ΔgE mutation, while gE
expression was unaffected by any of the other gene deletions (Figure 3.4).

Figure 3.4: Immunofluorescence detection of gE expression. Vero cells were infected at an MOI of
1 with the viruses indicated, and gE expression was detected by indirect immunofluorescence at
24 hpi. (Top row) Phase contrast micrographs of infected cells treated with anti-gE Mab; (bottom
row) fluorescent micrographs of the same infected cells. All mutant viruses containing the ATGto-CTG mutations in gE (ΔgE) failed to react with anti-gE antibody, while viruses expressing the
wild-type gE reacted with anti-gE antibody.
Ultrastructural characterization of wild-type and mutant viruses
The ultrastructural phenotypes of all viruses relative to the wild-type parental virus
were investigated at 16 hpi utilizing transmission electron microscopy and visually examining
more than 50 individual virus-infected Vero cells. As expected, the wild-type virus did not
exhibit any apparent defects in cytoplasmic virion envelopment or egress, as evidenced by the
presence of fully enveloped virions intracellularly and extracellularly (Figure 3.5). Ultrastructural
visualization of Vero cells infected with the different mutant viruses revealed a diverse range of
cytoplasmic defects in virion envelopment. The most pronounced effects were produced by the
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ΔUL20 and ΔUL11+ΔgM2 viruses, which produced numerous unenveloped capsids. In contrast,
the DME2 virus produced fully enveloped virions that were excreted out of infected cells
(Figure 3.5).

Figure 3.5: Ultrastructural morphology of wild-type and mutant viruses. Electron micrographs of
Vero cells infected with different viruses at an MOI of 3 and processed for electron microscopy
at 16 hpi are shown. Enlarged sections of each micrograph are included as insets in each panel.
The nucleus (n), cytoplasm (c), and extracellular space (e) are marked. Representative virions
are marked with black arrowheads.
Quantification of relative efficiency of infectious virus production and egress from infected
cells
The number of virus particles (enveloped and unenveloped capsids) can be indirectly
estimated by determining the number of viral genomes obtained after DNase I treatment (see
Materials and Methods). The ΔUL20 virus infection resulted in the least efficient production of
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infectious virus within cells, followed by infection with the ΔUL11+ΔgM2 virus. All other viruses
produced infectious virions with intermediate efficiencies ranging between those of virus
strains HSV-1(F), ΔUL20, and ΔUL11+ΔgM2 (Table 3.3). As expected, particle/PFU ratios in
supernatants of infected cells were much lower than those obtained from the cytoplasmic
fraction of infected cells for all viruses, with the exception of the ΔUL20 virus, which produced
high numbers of noninfectious virion particles in the supernatant.

Table 3.3: Determination of viral particle-to-PFU ratios. *Takes into account data from Q-PCR,
replication kinetics and plaque size quantification. †Cells infected with ΔUL20 HSV-1 display a
more apoptotic phenotype than cells infected with wild-type virus, leading to release of more
viral genomes into the supernatant.

Virus

Cytoplasm
(Particles/PFU)

Supernatant
(Particles/PFU)

Overall
defect*

Wild-type

109

6

+

ΔgE

425

4

++

gDΔct

381

10

++

gDΔct+ΔgE

855

218

+++

ΔgM2

2355

4

++

ΔgM2+ΔgE

417

9

++

gDΔct+ΔgM2+ΔgE

1779

12

+++

ΔUL11

590

60

+++

ΔUL11+ΔgM2

3460

70

++++

ΔUL20

8509

1702†

+++++
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Discussion
Mature virions acquire their viral envelopes by budding into cytoplasmic membranes
originating from the TGN. Multiple interactions between the cytoplasmic portions of viral
glycoproteins and tegument proteins facilitate cytoplasmic virion envelopment [reviewed in
references (32, 42)] (Figure 3.6). The fact that lack of expression of UL11, gD, gE, or gM alone
does not drastically affect cytoplasmic virion envelopment has led to the hypothesis that the
cytoplasmic portions of glycoproteins gD, gM, and gE and membrane-associated protein UL11

Figure 3.6: Diagrammatic description of glycoprotein-tegument protein interactions during
cytoplasmic virion envelopment at TGN-derived vesicles. (Right) The different steps in virion
egress from infected cells: I, budding of nuclear capsids into perinuclear spaces; II,
deenvelopment at the outer nuclear membrane and release of capsids into cytoplasm; III,
secondary envelopment at TGN membranes; IV, extracellular transport of enveloped virions.
Glycoproteins are shown as black bars being synthesized in the endoplasmic reticulum and
transported via vesicles to the Golgi apparatus and expressed on infected cell surfaces. (Left)
Interactions of tegumented capsids with the carboxyl termini of glycoproteins and membrane
proteins: UL49 (VP22) is shown to interact with gD, gM, and gE; UL48 (VP16) interacts with gH
and VP22; UL21 and UL16 interact with UL11 [reviewed in references (34, 42)]. UL20, UL11, gK,
gM, and gE are shown within a brown sphere to highlight their potential cooperative
relationships in infectious virion morphogenesis.
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function in a redundant manner to facilitate virion envelopment (16, 32, 37, 42). To directly test
this hypothesis and compare the relative importance of viral glycoproteins and membrane
proteins in virion envelopment, we generated a set of mutant viruses carrying one or multiple
mutations in viral glycoproteins gD, gE, and gM and in UL11 and compared them to viruses
lacking expression of UL20. The results presented herein show that lack of expression of the
UL20 (or gK) gene causes the most severe inhibition of cytoplasmic virion envelopment in
comparison to that for all other viruses lacking expression of one or more of the gD, gE, gM,
and UL11 genes.
Previously, we reported that a recombinant virus lacking expression of gE (ΔgE) and
expressing a truncated version of gD (gDΔct) did not exhibit any major defect in cytoplasmic
virion envelopment (28). These results suggest that gE and gD do not appear to function in a
redundant manner to facilitate cytoplasmic virion envelopment, despite their known
interactions with tegument proteins and the membrane-associated protein UL11 (18, 30, 32,
36, 43, 48, 57) (Figure 3.6). Deletion of the gM gene resulted in a reduction in the average size
of viral plaques produced (5) and an increase in the accumulation of unenveloped capsids in the
cytoplasm of HSV-1 infected cells (6, 39). Similar results have been reported for the
alphaherpesviruses pseudorabies virus (PRV) and equine herpesvirus 1 (EHV-1) (15, 44). These
defects in cytoplasmic virion envelopment are associated, at least in part, with the interactions
between gM and the major tegument protein UL49 demonstrated for PRV (26) and HSV-1 (48)
(Figure 3.6). We show here that simultaneous deletion of the carboxyl terminus of gD and the
entire gM and gE genes causes mild reductions in average plaque size, cytoplasmic virion
envelopment, and infectious virus production in comparison to those for the virus carrying the
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gDΔct+ΔgE combined mutations, suggesting that gM does not play a significant redundant role
with gD and gE in these events. Direct comparison with the ΔUL20 virus reveals that deletion of
the UL20 gene is substantially more deleterious to infectious virus production than the
combined effect of the gDΔct, ΔgM2, and ΔgE mutations.
Lack of gM expression caused decreased synthesis of gB, while deletion of the
carboxyl-terminal 29 amino acids of gD (gDΔct) caused decreased synthesis of UL11. It was
recently shown that the carboxyl terminus of gE interacts with UL11, causing their
coincorporation into virion particles (48). gD and gH have been shown to bind to gB and
modulate its fusogenicity (1-4, 14, 28). We have shown that gK and UL20 interact with both gB
and gH (13). We have recently found that UL20 interacts with gM (V. N. Chouljenko and K. G.
Kousoulas, unpublished data), suggesting that that the gK-UL20 and gM-gN complexes interact
(Figure 3.6). Virion tegument protein VP22 (UL49) interacts with cytoplasmic domains of gD, gE,
and gM, as well as its tegument partner, VP16 (UL48) (11, 18, 26). Moreover, VP16 binds to the
carboxyl terminus of gH (29). Collectively, these results suggest that there are multiple
interactions among viral glycoproteins and tegument proteins and that deletion of one or more
viral proteins may indirectly affect the functions and stability of other interacting proteins.
Lack of expression of both the UL11 and gM genes inhibited cytoplasmic virion
envelopment in Vero cells to a lesser extent than in other cells, while a similar deletion in PRV
caused drastic inhibition of infectious virus production (35, 37). Therefore, it was of interest to
generate a similar mutant virus in the HSV-1(F) genetic background to directly compare it with
other mutant viruses. Simultaneous deletion of the HSV-1(F) UL11 and gM genes caused a
substantial reduction in cytoplasmic virion envelopment and infectious virus production which
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was greater than that observed in the case of the gDΔct+ΔgM2+ΔgE triple mutant virus.
However, the ΔUL11 and ΔgM2 defects were markedly less severe than the ΔUL20 defect,
suggesting that UL20 and its interacting partner, gK (21, 24), play more important roles than gD,
gM, and gE alone or in combination. Recently, it was reported that gB may function with gD in a
redundant manner to facilitate cytoplasmic virion envelopment (34). Therefore, lack of gK or
UL20 may affect the binding ability of gB, gD, and gH to bind to tegument proteins.
Alternatively, gK and UL20 may directly bind to tegument proteins, facilitating cytoplasmic
virion envelopment. Additional experiments are needed to discern the functions of gK and UL20
in cytoplasmic virion envelopment, egress, and infectious virus production.
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CHAPTER IV: HERPES SIMPLEX VIRUS 1 PROTEIN UL37 INTERACTS WITH VIRAL
GLYCOPROTEIN K AND MEMBRANE PROTEIN UL20 AND FUNCTIONS IN
CYTOPLASMIC VIRION ENVELOPMENT*
Introduction
The herpes simplex virus 1 (HSV-1) double-stranded DNA genome is enclosed in an
icosahedral capsid and embedded within a proteinaceous tegument containing multiple viral
proteins, all of which is packaged within an envelope decorated with multiple membrane
proteins and glycoproteins (8, 21, 36, 49, 55). HSV-1 encodes at least 26 tegument proteins and
11 glycoproteins as well as several nonglycosylated membrane-associated proteins. The final
steps in virion envelopment occur in the cytoplasm of infected cells and involve multiple
interactions among viral proteins, including interaction between cytoplasmic portions of viral
glycoproteins and tegument proteins bound to cytoplasmic capsids, as well as tegumenttegument protein interactions (7, 8, 41, 51, 54).
HSV-1 UL37 is an approximately 120-kDa phosphorylated tegument protein expressed in
both mature virions and light particles (1). The UL37 protein localizes to both the nucleus and
cytoplasm in infected cells. The UL37 cytoplasmic localization is considered to be due to the
presence of a nuclear export signal (NES) sequence within the UL37 protein that mediates

*

This chapter previously appeared as N.Jambunathan & D.Chouljenko, P.Desai, A.S.Charles,
R.Subramanian, V.N.Chouljenko, K.G.Kousoulas, Herpes simplex virus 1 protein UL37
interacts with viral glycoprotein gK and membrane protein UL20 and functions in cytoplasmic
virion envelopment, Journal of Virology, June 2014, 88(11): 5927-5935. It is reprinted by
permission of the American Society for Microbiology. D.V.Chouljenko is co-first author.
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transport of the UL37 protein to the cytoplasm in the absence of any other viral proteins (10,
37, 49, 56). The UL37 protein is capable of self-association and interacts via its carboxyl
terminus with the UL36 major tegument protein, and this interaction is necessary and sufficient
for transport of the UL36-UL37 protein complex to the trans-Golgi network (TGN), where virion
envelopment is thought to occur (6, 10, 27, 30).
Deletion of the UL37 gene specified by either HSV-1 or pseudorabies virus (PRV) inhibits
cytoplasmic virion envelopment, causing the accumulation of unenveloped capsids in the
cytoplasm of infected cells (11, 33, 46). However, while the UL37 gene is absolutely essential for
HSV-1 replication, deletion of the PRV UL37 gene allows the resultant mutant virus to replicate,
albeit 100-fold less efficiently than the parental wild-type virus, thus demonstrating that certain
PRV UL37 functions may be shared with other PRV proteins (11, 29). The pUL36 in the UL37UL36 protein complex is thought to recruit the microtubule motors dynein, kinesin-1, and
kinsein-2 onto capsids in the cytosol (47). These interactions are further supported by in vitro
experiments in which capsids complexed with inner tegument proteins were able to associate
with the microtubule motors, while the capsids lacking the tegument proteins did not (44).
Thus, the UL37 protein plays important roles in capsid trafficking during virion entry, in a
retrograde manner, i.e., towards the nucleus, and in conjunction with dynein motors and the
microtubular network, while also playing an important role in capsid transport to the TGN (2,
12, 35, 42, 45, 57).
The UL36-UL37 protein complex is part of a multiprotein complex within the virion
particle and within infected cells. Specifically, the UL36 protein interacts with the outer
tegument protein pUL48 (55) and the minor capsid protein UL25 (43). Additionally, the UL37
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protein interacts with the UL46 and the UL35 proteins (32). Also, it has been reported that UL37
is phosphorylated by cellular enzymes and that it interacts in the cytoplasm with ICP8, the
major HSV-1 DNA binding protein, and is transported to the nucleus of infected cells (1). The
HSV-1 UL37 protein contains a TRAF6 (tumor necrosis factor receptor-associated factor 6)
binding domain that binds to TRAF6 and activates NF-kB expression, required for efficient viral
replication, in a Toll-like receptor 2 (TLR2)-independent manner (34). These results suggest that
the UL37 protein specifies additional functions in viral replication beyond its role in virion entry
and cytoplasmic virion envelopment.
HSV-1 gK is a multimembrane-spanning viral glycoprotein encoded by the UL53 gene. It
is expressed on virions, exists as a functional complex with the membrane-associated UL20 viral
protein, and plays a role in both virion entry and cytoplasmic virion envelopment (15, 18, 19).
The functions of the gK-UL20 protein complex in virion entry and cytoplasmic virion
envelopment can be segregated genetically and physically from each other (9, 14-16, 23, 39).
Functions of gK-UL20 in virion entry involve direct interactions of the amino termini of both gK
and UL20 with the fusogenic viral glycoprotein gB as well as with the membrane fusion
regulator glycoprotein gH (9). These glycoproteins regulate fusion of the viral envelope with
cellular membranes during virus entry, as well as virus-induced cell-to-cell fusion, i.e., formation
of multinucleated cells (syncytia) which allow the virus to spread from cell to cell (4, 5, 13, 40).
Here we demonstrate for the first time that the UL37 protein physically interacts with
both gK and UL20 proteins in infected cells. Moreover, overexpression of the UL20 protein in
FRT cells complements viral replication of the UL37 mutant DC480 virus, which is unable to
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acquire cytoplasmic envelopes, suggesting that the gK-UL20 interactions with UL37 facilitate
cytoplasmic virion envelopment.
Materials and Methods
Cell lines
African green monkey kidney (Vero) cells were obtained from the American Type
Culture Collection (Rockville, MD). The Vero-based UL37-complementing cell line BD45 was a
gift from Prashant Desai (Johns Hopkins University, Baltimore, MD). The construction and use of
the UL20-expressing FRT/UL20 cell line were detailed previously (39). The gK-transformed cell
line VK302 was a gift from David C. Johnson (Oregon Health Sciences University, Portland, OR).
All cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Grand Island, NY)
supplemented with 10% fetal calf serum and antibiotics.
Construction of HSV-1 mutant viruses
Mutagenesis was accomplished in Escherichia coli by using the markerless two-step Red
recombination mutagenesis system and synthetic oligonucleotides (31, 53) (DC480 Forward,
GGGTCGAACGTGTTTGGTCTGGCGCGGGAATACGGGTACTATGCCAACTACGATTACAAGGATGACGA
CGATAAG; and DC480 Reverse, CCGCCCGTGCGTGTGCTCGCTGGCGCCCTGGACCCGCCTGAAAGTT
TTTACCTTGCCATCGATCAGTCGCGGATCCACCTGGTCTCGTAGTTGGCATAGTACCCGTACAACCAATT
AACCAATTCTGATTAG) implemented on the bacterial artificial chromosome (BAC) plasmid
pYEbac102 carrying the HSV-1(F) genome (52) (a gift from Y. Kawaguchi, University of Tokyo,
Japan). Construction of the HSV-1 mutant virus ΔUL20 (UL20-null) was described previously
(31). The DC480 recombinant virus was constructed by inserting a 12-amino-acid epitope tag
(EDQVDPRLIDGK) for protein C (protC tag) into the HSV-1 UL37 gene immediately after the
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codon for amino acid 480 (Figure 4.1). The recombinant mutant virus YE102-VC1 was modified
to express gK and UL20 genes containing V5 and 3XFLAG antigenic epitopes, respectively, and
was described previously (23). Construction of the HSV-1 UL37-null mutant virus (generously
provided by Prashant Desai, Johns Hopkins University, Baltimore, MD) was described previously
(11).

Figure 4.1: Schematics of recombinant viruses and the UL37 gene. (A) Schematic arrangements
of the wild-type (WT) virus and mutant viruses VC1 and DC480, with the unique long (UL) and
unique short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions.
The VC1 virus expresses UL20 and gK tagged with 3XFLAG and V5 epitope tags, respectively.
The DC480 virus contains a 12-amino-acid (aa) protein C epitope tag inserted in frame
immediately following amino acid 480. (B) Schematic of the UL37 protein showing its functional
domains. (C) Western immunoblot of cell extracts obtained from Vero cells infected with the
DC480 virus, using anti-protC antibody. Lane 1, wild-type virus-infected cellular extracts; lane 2,
DC480 virus-infected cellular extracts.
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Confirmation of targeted mutations, recovery of infectious virus, and plaque morphology
analysis
HSV-1 BAC DNAs were purified from 50-ml overnight BAC cultures by use of a Qiagen
large-construct kit (Qiagen, Valencia, CA). All mutated DNA regions were sequenced to verify
the presence of the desired mutations in BACs. Similarly, viruses recovered from infected Vero
cells were sequenced to confirm the presence of the desired mutations. Viruses were recovered
from cells transfected with BACs as described previously (31). Visual analysis of the plaque
morphology of mutant viruses was performed as previously described (20, 31, 39, 40).
Viral growth kinetics
Analysis of viral growth kinetics was performed as we described previously (14, 19).
Briefly, nearly confluent Vero cell monolayers were infected with each virus at 4°C for 1 h at a
multiplicity of infection (MOI) of 0.2. Thereafter, plates were incubated at 37°C and 5% CO2,
and virus was allowed to penetrate for 1 h at 37°C. Any remaining extracellular virus was
inactivated by low-pH treatment (pH 3.0), and cells were incubated at 37°C and 5% CO2.
Electron microscopy
The ultrastructural morphology of virions within infected cells was examined by
transmission electron microscopy essentially as described previously (16, 17, 25, 31, 40). All
infected cells processed for electron microscopy were prepared at 18 h postinfection (hpi) and
visualized on a JEOL transmission electron microscope.
Quantitative PCR (qPCR) analysis of cytoplasmic virions
Cytoplasmic virions were separated by glycerol shock treatment essentially as
originally described by Sarmiento and Batterson (48) and later modified by our laboratory (8).
Real-time PCR was carried out on viral DNA from the cytoplasmic fractions of Vero cells.
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Specifically, the primers and probe (6-carboxytetramethylrhodamine [TAMRA]) for the real-time
PCR were designed to detect HSV-1 US6 (gD) (gD forward primer, ACGTACCTGCGGCTCGTGA
AGA; probe, 6-carboxyfluorescein [FAM]-GCCAAGGGCTCCTGTAAGTACGCCCT-TAMRA; and gD
reverse primer, TCACCCCCTGCTGGTAGGCC). The cytoplasmic suspensions were treated with
Turbo DNase I (Ambion, Inc.) for 1 h at 37°C. Viral DNA was extracted using a DNeasy blood and
tissue kit (Qiagen, Inc.) per the manufacturer's instructions. Equal volumes of viral DNA were
used for TaqMan PCR analysis. Purified HSV-1 bacterial artificial chromosome (YE102) DNA was
used to generate the standard curve (8).
Immunoprecipitation and immunoblot assays
Confluent Vero cells in T75 flasks were infected with the double-tagged recombinant
virus YE102-VC1 (gK-V5 and UL20-FLAG) or the UL37-null virus at an MOI of 2. At 24 hpi, the
infected cells were lysed with NP-40 cell lysis buffer (Life Technologies) supplemented with
protease inhibitor tablets (Roche). The samples were centrifuged at 13,000 rpm for 10 min at
4°C. The supernatants were then used for immunoprecipitation. The proteins from virusinfected cells were immunoprecipitated using protein G magnetic Dynabeads according to the
manufacturer’s instructions (Invitrogen). Briefly, the beads were bound to their respective
antibodies and left on a nutator for 10 min, followed by the addition of cell lysates. The lysatebead mixture was kept on the nutator for 10 min at room temperature and subsequently
washed three times with phosphate-buffered saline (PBS). The protein was eluted from the
magnetic beads in 40 μl of elution buffer and used for immunoblot assays. Sample buffer
containing 5% β-mercaptoethanol was added to the protein and heated at 55°C for 15 min.
Proteins were resolved in a 4 to 20% SDS-PAGE gel and immobilized on nitrocellulose

151

membranes. For Western immunoblots, subconfluent Vero cell monolayers were infected with
the indicated virus at an MOI of 3. At 24 hpi, cells were collected by low-speed centrifugation,
washed with PBS, and processed as described previously (15, 31). Immunoblot assays were
carried out using monoclonal mouse anti-protein C antibody (Abcam, Cambridge, England),
monoclonal mouse anti-VP5 antibody (Abcam, Inc., Cambridge, MA), monoclonal mouse antiFLAG antibody (Sigma-Aldrich, Inc., St. Louis, MO), monoclonal mouse anti-V5 antibody
(Invitrogen), horseradish peroxidase (HRP)-conjugated goat anti-mouse antibodies against the
light-chain (Fab) and heavy chain (Fc) (Abcam, Inc., Cambridge, MA), polyclonal rabbit anti-UL37
antibody (a gift from Frank J. Jenkins, University of Pittsburgh Cancer Institute), and HRPconjugated goat anti-rabbit antibody (Abcam, Inc., Cambridge, MA).
In situ PLA of protein interactions in virus-infected cells
Vero cells were grown on 8-well chamber slides (Nunc Lab-Tek II chamber slide system)
and infected with F strain virus (untagged) or the tagged virus VC1 (gk-V5 and UL20-FLAG) at an
MOI of 10. At 18 h postinfection, the cells were fixed with ice-cold methanol for 10 min at 20°C. After three washes with PBS, the samples were blocked for 2 h at 37°C with Duolink
blocking buffer in a humidity chamber. Primary antibodies that were raised in two different
species were diluted in antibody diluting buffer, added to the samples, and incubated overnight
at 4°C. Mouse anti-V5 antibody (Invitrogen) and rabbit anti-FLAG antibody (Sigma-Aldrich, Inc.,
St. Louis, MO) were used for gK and UL20 detection, respectively (positive control). Mouse antiFLAG and rabbit anti-UL37 antibodies were used for the HSV-1(F)-infected (virus with no
epitope tags) and VC1-infected cells to detect UL20-UL37 interaction. Mouse anti-V5 and rabbit
anti-UL37 antibodies were used for HSV-1(F)- and VC1-infected cells to detect gK-UL37
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interaction. Mouse anti-ICP8 (Abcam) and rabbit anti-FLAG was used to detect ICP8-UL20
interaction. Unbound primary antibodies were removed by washing with 1X Tris-buffered saline
(TBS)-Tween 20 (0.05%) three times for 5 min each. Duolink Anti-Rabbit Plus and Anti-Mouse
Minus in situ proximity ligation assay (PLA) probes were added to the samples (1:5 dilution) and
incubated at 37°C for 1 h. After the incubation step, washes were done with Duolink wash
buffer A, twice for five min each. The ligation stock was diluted 1:5 in high-purity water and
added to the wells (40 to 80 μl), and the slides were incubated at 37°C for 30 min. The slides
were washed with buffer A three times for five min each, amplification solution (40 to 50 μl)
was added, and the slides were incubated for 1.5 h at 37°C. The slides were then washed with
wash buffer B twice for 10 min each, and once with 0.01% buffer B. The slides were mounted
with mounting medium (Duolink II), stored at -20°C, and protected from light until confocal
images were taken. The confocal images were taken using a 60X objective on an Olympus
Fluoview FV10i confocal laser scanning microscope.
Results
Construction and characterization of UL37 mutant viruses
The recombinant virus DC480 was constructed by insertion of a protein C (protC)
epitope tag immediately after the UL37 gene region encoding amino acid 480 (Figure 4.1A).
The protC epitope tag was inserted in frame immediately after a conserved tyrosine residue
located within the central portion of UL37, distal to known functional domains of UL37 (Figure
4.1B). Expression of the UL37-protC-tagged protein was confirmed by Western immunoblot
analysis with anti-protC antibody. The UL37-protC construct was detected as a protein species
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migrating with an apparent electrophoretic mobility of approximately 120 to 130 kDa (Figure
4.1C), in agreement with previous published reports (10, 38, 49).
Plaque morphology and replication kinetics of the DC480 recombinant virus
The DC480 virus produced very small viral plaques on Vero and VK302 cells that were
similar in appearance to those produced by the UL20-null virus and comprised, on average, 5 to
10 cells, but it formed nearly wild-type-like viral plaques on BD45 cells expressing the UL37
gene (Figure 4.2). The UL37-null virus produced very small viral plaques on Vero, VK302, and
FRT cells but formed wild-type-like plaques on BD45 cells. The UL20-null virus formed wild-typelike viral plaques on the FRT cell line expressing the UL20 gene, as expected. Interestingly, the

Figure 4.2: Representative plaque morphologies of wild-type and mutant viruses. Vero, BD45
(UL37 expressing), FRT (UL20 expressing), and VK302 (gK expressing) cell monolayers were
infected at an MOI of 0.001, and viral plaques were visualized by immunohistochemistry using
polyclonal rabbit anti-HSV-1 antibody at 48 hpi.
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DC480 virus formed plaques on FRT cells that were approximately 5 to 10 times larger than the
plaques produced by the same virus on Vero or VK302 cells (Figure 4.2). We reported previously
that a lack of UL20 gene expression inhibits infectious virus production (17, 39). The DC480
virus replicated substantially less efficiently than the UL20-null virus in Vero cells, producing
infectious virion titers that were nearly 4 log lower than those of the wild-type virus at late
times postinfection, while the UL20-null titers were approximately 2 ½ log lower than those of
the wild-type virus (Figure 4.3A). In contrast, the DC480 virus replicated nearly 20-fold more
efficiently in FRT cells than in Vero cells, while the wild-type virus replicated equally efficiently
in both FRT and Vero cells (Figure 4.3B). The replication efficiency of the UL37-null virus on FRT
cells was approximately 20-fold lower than that of the DC480 virus. As expected, the UL20-null
virus was able to replicate in FRT cells substantially better than in Vero cells, although final
titers remained lower than those of the wild-type virus (Figure 4.3A and B).

Figure 4.3: Replication kinetics of wild-type and mutant viruses. Confluent Vero (A) or FRT (B)
cell monolayers were infected with each virus shown at an MOI of 0.2. Viral titers were
obtained by plaque assay on the appropriate cell lines. The titers obtained were averaged, and
the standard error of the mean was calculated for each time point.
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Evaluation of envelopment efficiencies of the DC480 virus
Ultrastructural visualization of infected cells revealed that the DC480 virus exhibited
drastic defects in virion envelopment, as evidenced by the accumulation of unenveloped
capsids in the cytoplasm of infected Vero cells and the absence of enveloped virions
extracellularly, as previously reported for the UL37-null virus (11, 42), in comparison to wildtype virus infection. In contrast, the DC480 virions appeared to be egressing efficiently out of
BD45 cells (Figure 4.4).

Figure 4.4: Ultrastructural morphology of wild-type and mutant viruses. Electron micrographs of
Vero or BD45 cells infected at an MOI of 3 with wild-type or DC480 virus and processed for
electron microscopy at 18 hpi are shown. Enlarged sections of the micrographs are included as
insets. The nucleus (n), cytoplasm (c), and extracellular space (e) are marked. Representative
virions are marked with black arrowheads.
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We previously described the use of qPCR for determination of the relative efficiency of
viral cytoplasmic envelopment (8). In this assay, the total number of viral genomes found
within DNase-resistant viral capsids is determined via qPCR and compared to the number of
infectious virions obtained by plaque assay. The wild-type virus was efficiently enveloped and
formed into infectious virions in both Vero and BD45 cells at an MOI of 1. In contrast, the viral
envelopment and infectious virion production efficiency of the DC480 virus were inhibited
>700-fold in Vero cells in comparison to BD45 cells. Ratios of the numbers of encapsidated
DC480 viral genomes and PFU were only approximately 2-fold lower than that of the wild-type
virus on BD45 cells (Figure 4.5).

Figure 4.5: Determination of relative efficiencies of virion envelopment of wild-type and mutant
viruses in Vero or BD45 cells. The total number of viral genomes in the cytoplasm of infected
Vero or BD45 cells at 24 hpi that were protected from DNase I treatment was obtained by qPCR.
The total number of intracellular infectious virions was obtained by plaque assay. Ratios
reflecting relative efficiencies of envelopment and infectious virion production were obtained
by dividing the average number of capsid-protected viral genomes by the number of PFU. Error
bars represent standard errors of the means.
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Determination of UL37 interactions with gK and UL20
To evaluate whether the UL37 protein interacts physically with either gK or the UL20
membrane protein, coimmunoprecipitation experiments were performed using the VC1 virus
(Figure 4.1A), which expresses gK tagged with a V5 epitope inserted in frame within the amino
terminus of gK and UL20 tagged with a 3XFLAG epitope inserted in frame after amino acid 4 of
the UL20 protein (23). Detection of the UL37 protein was achieved by using a rabbit anti-UL37
polyclonal antibody (49). The UL37 protein was detected as migrating with an apparent
molecular mass of 130 kDa (Figure 4.6A, arrow). Immunoprecipitation of cellular extracts
obtained from wild-type-infected cells by use of the UL37 antibody and subsequent
immunoblot detection by the UL37 antibody showed a UL37-specific protein species migrating
with an apparent molecular mass of 130 kDa (Figure 4.6A). However, this 130-kDa protein
species was absent in the lysate and the immunoprecipitates from the UL37-null virus (Figure
4.6A). Immunoblot probing of immunoprecipitates of the UL20 protein with the anti-3XFLAG
antibody or immunoprecipitates of gK with the anti-V5 antibody readily detected the presence
of the UL37 protein migrating at approximately 130 kDa (Figure 4.6A). Immunoblot probing of
infected lysate extracts with the anti-UL20 (anti-3XFLAG) antibody revealed the presence of
UL20 migrating with an apparent molecular mass of approximately 28 kDa (Figure 4.6B), as we
reported previously (9). The UL20 protein was also readily detected in UL20, gK, and UL37
immunoprecipitates (Figure 4.6B). The UL20 protein failed to immunoprecipitate VP5, while VP5
was readily detected in the lysate, migrating with an apparent molecular mass of 150 kDa
(Figure 4.6C) when probed with anti-VP5 antibody. Immunoblot probing with the anti-gK (antiV5) antibody readily detected gK in VC1 virus-infected cell extracts (Figure 4.6D) as well as gK,
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UL20, and UL37 immunoprecipitates. Although the apparent molecular mass of gK is
approximately 38 kDa (19, 22), larger gK-related protein species were detected in UL20 and
UL37 immunoprecipitates, presumably due to gK-UL20-UL37 protein complexes that were not
fully resolved to individual protein species (Figure 4.6D).

Figure 4.6: Western immunoblots of infected cell lysates and anti-UL37, anti-gK, and anti-UL20
immunoprecipitates. Vero cells were infected with the double-tagged virus YE102-VC1,
expressing gK tagged with the V5 epitope tag and UL20 tagged with the 3XFLAG epitope, or with
UL37-null virus. Infected cell lysates were obtained at 24 hpi, and immunoprecipitates were
obtained using anti-gK (anti-V5; gK-IP), anti-UL20 (anti-FLAG; UL20-IP), and anti-UL37 (UL37-IP)
antibodies in conjunction with magnetic beads. Immunoprecipitates were electrophoretically
separated by SDS-PAGE and transferred to nitrocellulose membranes. The blots were probed
with rabbit anti-UL37 antibody and HRP-conjugated secondary anti-rabbit antibody (A), mouse
anti-FLAG antibody and HRP-conjugated goat anti-mouse antibody against heavy chain (Fc) (B),
mouse anti-VP5 antibody and HRP-conjugated goat anti-mouse antibody (C), or mouse anti-V5
antibody and HRP-conjugated goat anti-mouse antibody against light chain (Fab) (D). In panels B,
C, and D, lanes labeled “lysate” denote cellular extracts of VC1, and the other lanes represent
immunoprecipitated samples from VC1-infected cells.
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Determination of UL37 interactions with gK and UL20 by PLA
To further validate the observed interactions of the UL37 protein with gK and the UL20
membrane protein, we utilized PLA. In this assay, primary antibodies against UL37, gK (anti-V5,)
and UL20 (anti-3XFLAG) are first bound to their respective antigens. Species-specific secondary
antibodies, called PLA probes, each having a unique short DNA primer covalently attached, are
used to bind to the primary antibodies. When the PLA probes are in close proximity, the DNA
primers can interact through two other circle-forming oligonucleotides that are added later.
Enzymatic ligation of these two fluorescently labeled oligonucleotides followed by polymerasedependent rolling circle amplification results in the generation of intense fluorescence, which is
visualized as distinct bright spots by use of a fluorescence microscope. This assay can determine
even transient or weak intracellular interactions (24, 50). PLA readily detected the known gKUL20 interactions (Figure 4.7F). Potential interactions were also detected between UL20 and
UL37 (Figure 4.7B) and between gK and UL37 (Figure 4.7E), while wild-type virus-infected cells
did not exhibit fluorescence signals (Figure 4.7A and D). The fluorescence signals were also
absent in our ICP8-UL20 control, suggesting the absence of potential interaction between these
proteins (Figure 4.7C).
Discussion
HSV-1 cytoplasmic virion envelopment involves multiple interactions among viral
glycoproteins and tegument proteins. The UL37 protein has been shown to be transported, in
complex with the UL36 protein and in a capsid-independent manner, to the TGN, where it
functions in cytoplasmic virion envelopment. Here we describe the phenotypic and replication
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Figure 4.7: PLA to determine UL37 interactions with gK and UL20. PLA was performed using
anti-UL37 (rabbit), anti-UL20 (anti-3xFLAG mouse antibody or anti-3XFLAG rabbit antibody),
anti-ICP8 (mouse), and anti-gK (anti-V5 mouse antibody) antibodies in conjunction with
appropriate secondary antibodies and oligonucleotides as described in Materials and Methods.
Fluorescence images of cells infected with wild-type or VC1 virus were recorded using an
Olympus confocal microscope at 18 hpi. (A and B) HSV-1(F)- and HSV-1(VC1)-infected Vero cells
treated with anti-FLAG (anti-UL20) and anti-UL37 antibodies, respectively. (C) HSV-1(VC1)infected Vero cells treated with anti-FLAG (anti-UL20) and anti-ICP8 antibodies. (D and E) HSV1(F)- and HSV-1(VC1)-infected Vero cells treated with anti-V5 (anti-gK) and anti-UL37
antibodies, respectively. (F) HSV-1(VC1)-infected Vero cells treated with anti-V5 (anti-gK) and
anti-FLAG (anti-UL20) antibodies.
properties of the UL37 mutant virus DC480, which contains a 12-amino-acid epitope tag
inserted in frame at approximately the middle portion of the UL37 protein. The DC480 virus
exhibits drastic defects in cytoplasmic virion envelopment, similar to those of mutant viruses
lacking either the gK or UL20 gene. Partial complementation of the UL37 mutant virus in UL20-
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expressing FRT cells, along with coimmunoprecipitation experiments, revealed that the UL37
protein interacts with gK and UL20, suggesting that these interactions facilitate cytoplasmic
virion envelopment.
Functional domains of the UL37 protein
The UL37 protein contains multiple domains that appear to have distinct functions
during virus replication. To facilitate detection of the UL37 protein, we inserted a protC epitope
tag within the central portion of the UL37 protein, distal to the amino acid regions that are
known to be involved in UL37 self-association, to bind to the UL36 protein, or to contain other
known functional domains (Figure 4.1). The mutant DC480 expressed a full-length UL37 protein
that was readily detectable by Western immunoblots using anti-protC antibody. However, this
epitope insertion resulted in a severe cytoplasmic envelopment defect similar to that of the
UL37-null virus, as evidenced by ultrastructural examination of infected cells showing
accumulation of unenveloped capsids in the cytoplasm. This apparent defect in cytoplasmic
virion envelopment in the DC480 virus was further supported by highly elevated DNaseresistant particle-to-PFU ratios in comparison to those for wild-type virus infections. Alignment
of a large subset of known UL37 amino acid sequences revealed the presence of highly
conserved residues among the alphaherpesviruses, as noted previously (28). The protC epitope
tag insertion was specifically targeted to be immediately adjacent to a highly conserved tyrosine
(Y) residue at amino acid position 480. UL37 is also reported to be phosphorylated in infected
cells (1). Reversible phosphorylation can result in conformational changes that can significantly
alter the functions of proteins, as evidenced by the regulation of the p53 tumor suppressor
protein via phosphorylation (3). Tyrosine sulfation is also a widespread posttranslational
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modification of eukaryotic proteins that modulate protein-protein interactions (26). Thus, it is
possible that the protC epitope insertion alters Y-specific posttranslational modifications of the
UL37 protein or alters protein-protein interactions that directly involve the amino acid region
immediately adjacent to the conserved Y residue. Alternatively, disruption of this UL37 domain
by the protC epitope insertion may change the overall conformation of the protein, thus
affecting other functional domains of the UL37 protein. It has been shown that the UL37
protein is phosphorylated by cellular enzymes and that it interacts in the cytoplasm with the
major DNA binding protein, ICP8. UL37 interactions with ICP8 enable transport of the UL37
protein to the nuclei of infected cells away from the cytoplasm; therefore, the UL37-ICP8
interactions are not likely to play a role in cytoplasmic virion envelopment (1).
As expected, both the DC480 and the UL37-null viruses were efficiently complemented
for virus replication and spread on the BD45 cells transformed with an HSV-1 gene fragment
containing the UL37 gene (11). Surprisingly, the DC480 virus was also complemented for virus
replication and virus spread in FRT cells expressing the UL20 gene under the control of its native
promoter, while the UL37-null virus was not. The observed DC480 virus complementation for
virus growth on UL20-expressing FRT cells strongly suggests direct or indirect physical
interactions

between

the

UL37

protein

and

the

UL20-gK

protein

complex.

Coimmunoprecipitation experiments using the available anti-UL37 polyclonal antibody and
either gK or UL20, tagged with a V5 or 3xFLAG epitope tag, respectively, showed that the UL37
protein interacted with both gK and UL20 in infected cells, thus providing additional evidence
for physical interactions between UL37 and the gK-UL20 protein complex. It has been reported
previously that the UL36-UL37 complex migrates to TGN membranes in the absence of capsids
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(10). There was no VP5 protein detected in UL20 immunoprecipitates, suggesting that the
observed interactions between UL20 and gK involved a UL37 protein that was not attached to
viral capsids. The UL37-UL36 protein complex may interact with gK-UL20 after its intracellular
transport to TGN membranes. Alternatively, the UL36-UL37 protein complex may interact with
gK-UL20 in the endoplasmic reticulum and be cotransported to the TGN sites of virion
envelopment. Additional experiments are required to distinguish between these two
possibilities.
We have shown that the gK-UL20 protein complex plays critical roles in cytoplasmic
virion envelopment and egress from infected cells. Our current results as well as previous
reports (6, 10, 27, 30) clearly indicate that the highly conserved UL37 protein is a crucial
determinant for cytoplasmic virion envelopment. Thus, the facts that these two protein
complexes (gK-UL20 and UL36-UL37) interact within infected cells and at TGN sites and are
involved in cytoplasmic virion envelopment are not surprising. Similar interactions must occur
within the virion particle, suggesting that during virion entry these interactions must be
regulated to allow the capsid to enter into the cytoplasm, while virion envelopes and their
glycoprotein content remain fused with cellular plasma membranes. Interactions of viral
glycoproteins, including gK and its partner protein, UL20, with cellular receptors may trigger
inhibition of the UL36-UL37 interactions with the gK-UL20 protein complex. Additional work is
required to investigate these possibilities.
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CHAPTER V: CONCLUDING REMARKS
Summary
Herpes simplex virus type-1 (HSV-1) virion assembly is a complex multi-step process.
HSV-1 DNA is packaged into capsids in the nucleus, forming mature nucleocapsids which
associate with a subset of tegument proteins such as pUL36, pUL37, pUL41, pUL48, pUL49 and
pUS3 and then undergo primary envelopment by budding at the inner nuclear membrane into
the perinuclear space, acquiring a temporary envelope studded with viral proteins (11-13). This
envelope is lost after the particle fuses with the outer nuclear membrane in a process that may
involve the fusion machinery implicated in viral entry which consists of gB, the heterodimer
gH/gL, and the gB-associated fusion regulators gK/UL20. Other mechanisms involving different
viral or host proteins that are not typically used during entry may also be involved in deenvelopment at the outer nuclear membrane because mutants lacking gB, gH/gL and gK/UL20
in various combinations do not exhibit a complete block in nuclear egress (2, 9). After deenvelopment, the nucleocapsid is deposited into the cytosol where additional inner tegument
proteins assemble at the capsid, while the outer tegument proteins along with the
glycoproteins and other membrane-associated viral proteins gather at the secondary
envelopment sites in cytoplasmic vesicles derived from the trans-Golgi network. In secondary
envelopment, tegumented capsids interact with the cytoplasmic domains of viral membrane
proteins embedded in TGN-derived vesicles, leading to acquisition of the final viral envelope by
budding into the vesicles (9). The enveloped virions are then transported in membrane vesicles
(which also contain embedded viral glycoproteins) to the plasma membrane for release by
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exocytosis, presumably assisted by microtubule-associated kinesin motors that ferry cargo
towards the plus-ends of microtubules in the cell periphery (3).
The secondary envelopment process involves an intricate web of protein-protein
interactions between capsid, tegument, and viral envelope proteins that is not fully
understood. It has been hypothesized that the HSV-1 membrane glycoproteins gD, gE and gM
play a crucial role in this process by acting in a redundant manner to promote secondary
envelopment via interactions with VP22 or pUL11 (9). To explore the relative importance of
these membrane proteins in secondary envelopment, we constructed recombinant mutant
viruses unable to express pUL11, gE, gM, or the carboxyl terminus of gD in a number of
combinations, and compared them to a mutant unable to express pUL20. Mutant viruses were
constructed using a markerless RED recombination system implemented on a bacterial artificial
chromosome (BAC), allowing us to abrogate expression of targeted genes without introducing
extraneous sequences or affecting nearby genes. To characterize the mutant viruses, we used
plaque morphology to assess virus spread, viral growth kinetics to measure infectious virus
production, ultrastructural morphology to examine virus intracellular localization and ability to
egress, and particle-to-PFU ratios to indirectly quantify cytoplasmic virion envelopment. A triple
mutant virus lacking expression of gE, gM and the carboxyl terminus of gD showed minimal
reduction in secondary envelopment and infectious virus production compared to single
mutants lacking pUL11, gE, gM or C-terminal gD and to wild-type virus. Double mutants unable
to express both gE and gM, or gE and C-terminal gD were likewise mildly affected, but a
pUL11/gM double mutant showed more significant replication defects. None of these mutants
approached the extent of egress defects exhibited by the pUL20 mutant virus, thus reinforcing
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the view that the membrane proteins gK and UL20 are the key determinants of viral secondary
envelopment (1).
An additional mutant virus was constructed with a protein C epitope tag inserted inframe immediately adjacent to Y480 (DC480) near the center of the multifunctional inner
tegument protein pUL37. Surprisingly, this 12 amino acid insertion was sufficient to block
infectious virus production on Vero cells, displaying a phenotype similar to that of pUL37-null,
pUL20-null or gK-null viruses. The DC480 mutant virus also showed partial complementation for
virus replication and spread when grown on cells engineered to express pUL20, suggesting a
potential interaction between the two proteins. We have provided compelling evidence for
such an interaction between pUL37 and pUL20, and also between pUL37 and gK by two-way coimmunoprecipitation and proximity ligation assays (7).
pUL20 and gK act as fusion modulators and have been shown to interact with each
other and with the major HSV-1 fusion protein gB (2, 4, 5, 10). In addition to their role in fusion,
pUL20 and gK are known as important mediators of secondary envelopment, and their
interactions with pUL37 may serve to facilitate the process of cytoplasmic virion envelopment
(1, 6-8).
In conclusion, this work has made contributions to understanding the relative
importance of a number of HSV-1 membrane and tegument proteins in cytoplasmic virion
envelopment and egress. It has also leveraged the emergence of powerful new technologies
such as proximity ligation assays to shed light on the complex tangle of protein-protein
interactions that underpins viral secondary envelopment.
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Current and Future Research
The work presented in the preceding two chapters raises interesting questions about
the identity of specific domains of pUL37 that are involved in binding to pUL20 and gK, and vice
versa, and work to determine the precise binding domains is ongoing. The close proximity of
the protein C epitope insert in the DC480 mutant to two highly conserved tyrosine residues,
and the fact that pUL37 is phosphorylated, also invites investigation into the role of
posttranslational modifications on pUL37 structure and function. Additional research involving
alanine-scanning mutagenesis of conserved pUL37 residues will investigate the role these and
other conserved residues play in posttranslational modification of pUL37 or in binding to the
pUL20/gK protein complex to facilitate cytoplasmic virion envelopment. The recently published
crystal structure of the amino terminal half of PRV pUL37 will further inform selection of
conserved residues for mutagenesis by allowing targeted modification of externally located
residues.
In order to investigate the possibility that groups of other viral glycoproteins act in a
redundant manner to promote secondary envelopment, additional multi-protein deletion
mutants could be created. Furthermore, to rule out spurious mutations that might be
introduced into the viral genome during mutagenesis, whole-genome sequencing of HSV-1
mutants can be performed. This is facilitated by the increasing prevalence and decreasing cost
of high-throughput sequencing. It is also possible that some of the mutant viral phenotypes
exhibiting partial defects in cytoplasmic envelopment presented in Chapter 2 were due to as
yet undiscovered direct or indirect interactions with the pUL20 or gK protein, leading to
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disruption of pUL20 or gK function in secondary envelopment. Alternatively, deleting enough
proteins will undoubtedly perturb the multitude of protein-protein interactions occurring
between the tegument and envelope during secondary envelopment, thus affecting the
stability or function of other viral proteins and creating defects even if the deleted proteins are
typically not involved in mediating envelopment. It is even possible that pUL20 and gK do not
actually prevent cytoplasmic envelopment from occurring. Instead, their absence may cause
the newly enveloped virions to immediately undergo de-envelopment back into the cytoplasm
due to fusion of the virion envelope with the surrounding TGN vesicle. This possibility creates a
ripe target for future investigation.
Vesicle formation in multivesicular bodies is mediated by endosomal sorting complexes
required for transport (ESCRT) components and associated proteins such as the ATPase VPS4.
Functional VPS4 was shown to be required for cytoplasmic virion envelopment in HSV-1,
presumably by facilitating ESCRT-mediated membrane deformation during cytoplasmic
envelopment and/or "pinching off" the viral envelope as the virus buds into TGN-derived
vesicles. Viral proteins likely interact with ESCRT components to recruit ESCRT machinery to
sites of cytoplasmic envelopment. gK is a prime candidate for such interactions due to the
presence of a putative ESCRT-binding motif in gK similar to retroviral motifs called late domains
which promote ESCRT recruitment (14). The presence of a putative ESCRT-binding motif in gK
provides a potential mechanism by which gK and its binding partner pUL20 may influence
cytoplasmic virion envelopment and merits further investigation.
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Many aspects of the HSV-1 secondary envelopment interactome remain undefined.
Obtaining a complete understanding of viral assembly will undoubtedly lead to more potent
antiviral targets and will also lay the groundwork for the construction of fully synthetic viral
particles that will put a biological twist on the concept of nanoscale robots.
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APPENDIX I: ADDITIONAL WORK
Introduction
The ubiquitous herpes simplex virus type-1 (HSV-1) is a prototypical member of the
Alphaherpesvirinae (7). HSV-1 possesses a ~152 kb double-stranded DNA genome enclosed
within an icosahedral capsid composed of 12 pentavalent and 150 hexavalent capsomeres (39).
The capsid is coated with a layer of viral proteins called the tegument, and is in turn enclosed
by a lipid envelope originating from host cellular membranes that is enriched with viral
glycoproteins and other membrane-associated proteins. A variety of interactions between the
viral proteins that make up the capsid, tegument and envelope are responsible for maintaining
the structural integrity of mature virions and for shepherding the viral particle through the
complex cytoplasmic envelopment process at trans-Golgi network-derived vesicles and
endosomes (16, 28).
The UL37 gene of HSV-1 encodes a large 1123 aa (120.6 kD) highly conserved tegument
protein that is essential for viral growth in cell culture and is crucial for viral assembly and
secondary envelopment in the cytoplasm (4, 18, 29). The quantity of pUL37 loaded onto mature
virions is tightly regulated, since overexpression of pUL37 does not increase the amount of
pUL37 detected in virions (26).
pUL37 forms a complex with pUL36, and this interaction is conserved across all three
subfamilies of the Herpesviridae. Interactions between proteins homologous to pUL36 and
pUL37 have been documented in the alphaherpesviruses HSV-1, PRV and VZV, in the
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betaherpesvirus HCMV and in the gammaherpesvirus KSHV (3, 21, 24, 30, 35-37). The presence
of pUL36 is necessary for incorporation of pUL37 onto capsids (23). pUL37 is likely added to
capsids after pUL36, since pUL36 is still detected on both HSV-1 and PRV capsids in mutants
lacking pUL37 (8, 22). Along with pUL36, pUL37 may be involved in the organization of
tegument structure. pUL37 attaches to capsid-bound pUL36 at the vertices, together forming
thin flexible strands ranging from 15 to 70 nm in length that extend throughout the tegument,
possibly providing a scaffold for the rest of the tegument (31). Deletion of either pUL36 or
pUL37 prevents the acquisition of appreciable amounts of tegument in the cytoplasm and
blocks cytoplasmic envelopment in HSV-1, resulting in cytoplasmic accumulation of
unenveloped capsids (8, 9, 33).
The UL37 protein encodes a variety of functional domains. Co-immunoprecipitation
experiments revealed that pUL37 domains spanning residues 1-300 and 568-1123 are involved
in self-association in the absence of its binding partner pUL36 (4). The amino terminus contains
an alanine-rich region (ARR) spanning residues 44-80, a leucine zipper motif covering residues
203-224 and a leucine-rich nuclear export signal (NES) encompassing residues 263-272 (4, 38).
The carboxyl terminus contains a domain spanning residues 1099-1104 involved in binding TNF
receptor-associated factor 6 (TRAF6) to activate NF-kappaB signaling (4, 25). The C-terminal
578-899 aa of pUL37 can interact with a spectraplakin protein called dystonin/BPAG1 known as
a cytoskeletal cross-linker that is involved in microtubule stabilization and transport. Viral
replication and cytoplasmic capsid mobility during egress from infected cells is impaired in
dystonin-depleted cells, suggesting that pUL37 may play a role in capsid trafficking along
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microtubules (32). The C-terminus of pUL37 is also responsible for binding to pUL36 (4, 19).
Scanning alanine mutagenesis of pUL37 revealed that residue D631 of pUL37 mediates binding
to pUL36. Knocking out this residue resulted in significantly decreased ability of the virus to
replicate, with mutant viral titers approximately 2 logs lower than those of wild type virus (19).
Trans-complementation experiments using a plasmid encoding the C-terminal portion of pUL37
spanning residues 568-1123 that includes the putative pUL36 interaction site showed that the
plasmid is sufficient to partially rescue a virus unable to express pUL37 (4).
The function of the central portion of pUL37 spanning aa 301-567 is not well defined. A
mutant HSV-1 with a 12 aa protein C epitope tag inserted in-frame immediately after residue
Y480 of pUL37 exhibited a severe defect in cytoplasmic envelopment, but was partially
complemented for replication and spread when grown on cells expressing pUL20 (14). Moving
the protein C epitope tag 100 nucleotides upstream of Y480 abrogated pUL20-mediated
complementation, resulting in a pUL37-null phenotype (data not shown). The protein C epitope
tag was inserted proximal to two highly conserved tyrosine residues Y474 and Y480. Tyrosine
sulfation is a common form of posttranslational modification, and insertion of the protein C
epitope may have altered posttranslational modification of the nearby tyrosine residues (17).
Alternatively, the protein C epitope may directly disrupt protein-protein interactions mediated
by adjacent residues, or even trigger a conformational change in the pUL37 protein that could
affect binding to other proteins (14).
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The UL37 protein is expressed late in the infection cycle and is stably phosphorylated
soon after translation of the UL37 gene. Phosphorylation of pUL37 is likely performed by a
cellular kinase and is not dependent on the presence of any known HSV-1 binding partner
because pUL37 expressed by a recombinant vaccinia virus is also phosphorylated (1).
Phosphorylation is a widespread form of posttranslational modification that can affect a
multitude of protein functions, including modulation of protein-protein interactions and control
of intracellular trafficking (1, 12). Phosphorylation of proteins such as the p53 tumor suppressor
has been shown to mediate conformational changes that can affect protein function and
regulation (2). Many viral proteins are also phosphorylated, by either viral or cellular kinases.
The HSV-1 tegument includes at least three components that are protein kinases, encoded by
the UL13, UL23 and US3 genes (18, 29).
Two-way interactions between pUL37 and the membrane proteins pUL20 and gK were
confirmed using co-immunoprecipitation and proximity ligation assays, thus providing the first
direct link between the inner tegument and the envelope, although the exact locations of the
relevant binding sites remain unknown (14). pUL20 and gK act as modulators of virus-induced
fusion and interact with each other in addition to binding the major HSV-1 fusion protein gB,
while pUL20 has also recently been shown to interact with gM (6, 10, 11, 20, 27). In addition to
their role in fusion, pUL20 and gK are known to be among the most important mediators of
secondary envelopment, and their interactions with pUL37 may serve to facilitate the process
of cytoplasmic virion envelopment (5, 13-15).

181

Results
Both pUL37 and the pUL20/gK complex are conserved within the alphaherpesvirinae
subfamily, reflecting their important roles in the viral life cycle (34). Alignments of a number of
alphaherpesviral UL37 homologs show the presence of highly conserved residues scattered
throughout the pUL37 ORF (19). We have performed additional alignments of UL37 homologs
from 19 different alphaherpesviruses, illustrating the highly conserved nature of a number of
residues including Y474 and Y480 (Figure A1.1). In order to discern the roles these conserved
residues may play in mediating interactions between pUL37 and pUL20/gK to promote
cytoplasmic virion envelopment, we have implemented a set of 13 single and double amino
acid changes of highly conserved pUL37 residues in transient expression vectors using alanine
scanning site-directed mutagenesis. Here we demonstrate that a subset of these pUL37
mutants is unable to complement infection with the DC480 mutant virus carrying a protein C
tag at pUL37 Y480 (Figure A1.2). The ability of these constructs to successfully complement
infection with pUL37-null virus will be characterized in future experiments. These constructs
will also be assessed for alterations in patterns of cellular localization in the context of
concurrent infection with pUL37-null, as well as for their ability to bind pUL20 and gK via coimmunoprecipitation. Changes in posttranslational modifications that may occur as a result of
the mutations in pUL37, particularly alterations in the phosphorylation profile, will be detected
via antibodies to phosphoserine and phosphotyrosine and by radiolabeling with P32 (Figure
A1.3).
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Figure A1.1: Partial alignment of UL37 homologs from 19 alphaherpesviruses. Y474 and Y480
are the only tyrosine residues conserved in the UL37 gene.
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Figure A1.2: Trans-complementation assay. A trans-complementation assay was performed on
Vero cells to assess a set of 13 pUL37 constructs for their ability to complement infection with
the DC480 mutant virus which contains a protein C epitope insertion adjacent to Y480 in pUL37.
Replication of the DC480 virus on Vero cells has previously been reported as highly impaired
and similar to that of pUL37-null and pUL20-null, with plaques mostly composed of single
infected cells (14). pUL37 constructs UL37-F68-A, UL37-PL262/263-AA, UL37-F294-A, UL37P408-A, UL37-GF420/421-AA, UL37-P519-A and UL37-P729-A with the noted residues altered to
alanine were able to complement the DC480 virus at least in part, while constructs UL37-L470A, UL37-Y474-A, UL37-Y480-A, UL37-GL504/505-AA, UL37-R530-A and UL37-F620-A with the
noted residues altered to alanine were not able to complement infection with the DC480
mutant, raising the possibility of these residues being important for virion assembly and/or
egress. Full or partial complementation is marked with a plus sign. Lack of complementation is
denoted by a minus sign. Mock signifies infection with the DC480 mutant virus followed by
mock transfection.
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Row A
Lane 1
Lane 2
Lane 3
Lane 4
Lane 5
Lane 6
Lane 7
Lane 8
Lane 9
Lane 10

Ladder
Calyculin/okadaic acid treated cell lysate
EGF-treated cell lysate
UL37 in reverse orientation
Wild-type pUL37
Ladder
Wild-type pUL20
pUL37-620F
pUL37-480Y
pUL37-474Y

Lane 1
Lane 2
Lane 3
Lane 4
Lane 5
Lane 6
Lane 7
Lane 8
Lane 9
Lane 10

Row B
Wild-type pUL20
Calyculin/okadaic acid treated cell lysate
EGF-treated cell lysate
Wild-type pUL37
pUL37-620F
pUL37-480Y
pUL37-474Y
Ladder
Wild-type pUL37 pulldown
pUL37-null pulldown

Figure A1.3: Phosphorylation assay. (Row A) Transfection with the specified constructs only.
Lanes 2 and 3 are positive controls for phosphorylation, while lanes 4 and 7 are negative
controls. (Row B) Transfection with the specified constructs followed by infection with DC480
mutant virus. Lane 1 is negative control, lanes 2 and 3 are positive controls for phosphorylation,
and lanes 9 and 10 are from a suboptimal pulldown. Red arrow is pointing at the 120 kD pUL37
band. Expression of pUL37 is readily detectable using anti-pUL37 antibody, but successful
detection of pUL37 phosphorylation using antibodies to phosphoserine or phosphotyrosine is
yet to be accomplished.
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